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Abstract 
 
Recently high oxidation state palladium chemistry has emerged as efficient tool 
for direct C−H bond functionalization that does not require prefunctionalized starting 
materials. Investigation of transition metal model complexes is an efficient approach for 
optimization of known reactions and development of new methodologies. This 
dissertation describes reactivity studies of Pd
IV
 model systems with an aim to gain better 
understanding of Pd
IV
 mediated C−H bond functionalization reactions. In addition, 
investigation of Pd
II
 model complexes to assess the feasibility of hypothetical Pd
0/II
 
catalyzed trifluoromethylation reaction with trifluoroacetic anhydride as a CF3 source is 
also described. 
In order to obtain detailed information about processes occurring at Pd
IV
 during 
catalysis, relatively stable yet reactive model systems had to be identified. First, we 
designed and synthesized a number of Pd
IV
 complexes supported by facial tridentate 
NNN and NCN ligands and investigated their reactivity. Next, we identified appropriate 
model system for detailed investigation of C−H bond cleavage at PdIV centers. 
Mechanistic information about this transformation was obtained through the following: 
(i) extensive one- and two-dimensional NMR analysis, (ii) reactivity studies of a series of 
substituted analogues, and (iii) isotope effect studies. These experiments suggest that 
C−H activation at [(Py3CH)Pd
IV
(biphenyl)Cl2]
+
 model system occurs via a multistep 
process involving chloride-to-acetate ligand exchange followed by conformational and 
 xvi 
 
configurational isomerization and then C−H cleavage. The data also suggest that C−H 
cleavage proceeds via an acetate-assisted mechanism with the carboxylate likely serving 
as an intramolecular base. 
In a unrelated project we propose a catalytic cycle for nickel(0/II) or 
palladium(0/II) catalyzed decarbonylative trifluoromethylation using trifluoroacetic esters 
as CF3 sources. The catalytic cycle consists of four elementary steps: (1) oxidative 
addition of a trifluoroacetic ester to M
0
 center, (2) CO deinsertion from the resulting 
trifluoroacyl M
II
 complex, (3) transmetallation of a zinc-aryl to M
II
, and (4) aryl–CF3 
bond-forming reductive elimination. We demonstrated that the use of RuPhos as the 
supporting ligand for palladium enables each of these steps to proceed under mild 
conditions. These studies set the stage for the development of catalytic arene 
trifluoromethylation and perfluoroalkylation reactions using inexpensive trifluoroacetic 
acid-derived CF3 sources. 
 
 
 
 
 
 1 
 
Chapter 1:Introduction 
 
Reactivity studies of well defined complexes have been an invaluable tool for the 
elucidation of transition metal catalyzed reaction mechanisms
1,2
 as well as for 
development and refinement of important industrial scale processes.
3,4 
This dissertation 
describes design, synthesis and reactivity studies of Pd model complexes with a goal to 
understand and optimize already known Pd
 
catalyzed reactions as well as to develop new 
synthetic methodology. Specifically, Pd
IV
 mediated C–H functionalization and PdII 
mediated trifluoromethylation reactions are the main research subjects in this dissertation. 
 
1.1 Reactivity Studies of Well Defined Palladium(IV) Centers 
Pd
IV
 mediated C–H bond functionalization reactions have emerged as practically 
useful methodology complementary to the conventional Pd
0/II
 catalyzed processes.
5
 In 
particular, Pd catalyzed oxidative amination, arylation, acetoxylation and alkylation of 
arenes and directed functionalization of unactivated aliphatic C–H bonds are extremely 
efficient transformations that do not require prefunctionalized starting materials.
6
 
Directing groups and temporary directing auxiliaries ensure high regioselectivities in 
these C–H functionalization reactions. Scheme 1.1 and Scheme 1.2 show particularly 
noteworthy examples. For instance, highly diastereoselective Csp
3
-H and Csp
2
-H 
iodinations of substrates bearing chiral oxazoline auxiliary were achieved with Pd(OAc)2 
 2 
 
catalyst (Scheme 1.1).
7
 8-Aminoquinoline, in turn, is a versatile temporary auxilary for 
acetoxylation and arylation of carboxylic acids (Scheme 1.2).
8,9
 
 
Scheme 1.1 Diastereoselective Csp
3
-H iodination 
 
 
Scheme 1.2 Acetoxylation and arylation of unactivated Csp
3
-H bonds 
 
 
 3 
 
The exact mechanism of Pd
IV
 mediated reactions is often unclear. Better 
understanding of processes occurring at Pd
IV
 would allow improvement of C–H 
functionalization regioselectivities and expansion of the substrate scope. A large number 
of model complexes have been investigated with an aim to gain insight in Pd
IV
 mediated 
C–H functionalization processes.5a PdIV complexes are typically obtained via oxidation of 
appropriate Pd
II
 precursor. Chlorine, bromine, iodine(III) compounds, peroxides, reactive 
alkylating agents and wide array of other reagents have been used as oxidants. Pd
IV
 
species undergo facile reductive elimination therefore, chelating supporting ligands such 
as bipyridine (BiPy) and hydrotris(pyrazolyl)borate (TP) are commonly used for 
stabilization of Pd
IV
 complexes. Scheme 1.3 shows examples of BiPy and TP supported 
complexes reported by Canty and coworkers.
10
 
 
Scheme 1.3 Synthesis of TP and BiPy supported Pd
IV
 complexes 
 
 
It has been demonstrated that even aryliodides can undergo oxidative addition to Pd
II
 to 
form Pd
IV
 species (Scheme 1.4).
11
 This suggests that Pd
IV
 species might be involved not 
only in oxidative C–H functionalization reactions but also in conventional catalytic 
 4 
 
processes such as Heck and Suzuki reactions that have been generally considered to 
proceed strictly via Pd
0/II
 catalytic cycle.
5a,12
  
 
 
Scheme 1.4 Formation of Pd
IV
 via oxidative addition of aryliodide to Pd
II
 
 
 
In several cases the intermediacy of Pd
IV
 in the catalytic turnover has been 
verified via synthesis of Pd
IV
 model complexes.
13
 For example, investigation of complex 
2 confirmed that Pd
IV
 species are involved in oxidative fluorination of arylboronic acids 
catalyzed by complex 1 (Scheme 1.5).
14
 In another study, Pd
IV
 species such as 3 were 
demonstrated to be likely intermediates in directed C–H chlorination of phenylpiridines 
with N-chlorosuccinimide as an oxidant (Scheme 1.6).
15,16 
 
Scheme 1.5 Oxidative Pd
IV
 mediated fluorination of arylboronic acids 
 
 
 5 
 
Scheme 1.6 Directed Pd
IV
 mediated C–H chlorination 
 
 
Synthesis and investigation of Pd
IV
 model complexes can also aid to disprove 
certain mechanistic hypothesis. For example, it was proposed that Pd catalyzed C–H 
sulfonylation of phenylpyridine proceeds with intermediacy of Pd
IV
 species such as 3 
(Scheme 1.7). Pure model complex 3 was obtained through independent synthesis. 
Further studies showed that even though complex 3 does reductively eliminate 
sulfonylated phenylpyridine, 3 is not kinetically competent catalyst in sulfonylation of 
phenyl pyridines, which means that this transformation proceeds through a different 
pathway.
17,18 
 
Scheme 1.7 Directed Pd
IV
 mediated C–H sulfonylation 
 
 Most catalytically relevant Pd
IV
 complexes are very reactive and unstable species, 
which greatly hampers investigation of fundamental Pd
IV
 chemistry. This issue is 
 6 
 
addressed in Chapter 2 which describes design and synthesis of new Pd
IV
 complexes 
stabilized by several diverse tridentate, facially coordinating ligands. The goal of Chapter 
2 is to elucidate the relationship between electronic and steric properties of supporting 
ligands and reactivity at Pd
IV
 as well as development of model systems for investigation 
of ligand exchange, migratory insertion and C–H activation at PdIV. 
C–H activation at PdIV has been proposed to be a key process in several recently 
reported C–H functionalization reactions19 however, comprehensive understanding of this 
process is lacking. Previous results from our group
20
 led to identification of appropriate 
model system for studies of C–H activation at PdIV. Chapter 3 describes detailed 
mechanistic investigation of acetate assited C–H cleavage at PdIV. It is demonstrated that 
concerted metallation-deprotonation (CMD) with acetate acting as an intramolecular base 
is a viable pathway for C–H activation at PdIV. 
 
1.2 Studies towards Nickel and Palladium Catalyzed 
Trifluoromethylation 
Trifluoromethyl moiety is used to modulate metabolic stability, lipophilicity and 
binding affinity of biologically active ingredients in many pharmaceuticals and 
agrochemicals (Figure 1.1).
21
 Medium and large scale syntheses of trifluoromethylated 
arenes are often inefficient and expensive processes. The lack of cheap, environmentally 
friendly and broadly applicable methods for the late stage trifluoromethylation of 
complex molecules has greatly impeded development and wider application of 
trifluoromethylated compounds in medicine and agriculture. 
 
 7 
 
Figure 1.1. Examples of trifluoromethylated pharmaceuticals and agrochemicals 
 
 
In Chapter 4 a novel approach towards the synthesis of trifluoromethylated 
compounds is presented. We propose a theoretical Ni and/or Pd catalyzed 
trifluoromethylation reaction that would employ trifluoroacetic anhydride (TFAA) and 
TFA esters as cheap and available CF3 sources. The catalytic cycle for this reaction is 
shown in Scheme 1.8. Such a trifluoromethylation reaction would be efficient and 
broadly applicable addition to the currently available methodologies. 
The proposed trifluoromethylation reaction seems reasonable. Step 1 (oxidative 
addition of trifluoroacetic esters to Pd
0
)
22
 as well as step 3 (transmetallation at Pd
II
)
23,24,25
 
both have significant precedent in the literature. In addition, the feasibility of aryl–CF3 
bond-forming reductive elimination from Pd
II
 (step iv) has also been confirmed by 
several reported examples. Grushin has achieved this transformation at 
(Xantphos)Pd
II
(aryl)(CF3) complexes,
4
 while Buchwald has demonstrated the use of 
BrettPhos and RuPhos as ligands for this coupling.
4
 
 8 
 
Scheme 1.8 Catalytic cycle for proposed trifluoromethylation reaction 
 
However, decarbonylation (step iii) has not been reported previously at 
trifluoroacetylpalladium and trifluoroacetylnickel complexes.
26
 Other second and third 
row transition metal trifluoroacetyl complexes are known to undergo decarbonylation; 
however, these transformations typically require high temperatures and long reaction 
times.
27,28,29,30
 Thus, we anticipated that CO deinsertion could present a major bottleneck 
for the envisioned trifluoromethylation reaction. For this reason, before attempting 
catalytic reaction, we decided to prepare Ni and Pd model complexes and investigate CO 
deinsertion step in detail with an aim that obtained information could then be used for 
development and optimization of catalytic trifluoromethylation reaction. Chapter 4 
describes study of decarbonylation of trifluoroacetyl ligand at Ni and Pd centers. The 
relationship between steric properties of the supporting ligand and facility of the 
decarbonylation process at Pd
II
 center is elucidated. In addition, new method for the 
synthesis of fluoroalkyl- Ni and Pd complexes via oxidative addition and CO deinsertion 
sequence is developed.  
After the key processes of decarbonylation had been worked out, an attempt was 
made to find a single supporting ligand that would promote all the elementary steps of 
 9 
 
catalytic cycle shown in Scheme 1.8. In Chapter 5 investigation of 2-
dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) supported Pd complexes in 
the context of decarbonylative trifluoromethylation is described. 
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Chapter 2: Design and Synthesis of Palladium(IV) Model 
Complexes Supported by Facial Tridentate Ligands
1
 
 
2.1 Introduction 
At the outset of this project our goal was to design and synthesize isolable yet 
reactive Pd
IV
 complexes, investigate electronic and steric effects of supporting ligands on 
reactivity of Pd
IV
 and elucidate mechanistic nuances of C–H activation at PdIV. With 
these goals in mind, we sought to identify ligands that would stabilize Pd
IV
 complexes, 
thereby slowing the relative rate of reductive elimination versus that of other 
transformations. Our studies targeted complexes of general structure (fac-
L2X)Pd
IV
(CF3)(aryl)(halide). The trifluoromethyl (CF3) ligand was selected in order to 
stabilize the Pd
IV
 center and render competing reductive elimination reactions relatively 
slow.
2
 The halide was anticipated to be a labile ligand that could serve as a site of 
reactivity at the high-oxidation-state Pd center.  
 
2.2 Synthesis of Supporting fac-L2X Ligands 
For this study facially coordinated monoanionic tridentate supporting ligands 
(fac-L2X) were selected, because these are known to stabilize a number of isolable 
organometallic Pd
IV
 complexes.
3,4,5
 Scheme 2.1 shows the structures of the ligands 1-4 
that were targeted for the preparation of (fac-L2X)Pd
IV
(CF3)(aryl)(halide) complexes. 
Ligands 1-4 differ with steric and electronic properties. Specifically, ligands 1-4 bear a 
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progressively stronger σ donor which might enhance the reactivity of PdIV complexes 
toward X-type ligand substitution and reductive elimination. The σ-aryl in NNC donor 
ligand 4 is expected to have especially large trans influence.
6
 Notably, while mer-NNC 
and mer-NCN pincer ligands have been widely used in high-valent Pd chemistry 
analogous fac-NNC ligands have not been well studied at Pd
IV
. It was anticipated that by 
screening number of diverse ligands we would be able to find a good balance between 
stability and reactivity at Pd
IV
 center.  
 
Figure 2.1 Selected (fac-L2X) supporting ligands 
 
 
Potassium trispyrazoylborate (1) is commercially available. Ligands 2-4, are new 
compounds and they were synthesized as shown in Scheme 2.1 and Scheme 2.2. 
Bis(pyridin-2-yl)methylamine (6) was obtained from dipyridyl ketone (5), according to 
the literature procedure.
7
 Precursor 6 was then reacted with Ac2O to form dppa (2) in 
80% yield and with (p-
t
BuC6H4)SO2Cl to afford dpsa (3) in 78% yield. Ligand 4 (dpph) 
was synthesized starting from 2-benzylpyridine (7) by sequential deprotonation/arylation 
with 2-bromopyridine followed by deprotonation/alkylation with CH3I. 
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Scheme 2.1 Synthesis of fac-L2X ligands 2 and 3 
 
 
Scheme 2.2 Synthesis of fac-L2X ligand 4 
 
 
2.3 Preparation of (fac-L2X)Pd
II
(Aryl)(CF3) Complexes 
We anticipated that targeted Pd
IV
 complexes could be synthesized via a two step 
procedure: first ligation of ligands 1-4 to appropriate Pd
II
 precursor would afford (fac-
L2X)Pd
II
(Aryl)(CF3) intermediates which would then be oxidized to (fac-
L2X)Pd
IV
(Aryl)(CF3)(X). Our initial synthetic efforts focused on identifying a 
(L)(L′)PdII(Aryl)(CF3) precursor that could be used for the synthesis of diverse (fac-
L2X)Pd
II
(Aryl)(CF3) intermediates. It was of particular importance that L and L′ be easily 
displaced by ligands 1-4. Previous reports have shown that (tmeda)Pd
II
(CH3)2 and 
(tmeda)Pd
II
(CH3)(C6H5) undergo facile ligand exchange with monophosphines, 
diphosphines, and bipyridine;
8
 as such, we initially hypothesized that 
(tmeda)Pd
II
(Aryl)(CF3) would be a convenient palladium starting material. While the 
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synthesis of (tmeda)Pd
II
(Aryl)(CF3) was straightforward and high yielding, clean ligand 
exchange was not observed with the fac-L2X ligands 1-4 investigated in this study. As 
such, we next targeted the Pd
II
 complex cis-(4-Mepy)2Pd(4-MeC6H4)(CF3) (10; 4-Mepy = 
4-methylpyridine), which contains more labile monodentate 4-Mepy ligands. 
 
Scheme 2.3 Preparation of cis-(4-Mepy)2Pd(4-MeC6H4)(CF3) 
 
As shown in Scheme 2.3, complex 10 was prepared in two straightforward steps. 
First, oxidative addition of 4-iodotoluene to Pd(dba)2 in the presence of 10 equiv of 4-
methylpyridine afforded trans-(4-Me-py)2Pd(4-MeC6H4)(I) (9) in 64% yield. Since it was 
not stable in solution, complex 9 was carried forward crude. In the second step, the 
treatment of 9 with excess CsF/TMSCF3 provided 10 in 54% yield as a white solid. 
Notably, the use of dry CsF and anhydrous solvent was essential in order to obtain 
reproducible yields of 10. The product was characterized by 
19
F, 
13
C, and 
1
H NMR 
spectroscopy. Complex 10 decomposes slowly over 24 h in CDCl3 solution with 
concomitant release of Pd black; however, it is stable in the solid state for several weeks 
at room temperature. 
Complex 10 turned out to be a practical precursor for targeted (fac-
L2X)Pd
II
(Aryl)(CF3) intermediates. For instance, when 10 was treated with slight excess 
of KTp (1) in acetone-d6 solution and reaction progress was monitored by 
1
H and 
19
F 
NMR spectroscopy, it was observed that complete conversion of 10 to 11 occurred within 
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5 minutes (Scheme 2.4). The ionic nature of 11 prevented its isolation in a pure form 
therefore; crude 11 was carried forward for the preparation of Pd
IV
 complex without 
further purification. In contrast, treatment of 10 with 1.15 equiv of ligands 2-4 at room 
temperature afforded isolable Pd
II
 products 12-14 (Scheme 2.5). Complexes 12-14 were 
characterized by 
1
H, 
13
C, and 
19
F NMR spectroscopy, and all resonances were assigned 
by 2D 
1
H/
1
H COSY, 
1
H/
13
C HSQC, and 
1
H/
13
C HMBC NMR spectra. 
 
Scheme 2.4 Preparation of (Tp)Pd
II
(4-MeC6H4)(CF3) 
 
 
Scheme 2.5 Preparation of (L2X)Pd
II
(4-MeC6H4)(CF3) complexes 
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The configurations of complexes 12-14 were established using 2D 
1
H/
1
H ROESY 
NMR experiments. Important correlations are shown in Figure 2.2. For (dpsa)Pd
II
(4-
MeC6H4)(CF3) (12) and (dpaa)Pd
II
(4-MeC6H4)(CF3) (13), the amide functionality is in 
the endo position over the square plane of palladium, as evidenced by (1) an NOE 
correlation between the NH proton of the amide and H
3
 and (2) strong correlation 
between H
1
 and H
2
/H
2′
 as well as by (3) the lack of NOE correlations between the NH 
proton and H
2
 and H
2′
. The preference for the endo isomer may be a consequence of a 
noncovalent interaction between the palladium and the NH proton. 
 
Figure 2.2 Determination of stereochemistry for (fac-L2X)Pd
II
(Aryl)(CF3) complexes 
 
 The stereochemistry of 14 was also elucidated via a 
1
H/
1
H ROESY experiment: 
H
2
/H
2′ 
protons of the pyridine rings show NOE correlations with the exo methy group but 
not with ortho protons of the endo phenyl ring (Figure 2.2). The structure and endo 
configuration of 14 was confirmed by single-crystal X-ray diffraction analysis. Crystals 
of 14 were obtained by slow evaporation of a saturated ethyl acetate solution at room 
temperature. A thermal ellipsoid plot of 14 as well as key bond distances and bond angles 
are shown in Figure 2.3. The phenyl ring above the square plane of palladium is inclined 
toward the trifluoromethyl group, with a C6−C5−C4−C3 torsion angle 103.80°. The 
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Pd−C4 (2.992 Å) and Pd−C3 (3.153 Å) distances are considerably longer than is typical 
(2.1−2.2 Å) in stable late-transition-metal η2-arene complexes;9 however, they are shorter 
than the sum of the van der Waals radii of the corresponding atoms. This apparent weak 
noncovalent interaction between palladium and the phenyl ring is likely the reason why 
14 is formed as a single endo isomer. 
 
Figure 2.3 Thermal ellipsoid plot of (dpph)Pd
II
(Aryl)(CF3) (14) 
 
 Thermal ellipsoids are shown at 50% probability. H atoms have been omitted for 
clarity. Selected bond lengths (Å) and angles (deg): Pd-C1, 2.013; Pd-C2, 1.99; Pd-N1, 
2.155; Pd-N2, 2.121; Pd-C4, 2.992; Pd-C3, 3.153; C6-C5-C4-C3, 103.80. 
 
2.4 Preparation and Reactivity of (fac-L2X)Pd
IV
(Aryl)(CF3)(Hal) 
Complexes 
With (fac-L2X)Pd
II
(Aryl)(CF3) precursors 12-14 in hand, we examined the 
synthesis and reactivity of (fac-L2X)Pd
IV
(Aryl)(CF3)(Cl) model complexes. Oxidation of 
K[(Tp)Pd
II
(Aryl)(CF3)] (11) with PhICl2 afforded 15 which was isolated in 49% yield 
after purification by flash chromatography (Scheme 2.6). Complex 15 was characterized 
by 
1
H, 
13
C, 
19
F, and 
11
B NMR spectroscopy. 
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Scheme 2.6 Preparation of (Tp)Pd
IV
(Aryl)(CF3)(Cl) 
 
 
Complex 15 was stable in CHCl3 solution for several days at room temperature as 
well as for up to 2 h at 80 ºC. Under these conditions the starting material could be 
recovered quantitatively from the reaction mixtures. In order to test the reactivity of 15 
towards C–H activation, we attempted to open a free coordination site via an abstraction 
of the chloride ligand.  We found that 15 is highly inert towards chloride abstraction. For 
example, the treatment of 15 with 10 equiv of AgOTf or AgBF4 in CDCl3 for 2 h at 50 ºC 
did not afford any substitution of the chloride ligand and unchanged 15 was recovered. 
 
Scheme 2.7 Reactivity of (Tp)Pd
IV
(Aryl)(CF3)(Cl) 
 
 
Quantitative reductive elimination of chlorotoluene (17) was observed when 
ligand exchange was attempted by treatment of 15 with 1 equivalent of trimethylsilyl 
triflate (TMSOTf) in CDCl3 solution at room temperature (Scheme 2.7). Apparently, 
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instead of chloride, Tp hydride was abstracted and in situ formed cationic Pd
IV
 
intermediate such as 16 underwent facile C–Cl bond forming reductive elimination. The 
high thermal stability of 15 is likely tied to the low lability of the Cl ligand, since ligand 
dissociation is the first step of many reductive elimination reactions from Pd
IV
 centers.  
We reasoned that unsymmetrical fac-tridentate ligands 2 and 3 containing a 
stronger σ-donor than pyrazole might enhance the reactivity of PdIV complexes towards 
X-type ligand abstraction. Thus we next investigated oxidation of previously obtained 
Pd
II
 complexes 12 and 13 (Table 2.1).  
 
Table 2.1 Preparation of (fac-L2X)Pd
IV
(Aryl)(CF3)(Cl) complexes 
 
 
Entry R (Complex) Oxidant X 
Yield 
(Product) 
1 p-
t
BuC6H4SO2 (12) 
 
Cl 42% (18) 
2 Ac (13) 
 
Cl 47% (19) 
3 p-
t
BuC6H4SO2 (12) 
 
F 68% (20) 
 
As shown in Table 2.1, the treatment of 12 and 13 with PhICl2 at room 
temperature in CH2Cl2 afforded 18 (42% yield) and 19 (47% yield), respectively. 
 20 
 
Complex 12 also reacted with N-fluoro-2,4,6-trimethylpyridinium triflate (NFTPT) to 
afford the corresponding Pd
IV
 fluoride 20 in 68% yield. In all three of these reactions, a 
single stereoisomer was detected in both the crude and isolated products. Complexes 18-
20 were all purified via column chromatography on silica gel. 
In contrast to the reactions in Table 2.1, the oxidation of 13 with NFTPT in 
CH2Cl2 at room temperature afforded two different isomeric products 21 and 22 (Table 
2.2). These compounds were purified by an aqueous work-up followed by 
chromatography on silica gel and were isolated in 40% and 33% yield, respectively. 
Interestingly, when 13 was treated with NFTPT in CH2Cl2 and crude reaction mixture 
was subjected directly to column chromatography with 10% MeOH in THF as mobile 
phase, complexes 21 and 23 were isolated in 39% and 24% yield. Moreover, when the 
reaction solvent was changed from CH2Cl2 to MeCN, 21 was obtained as sole reaction 
product in 53% isolated yield. 
 
Table 2.2 Reactions of (dpaa)Pd
II
(Aryl)(CF3) with NFTPT 
 
Entry Solvent 
Isolated yield 
of 21 (%) 
Isolated yield 
of 22 (%) 
Isolated yield 
of 23 (%) 
1 CH2Cl2 40 33 0 
2 CH2Cl2/MeOH 39 0 24 
3 MeCN 53 0 0 
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Complexes 18-23 were characterized by 
1
H, 
13
C, and 
19
F NMR spectroscopy, and 
all resonances were assigned by 2D 
1
H-
1
H COSY, 
1
H-
13
C HSQC, and 
1
H-
13
C HMBC 
NMR experiments.  For amide complexes 18, 20, 21, and 22, the stereochemistry about 
the Pd
IV
 centers was established via 
19
F-
1
H HOESY and 
1
H-
1
H ROESY NMR 
experiments. Significant hOe and nOe correlations are shown in Figure 2.4. The 
stereochemistry of complex 19 was assigned based on a very similar pattern of 
1
H NMR 
resonances to that of complex 21. 
 
Figure 2.4 Stereochemical assignment for (fac-L2X)Pd
IV
(Aryl)(CF3)(X) complexes 
 
The structure and stereochemistry of the Pd
IV
 sulfonamide complexes 18 and 20 
were further confirmed by single crystal X-ray diffraction analysis. Crystals of 18 and 20 
were obtained by slow diffusion of MTBE into a MeCN solution at –20 ºC. In each case, 
the solid-state structure was fully consistent with the solution NMR data presented above. 
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Thermal ellipsoid plots of 18 and 20 are shown in Figure 2.5. Thermal ellipsoids are 
shown at 50% probability. 
 
Figure 2.5 Thermal ellipsoid plots of (dpsa)Pd
IV
(Aryl)(CF3)(X) complexes 
       
  
Compounds 18-23 were inert toward carbon–halogen and/or carbon–CF3 bond 
forming reductive elimination. For example, they were stable in CDCl3 solution for at 
least 2 weeks at room temperature. Complexes 18-23 did decompose after heating at 80 
ºC for several hours in DMSO solution. However, this transformation yielded an 
intractable mixture of organic and inorganic products that precluded definitive 
characterization. 
We next examined the reactivity of 18-23 toward ligand substitution. Remarkably, 
despite the relatively large trans influence of amide X-type ligands,
10
 complexes 18-23 
showed no reaction upon treatment with 10 equiv of AgOTf or AgBF4 in CDCl3 or 
DMSO-d6 for 2 h at room temperature. In the reactions with Ag salts in CDCl3, 
1
H NMR 
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spectroscopic analysis of the crude mixtures showed some shifting of the amide ligand 
resonances; however, quenching with NBu4I returned only starting material. 
In contrast, these complexes did show reactivity with the highly electrophilic 
reagent TMSOTf. For example, the treatment of 21 with 1 equiv of TMSOTf in CD2Cl2 
solution at room temperature produced chloride complex 19 in quantitative yield 
(Scheme 2.8). This transformation presumably occurs via in situ generation of complex 
24, which abstracts chloride from a molecule of solvent.  Intermediate 24 was not 
detected by 
1
H or 
19
F NMR spectroscopy in CD2Cl2; however, when the reaction was 
conducted in CDCl3, this putative intermediate was observed but underwent fast 
decomposition (over 2 h at room temperature) to a complex mixture of unidentified 
products. 
 
Scheme 2.8 Reaction of (dpsa)Pd
IV
(Aryl)(CF3)(F) with TMSOTf 
 
 
We next pursued complexes containing facial tridentate NNC donor ligands 
where N = pyridine and C = σ-aryl. The σ-aryl is expected to have a large trans 
influence,
10
 thereby facilitating dissociation of a trans X-type ligand. On the basis of the 
results discussed above (and prior work from our group),
2
 we reasoned that NFTPT could 
oxidize 14 to form Pd
IV
 complex 25 (Scheme 2.9). We have also recently shown that 
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analogues of 25 can undergo intramolecular C–H activation to generate cyclometalated 
Pd
IV
 species.
11
 Thus, we hypothesized that 25 might be capable of C–H activation to 
generate the NNC ligated product 26. Gratifyingly, the treatment of 14 with NFTPT for 5 
min in CH2Cl2 at room temperature afforded 26. Notably, neither 25, nor any other 
intermediates were detected in this transformation.  An analogue of 14 without a methyl 
group in the benzylic position of the ligand gave only a complex mixture of products 
upon oxidation with NFTPT. This observation suggests that very close proximity 
between Pd and the C–H bond is necessary to achieve C–H activation at PdIV in this 
system. The triflate ligand of 26 was highly labile, and washing a CH2Cl2 solution of 26 
with aqueous NaCl afforded the readily isolable chloride product 27 in 59% yield. 
 
Scheme 2.9 Synthesis of (dpph)Pd
IV
(Aryl)(CF3)(Cl) 
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Complex 27 was characterized by 
1
H, 
13
C, and 
19
F NMR spectroscopy. 
Interestingly, rotation about the Pd-tolyl bond in 27 is slow on the NMR timescale. At 
room temperature, four broad but distinct 
1
H NMR signals are observed for the aromatic 
protons of this ligand. When the temperature is lowered to 0 ºC, these resonances resolve 
into four sharp doublets (Figure 2.6).  
 
Figure 2.6 
1
H NMR spectra of (dpph)Pd
IV
(Aryl)(CF3)(Cl) (27) at 20 
o
C and 0 
o
C 
 
 
The strongly σ-donating aryl arm of the tridentate ligand rendered this complex 
highly reactive towards X-type ligand substitution. For example, sonication of 27 with 
1.2 equiv of AgOTf for 10 min at room temperature in dichloromethane afforded 
complex 26 in situ. As shown in Scheme 2.10, this compound reacted with tert-
butylisocyanide to afford 28 in 95% yield and with PMe3 to generate 29 in 84% yield. 
Notably, examples of stable phosphine Pd
IV
 complexes like 29 remain rare,
12
 while 28 is, 
to our knowledge, the first example of a Pd
IV
 complex containing an isocyanide ligand. 
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Scheme 2.10 Reactivity of of (dpph)Pd
IV
(Aryl)(CF3)(Cl) with L-type ligands 
 
 
Chloride complex 27 also underwent facile substitution with X-type ligands. 
Relatively basic X-type ligands like p-nitrophenolate and phthalimide were introduced in 
high yield by reaction of 27 with the corresponding sodium or potassium salts (Scheme 
2.11). Examples of isolable Pd
IV
 phenolate and imide Pd
IV
 complexes remain rare in the 
literature,
13
 likely because these basic ligands tend to destabilize Pd
IV
 and participate in 
fast reductive elimination processes. X-ray quality crystals of phthalimide complex 30 
were obtained by vapor diffusion of hexanes into a CHCl3 solution at –20 ºC. X-ray 
structure of 30 is shown in Figure 2.7.  
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Scheme 2.11 Reactivity of of (dpph)Pd
IV
(Aryl)(CF3)(Cl) with X-type ligands 
 
Figure 2.7 Thermal ellipsoid plot of (dpph)Pd
IV
(Aryl)(CF3)(NPhth) 
 
Thermal ellipsoids are shown at 50% probability. H atoms omitted for clarity. 
 
Despite the fast rates of ligand substitution at 27, this complex is still highly inert 
towards reductive elimination. For example, 27 was stable for several weeks in CHCl3 at 
room temperature. Furthermore, only ~20% decomposition was observed after heating to 
110 ºC for 2 h in DMSO-d6. One possible explanation is that the restricted rotation about 
the Pd–tolyl bond precludes the complex from assuming the conformation required for 
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aryl–CF3 bond-forming reductive elimination. Complexes 28-31 were also stable for 
several days in CDCl3 solution at room temperature. When heated above 50 ºC, 
dissociation/decomposition of the labile ligand occurred, and complex mixtures of 
products were obtained. 
A final set of studies focused on the reactivity of these NNC-ligated complexes 
towards oxidatively induced C–H activation processes. As shown in Scheme 2.12, 
treatment of in situ-generated (dpph)Pd(2-PhC6H4)(TFA) (32) with NFTPT followed by 
aqueous NaCl at room temperature resulted in double C–H activation to generate the 
cyclometalated chloride complex 34. We propose that this transformation proceeds via 
intermediates like 35-37.
11
 This suggests the possibility that a single Pd
IV
 center can 
mediate more than one C–H activation event, a type of transformation that could 
potentially be exploited in catalytic C–C bond-forming reactions. 
 
Scheme 2.12 Preparation of (dpph)Pd
IV
(biphe)(Cl) 
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2.5 Conclusions 
In summary, this chapter describes the oxidation of a series of Pd
II
 precursors to 
form Pd
IV
-aryl products containing  fac-NNN and fac-NNC donor ligands. In all cases, 
the Pd
IV
 complexes were stable to reductive elimination processes for prolonged periods 
(at minimum several days) in solution at room temperature. The NNC-ligated Pd
IV
 center 
participated in facile ligand substitution reactions in which a halide and/or triflate ligand 
were displaced by phosphine, isocyanide, phenoxide, or phthalimide donors. 
Furthermore, several examples of oxidatively-induced C–H activation have been 
demonstrated. These systems add to a growing body of evidence that high oxidation state 
Pd centers are capable of participating in a diverse set of organometallic reactions beyond 
simply reductive elimination processes. 
 
2.6 Experimental Section 
General Procedures. All syntheses were conducted under a nitrogen atmosphere 
unless otherwise stated. All reagents were purchased from commercial sources and used 
as received. Bis(dibenzylideneacetone)palladium was obtained as described in 
literature.
14
 Tetrahydrofuran, dichloromethane and diethyl ether were purified using an 
Innovative Technologies (IT) solvent purification system consisting of a copper catalyst, 
activated alumina, and molecular sieves. NMR spectra were acquired using 400, 500 and 
700 MHz Varian spectrometers. All 
1
H/
1
H NOESY and 
1
H/
1
H ROESY correlation 
spectra were acquired on a 500 MHz instrument. 
1
H, 
19
F and 
13
C chemical shifts are 
reported in parts per million (ppm) relative to TMS, with the residual solvent peak used 
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as an internal reference. 
1
H
 
and 
19
F multiplicities are reported as follows: singlet (s), 
doublet (d), triplet (t), quartet (q), broad resonance (br) and multiplet (m).  
Preparation of N-Di(2-pyridyl)methylacetamide (dpaa) (2). To a solution of 
di(pyridin-2-yl)methylamine (6) (0.75 g; 4.05 mmol) in pyridine (5 mL) was added acetic 
anhydride (1.0 mL). The reaction mixture was stirred at rt for 2 h, then water (1 mL) was 
added, and stirring was continued for 30 min. The reaction mixture was poured into a 
saturated aq. NaHCO3 solution (50 mL), and the resulting solution was extracted with 
EtOAc (6 × 50 mL). The combined organic phases were washed with brine (100 mL) and 
dried over anhydrous MgSO4. The volatiles were evaporated under reduced pressure, and 
the resulting residue was suspended in diethyl ether (15 mL) and collected by filtration. 
The solid was washed with hexanes and dried under reduced pressure. Yield: 0.74 g 
(80%) of white crystals. Mp = 77-79 ºC. 
1
H NMR (CDCl3): δ 8.51 (d, J = 3.6 Hz, 2H), 
7.88 (bs, 1H), 7.60 (t, J = 7.4 Hz, 2H), 7.39 (d, J = 7.6 Hz, 2H), 7.12 (t, J = 5.9 Hz, 2H), 
6.19 (d, J = 6.8 Hz, 1H), 2.09 (s, 3H). 
13
C{
1
H} NMR (CDCl3): δ 169.55, 158.88, 149.20, 
136.81, 122.45, 122.20, 59.06, 23.36. HRMS electrospray (m/z): [M + H]
+
 calcd for 
C13H14N3O, 228.1131; found, 228.1131. 
Preparation of 4-tert-Butyl-N-[di(pyridin-2-yl)methyl]benzenesulfonamide 
(dpsa) (3). 4-tert-Butylbenzenesulfonyl chloride (1.05 g; 4.50 mmol) was added to a 
solution of di(pyridin-2-yl)methylamine (6) (0.75 g; 4.05 mmol) in pyridine (5 mL). The 
reaction mixture was stirred at rt for 2 h and then water (1 mL) was added. The solution 
was allowed to stir for 30 min. The reaction mixture was poured into water (100 mL), and 
the resulting suspension was extracted with EtOAc (100 mL). The organic phase was 
washed with water (3 × 50 mL) and brine (100 mL) and dried over anhydrous MgSO4. 
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The solvent was evaporated under reduced pressure and the residue was suspended in 
hexane (100 mL) and collected by filtration. Yield: 1.20 g (78%) of yellow crystals. Mp = 
178 ºC. 
1
H NMR (CDCl3): δ 8.41 (d, J = 4.4 Hz, 2H), 7.61 (d, J = 8.5 Hz, 2H), 7.49 (t, J 
= 6.4 Hz, 2H), 7.24 (multiple peaks, 5H), 7.05 (dd, J = 7.2, 5.0 Hz, 2H), 5.62 (d, J = 6.2 
Hz, 1H), 1.23 (s, 9H). 
13
C{
1
H} NMR (CDCl3): δ 157.84, 155.86, 148.75, 136.87, 136.71, 
126.99, 125.59, 122.52, 122.17, 62.08, 34.93, 31.00. HRMS electrospray (m/z): [M + H]
+
 
calcd for C21H24N3O2S, 382.1584; found, 382.1584. 
Preparation of di-(2-pyridyl)phenylmethane (8). Di-(2-pyridyl)phenylmethane 
(8) was obtained as described in literature.
15
 
Preparation of 1,1-di(2-pyridyl)phenylethane (dpph) (4). Butyllithium (2.5 M in 
hexanes, 4.8 mL, 12.0 mmol) was slowly added to a cooled (–78 oC) solution of 
dipyridylphenylmethane (8) (2.50 g; 10.15 mmol) in dry THF (50 mL). The resulting 
suspension was warmed to –20 oC over the period of 1 h, and then methyl iodide (1.25 
mL; 20.0 mmol) was added. The reaction mixture was stirred at rt for 3 h, then the 
volatiles were removed under reduced pressure. The resulting residue was suspended in 
diethyl ether, this suspension was filtered, and the filtrate was collected and concentrated 
under vacuum. The crude product was purified on a silica gel column (mobile phase: 
hexanes/EtOAc with gradient from 4/1 to 1/1) to yield thick oil that crystallized upon 
standing. Yield: 2.04 g (77%) of a colorless solid. Mp = 69-71 ºC. 
1
H NMR (CDCl3): δ 
8.60 (d, J = 4.7 Hz, 2H), 7.55 (td, J = 8.0 and 1.6 Hz, 2H), 7.27 (m, 2H), 7.21 (m, 1H), 
7.10 (multiple peaks, 4H), 7.05 (d, J = 8.0 Hz, 2H), 2.30 (s, 3H). 
13
C{
1
H} NMR (CDCl3): 
δ 166.48, 148.77, 147.61, 135.85, 128.47, 128.06, 126.21, 123.48, 121.07, 57.56, 28.33. 
HRMS electrospray (m/z): [M + H]
+
 calcd for C18H17N2, 261.1386; found, 261.1386. 
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Preparation of (4-MePy)2Pd(4-MeC6H4)(I)  (9). Pd(dba)2 (1.25 g; 2.17 mmol) 
was added to a solution of 4-iodotoluene (1.20 g; 5.50 mmol) and 4-methylpyridine (2.05 
g; 22.0 mmol) in THF (20 mL) at rt. The resulting homogenous solution was stirred at rt. 
After 15 min, product started to precipitate from solution. The thick suspension was 
stirred at room temperature for another 30 min, then hexane (30 mL) was added. The 
precipitate was filtered and washed with diethyl ether (4 × 50 mL) and hexanes (4 × 50 
mL). Yield: 1.42 g (64%) of yellow crystals. The crude product contains some minor 
impurities, but it was used directly in the next step as decomposition was observed during 
purification attempts. 
1
H NMR (CDCl3): δ 8.69 (d, J = 5.9 Hz, 4H), 7.00 (d, J = 5.9 Hz, 
4H), 6.87 (d, J = 7.6 Hz, 2H), 6.66 (d, J = 7.6 Hz, 2H), 2.27 (s, 6H), 2.13 (s, 3H). 
13
C{
1
H} NMR (CDCl3): δ 154.49, 153.02, 149.27, 132.82, 132.66, 127.86, 125.57, 21.06, 
20.61. 
Prepartion of (4-MePy)2Pd(4-MeC6H4)(CF3) (10). Cesium fluoride (1.06 g; 7.0 
mmol) was placed in a Schlenk flask and dried under vacuum at 100 
o
C for 2 h. The flask 
was then cooled to rt under an atmosphere of nitrogen, (4-MePy)2Pd(4-MeC6H4)(I) (9) 
(0.75 g; 1.7 mmol) was added, and the flask was then flushed with nitrogen and sealed 
with a rubber septum. Dry THF (20 mL) and TMSCF3 (1.1 mL; 7.0 mmol) were added 
via cannula. The resulting suspension was stirred at rt for 15 min. During this period, the 
color of the solution changed from yellow to dark green and some Pd black precipitate 
was observed. The volatiles were removed under reduced pressure at room temperature. 
The residue was suspended in dichloromethane (40 mL) and filtered through a pad of 
celite. The solution was evaporated under reduced pressure. The resulting residue was 
suspended in diethyl ether (10 mL) and collected by filtration. The solid was washed with 
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ethyl acetate (4 × 3 mL) and dried under reduced pressure. Yield: 0.36 g (54%) of white 
crystals. 
1
H NMR (CDCl3): δ 8.53 (d, J = 5.9 Hz, 2H), 8.14 (d, J = 5.9 Hz, 2H), 7.41 (d, J 
= 7.5 Hz, 2H), 7.12 (d, J = 5.5 Hz, 2H), 6.94 (d, J = 5.5 Hz, 2H), 6.81 (d, J = 7.5 Hz, 2H), 
2.34 (s, 3H), 2.23 (s, 3H), 2.20 (s, 3H). 
13
C{
1
H} NMR (CDCl3): δ 150.39, 150.04, 149.48 
(q, J = 9.3 Hz), 149.40, 149.37, 135.96, 134.89 (q, J = 364 Hz), 131.36, 127.21, 125.72, 
125.66, 21.07, 20.96, 20.94. 
19
F NMR (CDCl3): δ –21.00 (s). 
Preparation of (dpsa)Pd
II
(4-MeC6H4)(CF3) (12). (4-MePy)2Pd(4-MeC6H4)(CF3) 
(10) (81 mg; 0.18 mmol) was added to a solution of 4-tert-butyl-N-[di(pyridin-2-
yl)methyl]benzenesulfonamide (3)  (80 mg; 0.21 mmol) in EtOAc (2 mL) at rt. The 
reaction mixture was stirred at rt for 10 min, then filtered through a pad of celite. The 
volume of the solution was reduced to 1 mL and then hexane (10 mL) was added. The 
precipitate was collected by filtration, washed with a 1/1 mixture of hexane/diethyl ether 
(3 × 3 mL), and dried under reduced pressure. Yield: 106 mg (78%) of a white powder. 
1
H NMR (CDCl3): δ 8.80 (multiple peaks, 2H), 8.04 (d, J = 4.1 Hz, 1H), 7.68 (d, J = 6.9 
Hz, 2H), 7.65 (td, J = 7.7, 1.5 Hz, 1H), 7.48 (td, J = 7.5, 1.5 Hz, 1H), 7.45 (d, J = 7.7 Hz, 
1H), 7.38 (d, J = 6.9 Hz, 2H), 7.21 (d, J = 8.3 Hz, 2H), 7.13 (multiple peaks, 2H), 7.04 (t, 
J = 5.6 Hz, 1H), 6.87 (d, J = 7.5 Hz, 2H), 5.72 (d, J = 9.4 Hz, 1H), 2.23 (s, 3H), 1.21 (s, 
9H). 
13
C{
1
H} NMR (CDCl3): δ 156.49, 154.18, 153.48, 153.23, 152.69, 150.01 (q, J = 
9.5 Hz), 139.41, 138.59, 136.71, 135.70, 134.58 (q, J = 364 Hz), 132.41, 127.99, 127.04, 
126.99, 125.94, 124.96, 124.70, 124.14, 63.11, 34.97, 30.98, 20.97. 
19
F NMR (CDCl3): δ 
–20.29 (s). HRMS electrospray (m/z): [M – F]+ calcd for C29H30F2N3O2PdS, 628.1056; 
found, 628.1058. 
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Preparation of (dpaa)Pd
II
(4-MeC6H4)(CF3) (13). (4-MePy)2Pd(4-MeC6H4)(CF3)  
(10) (120 mg; 0.26 mmol) was added to a solution of N-di(2-pyridyl)methylacetamide (2) 
(68 mg; 0.30 mmol) in CH2Cl2 (3 mL) at rt. After the solution was stirred at rt for 5 min, 
it was filtered through a pad of celite. The volume of the CH2Cl2 solution was reduced to 
1 mL under reduced pressure, and the product was then precipitated with hexanes (15 
mL). The precipitate was collected by filtration, washed with diethyl ether (3 × 2 mL) 
and dried under reduced pressure. Yield: 115 mg (88%) of a white powder. 
1
H NMR 
(CDCl3): δ 9.07 (d, J = 8.7 Hz, 1H), 8.99 (d, J = 5.1 Hz, 1H), 8.10 (d, J = 5.1 Hz, 1H), 
7.86 (td, J = 7.8 Hz, 1.1 Hz, 1H), 7.73 (td, J = 6.6, 1.1 Hz, 1H), 7.61 (multiple peaks, 
2H), 7.40 (t, J = 6.6 Hz, 1H), 7.31 (d, J = 7.3 Hz, 2H), 7.10 (t, J = 6.4 Hz, 1H), 6.88 (d, J 
= 7.3 Hz, 2H), 6.34 (d, J = 8.7 Hz, 1H), 2.25 (s, 3H), 2.21 (s, 3H). 
13
C{
1
H} NMR 
(CDCl3): δ 169.86, 155.34, 154.47, 153.38, 152.76, 150.01 (q, J = 9.3 Hz), 139.35, 
139.11, 135.74, 134.82 (q, J = 363 Hz), 132.39, 127.93, 125.40, 125.12, 124.66, 124.52, 
59.62, 23.32, 20.95. 
19
F NMR (CDCl3): –20.39 (s). HRMS electrospray (m/z): [M – F]
+
 
calcd for C21H20F2N3OPd, 474.0604; found, 474.0605. 
Preparation of (dpph)Pd
II
(4-MeC6H4)(CF3) (14). (4-MePy)2Pd(4-MeC6H4)(CF3) 
(10) (300 mg; 0.66 mmol) was added to a solution of 1,1-di(2-pyridyl)phenylethane 
(dpph) (4)  (182 mg; 0.70 mmol) in EtOAc (15 mL) at rt. After the solution was stirred at 
rt for 5 min, it was filtered through a pad of celite. The volume of the solution was 
reduced to 3 mL, and the product then started to crystallize. This suspension was cooled 
at –20 oC for 2 h, and then the precipitate was collected by filtration, washed with ethyl 
acetate (3 × 1 mL), and dried under reduced pressure. Yield: 208 mg (60%) of a white 
powder. The mother liquor was evaporated under reduced pressure. The residue was 
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suspended in diethyl ether, collected by filtration and dried under reduced pressure to 
yield another 35 mg (10%) of the product. For complex 10 at room temperature there is a 
hindered rotation about palladium-tolyl and C-phenyl bonds on a NMR timescale. In 
order to resolve broad resonances 
1
H- and 
13
C-NMR spectra were measured at 50 
o
C and 
46 
o
C. 
1
H NMR (CDCl3 at 50 ºC): δ 9.09 (d, J = 4.9 Hz, 1H), 8.25 (d, J = 5.3 Hz, 1H), 
7.87 (td, J = 7.8, 1.5 Hz, 1H), 7.77 (multiple peaks, 3H), 7.41 (t, J = 7.6 Hz, 2H), 7.36 (t, 
J = 7.4 Hz, 1H), 7.33 (t, J = 6.5 Hz, 1H), 7.03 (td, J = 7.2 Hz, 1.7 Hz, 1H), 6.97 (d, J = 
7.0 Hz, 2H), 6.78 (d, J = 7.8 Hz, 2H), 6.73 (d, J = 7.6 Hz, 2H), 2.24 (s, 3H), 2.18 (s, 3H). 
13
C{
1
H} NMR (CDCl3 at 46 ºC): δ 162.24, 160.53, 153.38, 152.78, 151.70 (q, J = 9.8 
Hz), 148.27, 138.35, 138.10, 135.96, 134.61 (q, J = 366 Hz), 131.19, 128.87, 127.87, 
127.12, 127.06, 123.04, 122.99, 122.78, 122.54, 57.52, 29.76, 20.91. 
19
F (CDCl3 at 25 
ºC): δ –21.82 (s). HRMS electrospray (m/z): [M – F]+ calcd for C26H23F2N3Pd, 507.0859; 
found, 507.0855. 
Preparation of (Tp)Pd
IV
(4-MeC6H4)(CF3)(Cl) (15). (4-MePy)2Pd(4-
MeC6H4)(CF3) (10) (100 mg; 0.22 mmol) was added to the solution of KTp (58 mg; 0.23 
mmol) in acetone (10 mL) at rt. The reaction mixture was stirred for 5 min at rt and then 
triethylamine (25 mg; 0.25 mmol) and iodobenzene dichloride (61 mg; 0.22 mmol) were 
added. The solution was stirred at rt for 10 min and then the volatiles were removed 
under reduced pressure. The resulting residue was purified on a silica gel column (mobile 
phase: hexanes/EtOAc with gradient from 10/1 to 6/1). Yield: 56 mg (49%) of yellow 
crystals. 
1
H NMR (CDCl3): δ 8.00 (d, J = 1.4 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.71 (d, J 
= 2.2 Hz, 1H), 7.67 (d, J = 2.2 Hz, 1H), 7.51 (d, J = 2.1 Hz, 1H), 7.33 (d, J = 1.9 Hz, 1H), 
6.84 (d, J = 8.6 Hz, 2H), 6.80 (d, J = 8.6 Hz, 2H), 6.31 (multiple peaks, 2H), 6.16 (t, J = 
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2.2 Hz, 1H), 4.1-5.0 (br, 1H), 2.30 (s, 3H). 
13
C{
1
H} NMR (CDCl3): δ 149.35 (q, J = 2.2 
Hz), 142.15 (q, J = 2.1 Hz), 141.40, 141.36, 136.62, 136.08, 134.96, 134.89, 134.75, 
129.01, 114.25 (q, J = 376 Hz), 106.81, 106.32, 106.10, 20.40. 
19
F NMR (CDCl3): δ –
17.30 (s). 
11
B NMR (CDCl3): δ –3.44 (d, J = 74 Hz). HRMS electrospray (m/z): [M – Cl 
+ MeCN]
+
 calcd for C19H20BF3N7Pd, 520.0855; found 520.0849. 
Preparation of (dpsa)Pd
IV
(4-MeC6H4)(CF3)(Cl) (18). Iodobenzene dichloride (60 
mg; 0.22 mmol) was added to a solution of (dpsa)Pd
II
(4-MeC6H4)(CF3) (12) (130 mg; 
0.20 mmol) in MeCN (4 mL) at rt. The reaction mixture was stirred at rt for 15 min and 
then the volatiles were removed under reduced pressure. The crude product was purified 
on a silica gel column (mobile phase: hexane/EtOAc = 1/1). Fractions containing pure 
product (TLC control) were evaporated under reduced pressure. The resulting residue 
was dissolved in dichloromethane (~0.5 mL), and the product was precipitated with the 
addition of hexane (20 mL). The precipitate was collected by filtration, washed with 
diethyl ether and dried under reduced pressure. Yield: 57 mg (42%) of a yellow powder. 
1
H NMR (CDCl3): δ 9.01 (d, J = 5.2 Hz, 1H), 8.57 (d, J = 5.2 Hz, 1H), 7.83 (td, J = 7.8, 
1.0 Hz, 1H), 7.79 (td, J = 7.6, 1.0 Hz, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.55 (d, J = 8.4 Hz, 
2H), 7.50 (d, J = 7.7 Hz, 1H), 7.38 (t, J = 6.5 Hz, 1H), 7.28 (t, J = 6.4 Hz, 1H), 7.24 (d, J 
= 8.4 Hz, 2H), 7.22 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 6.14 (s, 1H), 2.26 (s, 
3H), 1.24 (s, 9H). 
13
C{
1
H} NMR (CDCl3): δ 158.69, 157.62, 154.63, 149.79, 149.76, 
146.96, 140.67, 140.30. 139.66, 135.70, 135.52, 129.11, 126.60, 125.22, 124.48, 124.14, 
120.66, 120.59, 115.03 (q, J = 378 Hz), 74.80, 34.83, 31.08, 20.42. 
19
F NMR (CDCl3): δ 
–11.90 (s). HRMS electrospray (m/z): [M + Na]+ calcd for C29H29ClF3N3NaO2PdS, 
704.0548; found, 704.0548. 
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Preparation of (dpaa)Pd
IV
(4-MeC6H4)(CF3)(Cl) (19). Iodobenzene dichloride 
(77 mg; 0.28 mmol) was added to a solution of (dpaa)Pd
II
(4-MeC6H4)(CF3) (13) (110 mg; 
0.22 mmol) in acetonitrile (5 mL) at rt. The reaction mixture was stirred at rt for 20 min, 
then solvent was removed under reduced pressure. The residue was purified on a silica 
gel column that was eluted first with ethyl acetate, then with THF, and finally with 10% 
methanol in THF. Fractions that contained pure product (TLC control) were evaporated 
under reduced pressure, and the resulting residue was dissolved in diethyl ether (20 mL). 
This solution was filtered through a cotton plug, and the volume of the solution was 
reduced to 10 mL. The product was then precipitated with hexanes (30 mL), collected by 
filtration, washed with hexanes, and dried under reduced pressure. Yield: 55 mg (47%) of 
an orange powder. 
1
H NMR (CDCl3): δ 9.03 (d, J = 5.0 Hz, 1H), 8.49 (d, J = 5.3 Hz, 1H), 
7.87 (multiple peaks, 2H), 7.73 (multiple peaks, 2H), 7.43 (t, J = 6.0 Hz, 1H), 7.25 
(multiple peaks, 2H), 6.95 (broad d, J = 8.1 Hz, 2H), 6.79 (d, J = 8.1 Hz, 2H), 2.25 (s, 
3H), 1.69 (s, 3H). 
13
C{
1
H} NMR (CDCl3): δ 175.06, 158.16, 158.10, 149.75, 149.49, 
148.94 (q, J = 2.9 Hz), 140.43, 140.17, 135.76, 135.55, 129.15, 124.40, 124.19, 121.66, 
121.32, 116.42 (q, J = 376 Hz), 71.72, 24.89 (q, J = 2.7 Hz), 20.40. 
19
F NMR (CDCl3): δ 
–13.08 (s). HRMS electrospray (m/z): [M + H]+ calcd for C21H20ClF3N3OPd, 528.0276; 
found, 528.0269. 
Preparation of (dpsa)Pd
IV
(4-MeC6H4)(CF3)(F) (20). NFTPT (64 mg; 0.22 mmol) 
was added to a solution of complex 12 (130 mg; 0.20 mmol) in MeCN (3 mL) at rt. The 
reaction mixture was stirred at rt for 15 min. The volatiles were removed under reduced 
pressure. The resulting residue was dissolved in CH2Cl2 (15 mL), and this solution was 
washed with water (4 × 15 mL), dried over anhydrous Na2SO4, and evaporated under 
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reduced pressure. The crude product was purified on a silica gel column that was eluted 
first with ethyl acetate and then with THF. Fractions containing pure product (TLC 
control) were evaporated under reduced pressure. The resulting residue was dissolved 
dichloromethane (0.5 mL), and the product was precipitated with the addition of hexane 
(20 mL). This precipitate was collected by filtration, washed with diethyl ether and dried 
under reduced pressure. Yield: 91 mg (68%) of a yellow powder. 
1
H NMR (CDCl3): δ 
8.82 (d, J = 5.1 Hz, 1H), 8.30 (d, J = 5.2 Hz, 1H), 7.70 (d, J = 8.8 Hz, 2H), 7.67 (td, J = 
6.7, 1.5 Hz, 1H), 7.60 (multiple peaks, 3H), 7.50 (td, J = 7.7, 1.3 Hz, 1H), 7.28 (t, J = 6.8 
Hz, 1H), 7.24 (d, J = 8.8 Hz, 2H), 7.12 (t, J  = 6.4 Hz, 1H), 6.90 (d, J = 8.6 Hz, 2H), 6.26 
(d, J = 5.4 Hz, 1H), 2.28 (s, 3H), 1.22 (s, 9H). 
13
C{
1
H} NMR (CDCl3): δ 157.94, 157.10, 
155.10, 150.88 (m), 149.27, 148.23, 140.07, 139.52, 136.07, 131.58, 131.53, 129.08, 
127.09, 125.28, 124.18, 124.02, 121.64, 121.08, 114.69 (q, J = 378 Hz), 74.26, 34.86, 
31.07, 20.51. 
19
F NMR (CDCl3): δ –20.44 (d, J = 4.8 Hz), –285.11 (br. m). HRMS 
electrospray (m/z): [M + H]
+
 calcd for C29H30F4N3O2PdS, 666.1024; found, 666.1021. 
Preparation of (dpaa)Pd
IV
(4-MeC6H4)(CF3)(F) (21) and (22). (dpaa)Pd
II
(4-
MeC6H4)(CF3) (13) (58 mg; 0.12 mmol) was dissolved in CH2Cl2 (4 mL) and NFTPT (38 
mg; 0.13 mmol) was added at rt. The reaction mixture was stirred at rt for 20 min. The 
CH2Cl2 solution was then washed with water (4 × 5 mL), dried over anhydrous Na2SO4, 
filtered, and evaporated under reduced pressure. 
1
H-NMR and 
19
F-NMR analysis of the 
crude residue showed the presence of two Pd(IV) complexes in an approximately 2:1 
ratio. These compounds were separated by preparative TLC (mobile phase: 10% 
methanol in THF) to yield the major isomer 21 (24 mg 40%) and minor isomer 22 (20 
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mg; 33%) as yellow powders. When oxidation was conducted in acetonitrile only 21 
isomer was formed (53% isolated yield).  
Analytical data for 21: 
1
H NMR (CDCl3): δ 9.01 (d, J = 5.4 Hz, 1H), 8.25 (d, J = 
5.4 Hz, 1H), 7.91 (multiple peaks, 2H), 7.74 (multiple peaks, 2H), 7.48 (t, J = 5.4 Hz, 
1H), 7.27 (t, J = 6.1 Hz, 1H), 7.14 (d, J = 5.4 Hz, 1H; coupled with F), 7.09 (multiple 
peaks, 2H), 6.90 (d, J = 7.8 Hz, 2H), 2.32 (s, 3H), 1.82 (s, 3H). 
13
C{
1
H} NMR (CDCl3): δ 
175.19 (d, J = 3.1 Hz), 157.69, 157.56, 152.01 (m), 149.22, 149.00, 140.46, 140.21, 
136.01, 132.34 (d, J = 6.6 Hz), 129.05, 124.33, 124.25, 121.80, 121.33, 116.84 (q, J = 
376 Hz), 71.03, 24.75 (m), 20.51. 
19
F NMR (CDCl3): δ –290.85 (m), –23.84 (d, J = 3.8 
Hz). HRMS electrospray (m/z): [M + H]
+
 calcd for C21H20F4N3OPd, 512.0572; found, 
512.0574.  
Analytical data for 22: 
1
H NMR (CDCl3): δ 8.98 (d, J = 5.1 Hz, 1H), 8.55 (d, J = 
5.5 Hz, 1H), 8.03 (t, J = 7.7 Hz, 1H), 7.89 (t, J = 7.7 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 
7.80 (d, J = 7.7 Hz, 1H), 7.26 (multiple peaks, 2H), 7.07 (s, 1H), 6.90 (d, J = 8.0 Hz, 2H), 
6.81 (multiple peaks, 2H), 2.32 (s, 3H) and 1.43 (s, 3H). 
13
C{
1
H} NMR (CDCl3): δ 
175.94, 161.56, 158.30, 151.35 (m), 151.21 (m), 150.16, 141.64, 140.00, 136.46, 130.67 
(d, J = 16.4 Hz), 129.50, 125.24, 124.37, 122.80, 122.21, 121.90 (q, J = 384 Hz) 69.97, 
22.98 (d, J = 4 Hz), 20.49. 
19
F NMR (CDCl3): δ –312.97 (m), –33.80 (d, J = 3.2 Hz). 
HRMS electrospray (m/z): [M + H]
+
 calcd for C21H19F4N3OPd, 512.0572; found, 
512.0570. 
Preparation of (MeO-dpaa)Pd
IV
(4-MeC6H4)(CF3)(F) (23). When the reaction of 
13 with NFTPT was carried out under slightly different conditions, compound 23 was 
formed as a by-product. The procedure that generated 23 is as follows: (dpaa)Pd
II
(4-
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MeC6H4)(CF3) (13) (150 mg; 0.30 mmol) was dissolved in CH2Cl2 (5 mL), and NFTPT 
(110 mg; 0.38 mmol) was added. The reaction mixture was stirred at rt for 20 min. The 
solvent was then removed under reduced pressure, and the crude mixture was purified on 
a silica gel column that was eluted first with ethyl acetate, then with THF, and finally 
with 10% methanol in THF. The major isomer 21 eluted first followed by the minor side 
product 23. Both products 21 (60 mg; 39%) and 23 (38 mg; 24%) were obtained as 
yellow powders. Analytical data for 23: 
1
H NMR (CDCl3): δ 8.88 (d, J = 5.2 Hz, 1H), 
8.25 (d, J = 5.2 Hz, 1H), 7.93 (multiple peaks, 3H), 7.74 (d, J = 7.9 Hz, 1H), 7.41 (m, 
1H), 7.28 (multiple peaks, 3H), 6.92 (d, J = 8.1 Hz, 2H), 3.16 (s, 3H), 2.32 (s, 3H), 1.86 
(s, 3H). 
13
C{
1
H} NMR (CDCl3): δ 182.17, 158.95, 158.58, 152.52 (m), 147.98, 147.86, 
140.42, 140.11, 135.98, 132.04, 132.00, 129.12, 125.04, 124.50, 121.34, 120.94, 116.81 
(q, J = 378 Hz), 99.87, 52.69, 26.11 (m), 20.56. 
19
F NMR (CDCl3): δ –284.40 (s), –25.58 
(s). HRMS electrospray (m/z): [M + H]
+
 calcd for C22H22F4N3O2Pd, 542.0678; found, 
542.0678.   
Preparation of (dpph)Pd
IV
(4-MeC6H4)(CF3)(Cl) (27). NFTPT (230 mg; 0.80 
mmol) was added to a solution of (dpph)Pd
II
(4-MeC6H4)(CF3) (14) (340 mg; 0.64 mmol) 
in CH2Cl2 (30 mL) at rt. The reaction mixture was stirred at rt for 10 min, and then it was 
washed with water (4 × 15 mL) and brine (2 × 15 mL). The CH2Cl2 layer was collected, 
dried over anhydrous Na2SO4, and evaporated under reduced pressure. The resulting 
residue was suspended in ethyl acetate (5 mL), and the suspended solids were collected 
by filtration and washed with ethyl acetate (2 x 3 mL). The resulting white powder was 
dissolved in chloroform (4 mL) from which a crystalline product started to precipitate. 
This product was collected by filtration and dried under reduced pressure. Yield: 213 mg 
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(59%) of a white powder. In order to resolve broad resonances, the 
1
H- and 
13
C-NMR 
spectra were obtained at 0 
o
C. Rotation around palladium-tolyl bond at room temperature 
and below is slow on the NMR timescale, so there is a distinct signal for each tolyl CH in 
both the 
1
H- and 
13
C-NMR spectra. 
1
H NMR (CD2Cl2 at 0
 ºC): δ 9.42 (d, J = 5.4 Hz, 1H), 
8.44 (d, J = 5.1 Hz, 1H), 8.12 (d, J = 7.8 Hz, 1H), 7.92 (t, J = 7.7 Hz, 1H), 7.84 (multiple 
peaks, 2H), 7.78 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.44 (multiple peaks, 2H), 
7.22 (t, J = 7.3 Hz, 1H), 7.13 (t, J = 6.6 Hz, 1H), 7.06 (multiple peaks, 2H), 6.55 (d, J = 
7.8 Hz, 1H), 5.83 (d, J = 7.7 Hz, 1H), 2.71 (br. s, 3H), 2.27 (s, 3H). 
13
C{
1
H} NMR 
(CD2Cl2 at 0
 ºC): δ 159.84 (q, J = 2.4 Hz), 157.27, 156.78, 155.57 (q, J = 3.9 Hz), 154.20, 
152.64, 139.96, 139.88, 137.35, 136.73, 136.47, 134.97, 134.35, 128.22, 128.13, 127.66, 
126.20, 126.07 (q, J = 369 Hz), 124.84, 123.58, 123.27, 121.58, 121.26, 56.50, 23.24, 
20.44. 
19
F NMR (CD2Cl2 at 0 ºC): δ –23.89 (s). HRMS electrospray (m/z): [M – Cl]
+
 
calcd for C26H22F3N2Pd, 525.0764; found, 525.0763. 
Preparation of [(dpph)Pd
IV
(4-MeC6H4)(CF3)(t-BuNC)]OTf (28). A suspension 
of (dpph)Pd
IV
(4-MeC6H4)(CF3)(Cl) (27) (110 mg; 0.20 mmol) and silver triflate (62 mg; 
0.24 mmol) in CH2Cl2 (15 mL) was sonicated for 15 min at rt. The AgCl precipitate was 
removed by filtration, tert-butyl isocyanide (25.0 mg; 0.30 mmol) was added, and the 
resulting solution was stirred for 3 min. The volatiles were removed under reduced 
pressure, and the product was suspended in diethyl ether (10 mL), filtered, washed with 
diethyl ether (3 × 3 mL), and dried under reduced pressure. Yield: 114 mg (95%) of a 
white powder. In order to resolve broad resonances, the 
1
H- and 
13
C-NMR spectra were 
measured at 0 
o
C. Rotation around the palladium-tolyl bond at room temperature and 
below is slow on the NMR timescale so there is a distinct signal for each tolyl CH 
 42 
 
fragment in both 
1
H- and 
13
C-NMR spectra. Several overlapping signals in the 
13
C-NMR 
spectrum were resolved by 
1
H-
13
C HSQC, 
1
H-
13
C HMBC, 
19
F-
13
C HSQC, and 
19
F-
13
C 
HMBC NMR experiments. Because of a very low intensity, the carbon resonance of the 
CF3 group could not be observed directly in the 
13
C-NMR spectrum. This value was 
extracted from the 
19
F-
13
C HSQC NMR spectrum.  
1
H NMR (CDCl3 at 0 ºC): δ 8.87 (d, J 
= 4.9 Hz, 1H), 8.12 (multiple peaks, 4H), 7.93 (d, J = 5.1 Hz, 1H), 7.69 (d, J = 8.1 Hz, 
1H), 7.51 (multiple peaks 2H), 7.42 (d, J = 8.1 Hz, 1H), 7.29 (t, J = 6.4 Hz, 1H), 7.22 (t, 
J = 7.6 Hz, 1H), 7.06 (multiple peaks, 2H), 6.63 (d, J = 8.1 Hz, 1H), 5.81 (d, J = 8.1 Hz, 
1H), 2.77 (br, 3H), 2.27 (s, 3H), 1.55 (s, 9H). 
13
C{
1
H} NMR (CDCl3 at 0 ºC): δ 159.77, 
157.55, 157.17, 152.77, 151.80, 150.83, 142.32, 141.88, 137.18, 136.07 (two overlapping 
resonances), 135.60 (two overlapping resonances), 133.80, 130.38, 128.89, 128.84, 
127.23, 125.84 (shift for the CF3 group extracted from the 
19
F-
13
C HSQC spectrum), 
125.49, 124.71, 124.69, 124.50 (two overlapping resonances), 120.75 (q, J = 321 Hz 
CF3SO2O
–
), 59.71, 57.41, 29.52, 23.36, 20.72. 
19
F (CDCl3 at 0 ºC): –20.12 (s), –78.28 (s). 
HRMS electrospray (m/z): [M – OTf]+ calcd for C31H31F3N3Pd, 608.1499; found, 
608.1500. IR (KBr): ν 3490 (s, br), 2987 (s, br), 2225 (s), 1602 (s), 1561 (w), 1470 (s), 
1275 cm
-1
 (s, br). 
Preparation of [(dpph)Pd
IV
(4-MeC6H4)(CF3)(PMe3)]OTf (29). A suspension of 
(dpph)Pd
IV
(4-MeC6H4)(CF3)(Cl) (27) (110 mg; 0.20 mmol) and silver triflate (62 mg; 
0.24 mmol) in CH2Cl2 (15 mL) was sonicated for 15 min at rt. The AgCl precipitate was 
removed by filtration, PMe3 (50.0 mg; 0.66 mmol) was added, and the resulting solution 
was stirred for 3 min. The volatiles were removed under reduced pressure, and the 
product was suspended in diethyl ether (10 mL). The suspended solids were collected by 
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filtration, washed with diethyl ether (3 × 3 mL), and dried under reduced pressure. Yield: 
124 mg (84%) of a white powder. 
1
H NMR (CD2Cl2): δ 8.86 (d, J = 5.4 Hz, 1H), 8.18 
(multiple peaks, 4H), 8.08 (d, J = 5.6 Hz, 1H), 7.32 (t, J = 6.1 Hz, 1H), 7.58 (multiple 
peaks, 2H), 7.48 (dd, J = 9.6, 8.4 Hz, 1H), 7.40 (t, J = 6.2 Hz, 1H), 7.25 (t, J = 7.5 Hz, 
1H), 7.17 (dd, J = 8.2, 1.9 Hz, 1H), 7.09 (m, 1H), 6.78 (d, J = 7.9 Hz, 1H), 6.09 (d, J = 
7.9 Hz, 1H), 2.82 (br. s, 3H), 2.34 (s, 3H), 1.11 (d, J = 8.8 Hz, 9H). 
13
C{
1
H} NMR 
(CD2Cl2): δ 163.27 (d, J = 133.5 Hz), 158.78, 158.10, 153.77, 151.42 (d, J = 3.4 Hz), 
150.87 (d, J = 4.1 Hz), 142.12, 141.88, 137.19, 136.48 (d, J = 13.6 Hz), 136.24, 135.86, 
134.32, 130.22, 128.87, 128.58 (d, J = 10.9 Hz), 127.47 (shift for the CF3 group extracted 
from the 
19
F/
13
C ASAPHMQC spectrum), 126.87, 125.48 (d, J = 9.5 Hz), 124.70, 124.51, 
124.34, 124.17, 120.97 (q, J = 321.5 Hz), 57.31, 23.78, 20.31, 13.45 (d, J = 19.1 Hz). 
19
F 
NMR (CDCl3): δ –18.11 (d, J = 20.7 Hz), –76.88 (s). 
31
P{
1
H} NMR (CD2Cl2): –16.38 (q, 
J = 20.8 Hz). HRMS electrospray (m/z): [M – OTf]+ calcd for C29H31F3N2PPd, 601.1206; 
found, 601.1196. 
Preparation of [(dpph)Pd
IV
(4-MeC6H4)(CF3)(NPhth)] (30). A suspension of 
(dpph)Pd
IV
(4-MeC6H4)(CF3)(Cl) (27) (50.0 mg; 0.089 mmol) and silver triflate (29 mg; 
0.11 mmol) in CH2Cl2 (15 mL) was sonicated for 15 min at rt. The AgCl precipitate was 
removed by filtration, and the resulting CH2Cl2 solution was washed with solution of 
potassium phthalimide (74 mg; 0.40 mmol) in water (2 mL). The CH2Cl2 solution was 
then washed with water (3 × 5 mL) and dried over anhydrous Na2SO4. The solvent was 
removed under reduced pressure, and the product was suspended in diethyl ether (10 
mL). The suspended solids were collected by filtration, washed with diethyl ether (3 × 3 
mL), and dried under reduced pressure. Yield: 45 mg (75%) of a white powder. In order 
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to resolve broad resonances, the 
1
H- and 
13
C-NMR spectra were measured at –51 ºC. 
Rotation around palladium-tolyl and palladium-NPhth bond at –51oC is slow on the NMR 
timescale, so there is a distinct signal for each tolyl and NPhth atom in both 
1
H- and 
13
C-
NMR spectra. 
1
H NMR (CDCl3 at –51 ºC): δ 9.37 (d, J = 8.3 Hz, 1H), 8.89 (d, J = 5.1 
Hz, 1H), 8.08 (d, J = 5.1 Hz, 1H), 7.92 (multiple peaks, 2H), 7.84 (multiple peaks, 2H), 
7.78 (d, J = 7.3 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.52 (t, J = 7.2 Hz, 1H), 7.43 (d, J = 
8.1 Hz, 1H), 7.28 (t, J = 7.2 Hz, 1H), 7.10-7.22 (multiple peaks, 4H), 7.02 (t, J = 7.5 Hz, 
1H), 6.96 (t, J = 6.4 Hz, 1H), 6.40 (d, J = 8.3 Hz, 1H), 5.55 (d, J = 8.3 Hz, 1H), 2.96 (t, J 
= 12.5 Hz, 1H), 2.78 (t, J = 12.8 Hz, 1H), 2.71 (t, J = 12.6 Hz, 1H), 2.22 (s, 3H). 
13
C{
1
H} 
NMR (CDCl3 at –51 ºC): δ 180.67, 180.52, 159.04, 156.40, 156.21, 155.66, 153.40, 
150.28, 140.02 (two overlapping signals as evident in the 
1
H/
13
C ASAPHMQC 
spectrum), 139.72, 139.50, 138.27, 137.06, 135.63, 134.32, 134.21, 132.06, 131.68, 
128.04, 128.01, 127.82, 125.98, 125.59 (shift for the CF3 group extracted from the 
19
F/
13
C ASAPHMQC spectrum), 124.68, 123.81 (two overlapping signals as evident in 
the 
1
H/
13
C ASAPHMQC spectrum), 123.36, 121.89, 121.52, 120.76, 56.78, 24.00, 20.98. 
19
F NMR (CDCl3 at –51 ºC): δ –23.03 (s). HRMS electrospray (m/z): [M – NPhth]
+
 calcd 
for C26H22F3N2Pd, 525.0764; found, 525.0769. 
Preparation of [(dpph)Pd
IV
(4-MeC6H4)(CF3)(4-NO2-C6H4O)] (31). A 
suspension of (dpph)Pd
IV
(4-MeC6H4)(CF3)(Cl) (27) (55 mg; 0.10 mmol) and silver 
triflate (33 mg; 0.13 mmol) in CH2Cl2 (15 mL) was sonicated for 15 min at rt. The AgCl 
precipitate was removed by filtration, and the resulting CH2Cl2 solution was washed with 
solution of sodium 4-nitrophenolate (21 mg; 0.13 mmol) in water (2 mL). The CH2Cl2 
solution was then washed with water (5 × 5 mL) and dried over anhydrous Na2SO4. The 
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solvent was removed under reduced pressure, and the product was suspended in diethyl 
ether (10 mL). The suspended solids were collected by filtration, washed with diethyl 
ether (3 × 3 mL), and dried under reduced pressure. Yield: 50 mg (77%) of a yellow 
powder. In order to resolve broad resonances, the 
1
H- and 
13
C-NMR spectra were 
measured at –27 oC and –21 oC, respectively. Rotation around palladium-tolyl bond at 
room temperature and below is slow on the NMR timescale so there is a distinct signal 
for each tolyl CH fragment in both 
1
H- and 
13
C-NMR spectra. 
1
H NMR (CD2Cl2 at –27 
ºC): δ 8.94 (d, J = 5.3 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.97 (multiple peaks, 2H), 7.89 
(d, J = 8.1 Hz, 1H), 7.83 (t, J = 7.5 Hz, 1H), 7.64 (d, J = 5.2 Hz, 1H), 7.55 (d, J = 7.9 Hz, 
1H), 7.52 (d, J = 7.9 Hz, 1H), 7.46 (d, J = 9.1 Hz, 2H), 7.29 (t, J = 6.6 Hz, 1H), 7.24 (t, J 
= 7.2 Hz, 1H), 7.20 (d, J = 7.9 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 6.87 (t, J = 6.4 Hz, 1H), 
6.62 (d, J = 7.6 Hz, 1H), 5.99 (d, J = 7.9 Hz, 1H), 5.33 (d, J = 8.9 Hz, 2H), 2.73 (br. s, 
3H), 2.29 (s, 3H). 
13
C{
1
H} NMR (CD2Cl2 at –21 ºC): δ 178.23, 159.18, 158.99, 158.75, 
156.74, 154.37, 153.29, 142.45, 142.38, 138.68, 137.99, 137.71, 136.99, 136.14, 135.54, 
130.68, 130.57, 130.16, 128.24, 127.99, 126.86, 126.77 (shift for the CF3 group extracted 
from the 
19
F/
13
C ASAPHMQC spectrum), 125.96, 125.67, 124.22, 123.93, 121.50, 58.62, 
24.97, 22.50. 
19
F NMR (CD2Cl2 at –21 ºC): δ –29.67 (s). HRMS electrospray (m/z): [M – 
NO2C6H4O]
+
 calcd for C26H22F3N2Pd, 525.0764; found, 525.0771. 
Preparation of (dpph)Pd
II
(2-PhC6H4)(I) (32). Pd(dba)2 (316 mg; 0.66 mmol) was 
added to a solution of 2-iodobiphenyl (390 mg; 1.40 mmol) and 4-tert-butylpyridine (300 
mg; 2.2 mmol) in THF (12 mL) at rt. The resulting homogenous solution was stirred at rt 
for 1 h, and then 1,1-di-(2-pyridyl)phenylethane (dpph) (6) (364 mg; 1.40 mmol) was 
added. The reaction mixture was stirred for 5 min and then filtered through a pad of 
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celite. The volatiles were removed under reduced pressure. The resulting residue was 
suspended in hexanes (30 mL), and the suspended solids were collected by filtration and 
washed with diethyl ether (5 × 15 mL).  The crude product was obtained as a yellowish 
powder (387 mg; 46%) and it was typically used without further purification. A sample 
for characterization was obtained by crystallization from ethyl acetate. Rotation around 
C-phenyl bond is slow on the NMR timescale at room temperature. In order to resolve 
broad resonances, the 
1
H- and 
13
C-NMR spectra were measured at 46 ºC. 
1
H NMR 
(CDCl3 at 46 ºC): δ 9.52 (d, J = 4.5 Hz, 1H), 8.47 (d, J = 6.2 Hz, 2H), 8.04 (d, J = 5.2 Hz, 
1H), 7.83 (t, J = 7.6 Hz, 1H), 7.73 (multiple peaks, 2H), 7.68 (d, J = 7.2 Hz, 1H), 7.40 
(multiple peaks, 5H), 7.28 (t, J = 6.6 Hz, 1H), 7.21 (multiple peaks, 2H), 6.96 (dd, J = 
5.3, 9.1 Hz, 1H), 6.84 (t, J = 7.2 Hz, 1H), 6.74 (bs, 2H), 6.62 (t, J = 6.9 Hz, 1H), 6.52 (br. 
s, 1H), 2.19 (s, 3H). 
13
C{
1
H} NMR (CDCl3 at 46 ºC): δ 161.80, 159.86, 155.36, 153.03, 
148.03, 145.31, 144.77, 142.47, 138.66, 137.97, 137.76, 130.59, 129.46, 129.28, 128.95, 
127.43, 127.32, 126.07, 123.59, 123.40, 123.25, 123.17, 123.11, 122.45, 57.89, 30.30. 
HRMS electrospray (m/z): [M – I]+ calcd for C30H25N2Pd, 519.1047; found, 519.1052. 
Preparation of (dpph)Pd
IV
(biphe)(Cl) (34). Silver trifluoroacetate (77 mg; 0.35 
mmol) was added to a solution of (dpph)Pd
II
(2-PhC6H4)(I) (32) (200 mg; 0.31 mmol) in 
CH2Cl2 (10 mL) at rt. The reaction mixture was stirred at rt for 15 min, and then this 
mixture was filtered through a pad of celite. The volume of the solution was reduced to 
15 mL. NFTPT (116 mg; 0.4 mmol) was added, and the reaction was stirred at room 
temperature for 15 min. The reaction mixture was then was washed with water (3 × 10 
mL) and brine (2 × 10 mL), dried over anhydrous Na2SO4, and concentrated under 
reduced pressure. The resulting residue was dissolved in minimal amount of CH2Cl2 and 
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filtered through a plug of silica gel that had been pre-equilibrated with a 1/1 mixture of 
MeOH and CH2Cl2. The filtrate was collected and evaporated under reduced pressure, 
and the resulting residue was suspended in ethyl acetate (5 mL), and the suspended solids 
were collected by filtration, washed with ethyl acetate (3 × 3 mL), and dried under 
vacuum. Yield: 89 mg (52%) of a white powder. 
1
H NMR (CD2Cl2): δ 9.26 (dd, J = 5.5, 
1.7 Hz, 2H), 7.95 (td, J = 7.7, 1.7 Hz, 2H), 7.88 (d, J = 8.3 Hz, 2H), 7.74 (dd, J = 7.6 Hz, 
1.6 Hz, 2H), 7.54 (dd, J = 7.9, 1.2 Hz, 1H), 7.48 (t, J = 4.5 Hz, 2H), 7.20 (t, J = 7.4 Hz, 
2H), 7.00 (t, J = 5.3 Hz, 1H), 6.83 (td, J = 7.4, 1.4 Hz, 2H), 6.73 (d, J = 7.9 Hz, 2H), 6.64 
(t, J = 5.4 Hz, 1H), 6.46 (dd, J = 7.9, 1.2 Hz, 1H), 2.77 (s, 3H). 
13
C{
1
H} NMR (CD2Cl2): 
δ 169.60, 157.85, 152.98, 151.22, 149.69, 139.49, 137.28, 136.60, 130.57, 126.84, 
125.97, 125.25, 125.12, 124.75, 123.67, 123.11, 121.15, 56.24, 23.40. HRMS 
electrospray (m/z): [M + Na]
+
 calcd for C30H23ClN2NaPd, 575.0477; found 575.0479. 
 
X-ray structure determination for (dpph)Pd
II
(4-MeC6H4)(CF3) (14). Colorless 
needles of 14 were grown from an ethyl acetate solution of the compound at 23 deg. C.  
A crystal of dimensions 0.14 x 0.10 x 0.09 mm was mounted on a Rigaku AFC10K 
Saturn 944+ CCD-based X-ray diffractometer equipped with a low temperature device 
and Micromax-007HF Cu-target micro-focus rotating anode ( = 1.54187 A) operated at 
0.2 kW power (20 kV, 10 mA).  The X-ray intensities were measured at 85(1) K with the 
detector placed at a distance 42.00 mm from the crystal.  A total of 1561 images were 
collected with an oscillation width of 2.0 in  The exposure time was 20 sec. for the 
low angle images, 45 sec. for high angle.  The integration of the data yielded a total of 
23642 reflections to a maximum 2 value of 136.46 of which 3880 were independent 
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and 3814 were greater than 2(I).  The final cell constants were based on the xyz 
centroids of 22979 reflections above 10(I).  Analysis of the data showed negligible 
decay during data collection; the data were processed with CrystalClear 2.0 and corrected 
for absorption.  The structure was solved and refined with the Bruker SHELXTL (version 
2008/4) software package, using the space group P1bar with Z = 2 for the formula 
C26H23N2F3Pd, 2(C24H20B).  Full matrix least-squares refinement based on F2 
converged at R1 = 0.0173 and wR2 = 0.0425 [based on I > 2sigma(I)], R1 = 0.0176 and 
wR2 = 0.0427 for all data.  There is a minor substitutional site disorder of the –CF3 
group bonded to palladium, which was refined as the contribution of 6.0% iodide.  
Additional details are presented below. 
 
Crystal data and structure refinement for 14. 
  
      Identification code                am352 
      Empirical formula                  C25.94 H23 F2.82 I0.06 N2 Pd 
      Formula weight                     529.95 
      Temperature                        85(2) K 
      Wavelength                         1.54178 A 
      Crystal system, space group        Triclinic,  P -1 
      Unit cell dimensions               a = 9.6736(2) A   alpha = 73.482(5) deg. 
                                          b = 11.0702(2) A  beta = 75.138(5) deg. 
                                          c = 11.2344(8) A  gamma = 73.681(5) deg. 
      Volume                              1086.38(8) A^3 
      Z, Calculated density              2,  1.620 Mg/m^3 
      Absorption coefficient             7.850 mm^-1 
      F(000)                              533.1 
      Crystal size                        0.14 x 0.10 x 0.09 mm 
      Theta range for data collection    4.18 to 68.23 deg. 
      Limiting indices                   -11<=h<=11, -13<=k<=13, -13<=l<=13 
      Reflections collected / unique     23642 / 3880 [R(int) = 0.0297] 
      Completeness to theta = 68.23     97.5% 
      Absorption correction              Semi-empirical from equivalents 
      Max. and min. transmission         0.521 and 0.411 
      Refinement method                  Full-matrix least-squares on F^2 
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      Data / restraints / parameters     3880 / 0 / 301 
      Goodness-of-fit on F^2             1.034 
      Final R indices [I>2sigma(I)]      R1 = 0.0173, wR2 = 0.0425 
      R indices (all data)               R1 = 0.0176, wR2 = 0.0427 
      Largest diff. peak and hole        0.299 and -0.381 e.A^-3 
  
 
Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 x 
10^3) for 14. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
__________________________________________________________________________  
 
                            x                 y                  z        U(eq) 
__________________________________________________________________________ 
           Pd(1)         3046(1)        3185(1)        7036(1)        9(1) 
           F(1)          5380(1)        1940(1)        8416(1)       17(1) 
           F(2)          5321(1)         881(1)        7105(1)       20(1) 
           F(3)          6249(1)        2565(1)        6435(1)       23(1) 
           N(1)          2260(1)        1721(1)        6654(1)       11(1) 
           N(2)           896(2)        4288(1)        6870(1)       12(1) 
           C(1)          3019(2)        1070(2)        5759(2)       14(1) 
           C(2)          2533(2)         143(2)        5477(2)       18(1) 
           C(3)          1236(2)        -162(2)        6186(2)       22(1) 
           C(4)           433(2)         510(2)        7109(2)       20(1) 
           C(5)           952(2)        1476(2)        7306(2)       13(1) 
           C(6)            42(2)        2351(2)        8214(2)       13(1) 
           C(7)          -268(2)        3745(2)        7403(2)       13(1) 
           C(8)         -1670(2)        4427(2)        7211(2)       18(1) 
           C(9)         -1873(2)        5678(2)        6468(2)       20(1) 
           C(10)         -678(2)        6222(2)        5928(2)       18(1) 
           C(11)         693(2)        5499(2)        6148(2)       14(1) 
           C(12)          821(2)        2288(2)        9276(2)       13(1) 
           C(13)         2013(2)        1302(2)        9605(2)       14(1) 
           C(14)         2554(2)        1208(2)       10672(2)     17(1) 
         C(15)         1902(2)        2094(2)       11423(2)     18(1) 
           C(16)          722(2)        3086(2)       11097(2)     20(1) 
           C(17)          191(2)        3184(2)       10032(2)     16(1) 
           C(18)        -1394(2)        1923(2)        8894(2)       20(1) 
           C(19)         3626(2)        4623(2)        7395(2)       12(1) 
           C(20)         3963(2)        5673(2)        6427(2)       14(1) 
           C(21)         4180(2)        6754(2)        6695(2)       16(1) 
           C(22)         4111(2)        6816(2)        7928(2)       15(1) 
           C(23)         3827(2)        5749(2)        8890(2)       15(1) 
           C(24)         3585(2)        4674(2)        8631(2)       14(1) 
           C(25)         4309(2)        8007(2)        8211(2)       22(1) 
           C(26)         5072(3)        2136(2)        7254(2)       14(1) 
           I(1)          5682(3)        1962(2)        6990(2)       15(1) 
________________________________________________________________________  
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X-ray structure determination for (dpsa)Pd
IV
(4-MeC6H4)(CF3)(Cl) (18). 
Yellow, block-like crystals of 18 were grown from an acetonitrile/methyl t-butyl ether 
solution at 23 deg. C.  A crystal of dimensions 0.15 x 0.13 x 0.12 mm was mounted on a 
Rigaku AFC10K Saturn 944+ CCD-based X-ray diffractometer equipped with a low 
temperature device and Micromax-007HF Cu-target micro-focus rotating anode ( = 
1.54187 A) operated at 0.2 kW power (20 kV, 10 mA).  The X-ray intensities were 
measured at 85(1) K with the detector placed at a distance 42.00 mm from the crystal.  A 
total of 1506 images were collected with an oscillation width of 2.0 in  The exposure 
time was 10 sec. per image for low angle and 30 seconds for high angle images.   The 
integration of the data yielded a total of 34052 reflections to a maximum 2 value of 
136.44 of which 5929 were independent and 5842 were greater than 2(I).  The final 
cell constants were based on the xyz centroids of 18798 reflections above 10(I).  
Analysis of the data showed negligible decay during data collection; the data were 
processed with CrystalClear 2.0 and corrected for absorption.  The structure was solved 
and refined with the Bruker SHELXTL (version 2008/4) software package, using the 
space group P1bar with Z = 2 for the formula C29H35ClF3N5O2PdS, 2(C2H3N).  Full 
matrix least-squares refinement based on F2 converged at R1 = 0.0297 and wR2 = 0.0729 
[based on I > 2sigma(I)], R1 = 0.0304 and wR2 = 0.0734 for all data.  The acetonitrile 
solvates and the t-butylphenylsulfonamido ligand are disordered.  Additional details are 
presented in below. 
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Crystal data and structure refinement for 18. 
  
      Identification code                am341 
      Empirical formula                  C33 H35 Cl F3 N5 O2 Pd S 
      Formula weight                     764.57 
      Temperature                        85(2) K 
      Wavelength                         1.54178 A 
      Crystal system, space group        Triclinic,  P -1 
      Unit cell dimensions               a = 9.9337(2) A   alpha = 67.070(5) deg. 
                                          b = 13.4448(3) A    beta = 78.111(5) deg. 
                                          c = 14.1447(10) A   gamma = 73.844(5) deg. 
      Volume                              1660.93(13) A^3 
      Z, Calculated density              2,  1.529 Mg/m^3 
      Absorption coefficient             6.306 mm^-1 
      F(000)                              780 
      Crystal size                        0.15 x 0.13 x 0.12 mm 
      Theta range for data collection    3.41 to 68.22 deg. 
      Limiting indices                   -11<=h<=11, -16<=k<=16, -17<=l<=17 
      Reflections collected / unique     34052 / 5929 [R(int) = 0.0485] 
      Completeness to theta = 68.22      97.6% 
      Absorption correction              Semi-empirical from equivalents 
      Max. and min. transmission         0.474 and 0.416 
      Refinement method                  Full-matrix least-squares on F^2 
      Data / restraints / parameters     5929 / 183 / 560 
      Goodness-of-fit on F^2             1.056 
      Final R indices [I>2sigma(I)]      R1 = 0.0270, wR2 = 0.0694 
      R indices (all data)               R1 = 0.0273, wR2 = 0.0696 
      Largest diff. peak and hole        0.472 and -0.599 e.A^-3 
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 Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 x 
10^3) for 18. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
__________________________________________________________ 
                              x                  y                  z            U(eq) 
__________________________________________________________ 
          S(1)  2806(1)        1439(1)        3965(1)        23(1) 
          Pd(1)  4004(1)        2579(1)        1436(1)        14(1) 
          Cl(1)  4659(1)        3494(1)        -277(1)        28(1) 
          F(1)  1478(1)        3814(1)        2163(1)        43(1) 
          F(2)  2453(2)        4834(1)         774(1)        49(1) 
          F(3)  3350(1)        4303(1)        2192(1)        42(1) 
          O(1)  1414(1)        1705(1)        3672(1)        33(1) 
          O(2)  3273(1)         362(1)        4725(1)        27(1) 
          N(1)          5352(2)        1056(1)        1368(1)        15(1) 
          N(2)          5860(2)        2751(1)        1917(1)        18(1) 
          N(3)          3908(2)        1560(1)        2954(1)        16(1) 
          C(1)          5718(2)         689(2)         580(1)        22(1) 
          C(2)          6599(2)        -335(2)         680(2)        32(1) 
          C(3)          7126(2)        -982(2)        1615(2)        31(1) 
          C(4)          6761(2)        -598(2)        2429(2)        24(1) 
          C(5)          5856(2)         425(1)        2283(1)        16(1) 
          C(6)          5402(2)         998(1)        3066(1)        16(1) 
          C(7)          6300(2)        1857(1)        2733(1)        17(1) 
          C(8)          7515(2)        1716(2)        3148(1)        21(1) 
          C(9)          8305(2)        2524(2)        2693(2)        24(1) 
          C(10)         7839(2)        3447(2)        1855(2)        28(1) 
          C(11)         6600(2)        3541(2)        1491(2)        24(1) 
          C(12)         2914(5)        2488(4)        4440(3)        20(1) 
          C(13)         1882(4)        3498(3)        4323(3)        21(1) 
          C(14)         1888(4)        4209(3)        4815(3)        22(1) 
          C(15)         2910(4)        3984(3)        5458(3)        19(1) 
          C(16)         3910(5)        3037(4)        5561(4)        19(1) 
          C(17)         3986(5)        2293(4)        5066(3)        16(1) 
          C(18)         2748(4)        4730(3)        6082(3)        17(1) 
          C(19)         4049(5)        4509(4)        6600(4)        29(1) 
          C(20)         1543(5)        4447(4)        6948(4)        27(1) 
          C(21)         2352(6)        5973(4)        5409(4)        26(1) 
          C(12A)        2773(6)        2318(4)        4612(3)        24(1) 
          C(13A)        1494(4)        2957(3)        4779(3)        23(1) 
          C(14A)        1455(4)        3644(3)        5310(3)        26(1) 
          C(15A)        2650(5)        3681(3)        5654(3)        18(1) 
          C(16A)        3980(7)        3000(5)        5419(4)        25(1) 
          C(17A)        3989(6)        2318(5)        4891(4)        24(1) 
          C(18A)        2526(5)        4457(4)        6246(4)        20(1) 
          C(19A)        3811(5)        4083(4)        6869(4)        31(1) 
          C(20A)        1182(6)        4495(5)        6987(4)        19(1) 
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          C(21A)        2565(6)        5622(4)        5453(4)        23(1) 
          C(22)         2337(2)        2251(2)        1059(1)        18(1) 
          C(23)         2057(2)        1210(2)        1580(1)        18(1) 
          C(24)          944(2)         953(2)        1322(1)        21(1) 
          C(25)          127(2)        1709(2)         552(1)        24(1) 
          C(26)          445(2)        2746(2)          32(2)        27(1) 
          C(27)         1554(2)        3021(2)         277(2)        26(1) 
          C(28)        -1077(2)        1420(2)         288(2)        33(1) 
          C(29)         2736(2)        3958(2)        1644(2)        31(1) 
          N(4)          3174(4)        8335(3)        3452(4)        53(1) 
          C(30)         2120(5)        8741(3)        3769(3)        33(1) 
          C(31)          725(6)        9325(4)        4106(4)        33(1) 
          N(6)          -232(4)        8106(4)        3241(4)        48(1) 
          C(34)          266(5)        8481(4)        3667(4)        36(1) 
          C(31A)         941(7)        8930(4)        4198(4)        35(1) 
          N(5)           183(4)        8098(3)        2542(3)        38(1) 
          C(32)         1184(4)        7462(3)        2492(3)        24(1) 
          C(33)         2550(3)        6687(2)        2334(2)        41(1) 
          N(7)          3496(4)        8367(3)        2271(3)        40(1) 
          C(35)         3107(5)        7639(3)        2259(3)        32(1) 
          C(33A)        2550(3)        6687(2)        2334(2)        41(1) 
 ____________________________________________________________________ 
 
X-ray structure determination for (dpsa)Pd
IV
(4-MeC6H4)(CF3)(F) (20). 
Yellow plates of 20 were grown from an acetonitrile/methyl t-butyl ether solution at 23 
deg. C.  A crystal of dimensions 0.20 x 0.10 x 0.06 mm was mounted on a Rigaku 
AFC10K Saturn 944+ CCD-based X-ray diffractometer equipped with a low temperature 
device and Micromax-007HF Cu-target micro-focus rotating anode ( = 1.54187 A) 
operated at 0.25 kW power (25 kV, 10 mA).  The X-ray intensities were measured at 
85(1) K with the detector placed at a distance 42.00 mm from the crystal.  A total of 3147 
images were collected with an oscillation width of 1.0 in  The exposure time was 10 
sec. per image for low angle and 40 seconds for high angle images.   The integration of 
the data yielded a total of 67691 reflections to a maximum 2 value of 136.46 of which 
5932 were independent and 5725 were greater than 2(I).  The final cell were based on 
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the xyz centroids of 67691 reflections above 10(I).  Analysis of the data showed 
negligible decay during data collection; the data were processed with CrystalClear 2.0 
and corrected for absorption.  The structure was solved and refined with the Bruker 
SHELXTL (version 2008/4) software package, using the space group C2/c with Z = 8 for 
the formula C29H29F4N3O2PdS, (C2H3N), (C5H12O)0.5.  Full matrix least-squares 
refinement based on F2 converged at R1 = 0.0470 and wR2 = 0.1170 [based on I > 
2sigma(I)], R1 = 0.0482 and wR2 = 0.1181 for all data. The acetonitrile and methyl t-
butyl ether solvates are disordered.  Additional details are presented in below. 
 
Crystal data and structure refinement for 20. 
      Identification code                am355 
      Empirical formula                  C33.50 H38 F4 N4 O2.50 Pd S 
      Formula weight                     751.14 
      Temperature                        85(2) K 
      Wavelength                         1.54178 A 
      Crystal system, space group        Monoclinic,  C2/c 
      Unit cell dimensions               a = 17.4944(3) A   alpha = 90 deg. 
                                          b = 22.1204(4) A   beta = 114.778(8) deg. 
                                          c = 18.4391(13) A   gamma = 90 deg. 
      Volume                              6478.7(5) A^3 
      Z, Calculated density              8,  1.540 Mg/m^3 
      Absorption coefficient             5.760 mm^-1 
      F(000)                              3080 
      Crystal size                        0.20 x 0.10 x 0.06 mm 
      Theta range for data collection    3.43 to 68.23 deg. 
      Limiting indices                   -21<=h<=21, -26<=k<=26, -22<=l<=22 
      Reflections collected / unique     67911 / 5932 [R(int) = 0.0499] 
      Completeness to theta = 68.23      100.0% 
      Absorption correction              Semi-empirical from equivalents 
      Max. and min. transmission         0.712 and 0.544 
      Refinement method                  Full-matrix least-squares on F^2 
      Data / restraints / parameters     5932 / 75 / 479 
      Goodness-of-fit on F^2             1.069 
      Final R indices [I>2sigma(I)]      R1 = 0.0470, wR2 = 0.1170 
      R indices (all data)               R1 = 0.0482, wR2 = 0.1181 
      Largest diff. peak and hole        1.075 and -1.361 e.A^-3  
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Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 x 
10^3) for 20. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________________ 
                               x                  y                  z            U(eq) 
__________________________________________________________________________ 
          S(1)          4127(1)        2737(1)        5379(1)        31(1) 
          Pd(1)         4866(1)        1952(1)        4238(1)        34(1) 
          F(1)          5390(1)        1590(1)        3595(1)        47(1) 
          F(2)          5830(2)        2740(1)        3773(2)        63(1) 
          F(3)          4736(1)        3162(1)        3793(2)        53(1) 
          F(4)          5833(1)        3024(1)        4877(1)        47(1) 
          O(1)          4985(1)        2844(1)        5926(1)        37(1) 
          O(2)          3537(1)        2567(1)        5705(1)        35(1) 
          N(1)          3678(2)        2088(1)        3193(2)        31(1) 
          N(2)          4261(2)        1128(1)        4285(2)        43(1) 
          N(3)          4124(2)        2215(1)        4776(2)        35(1) 
          C(1)          3534(2)        2129(1)        2425(2)        34(1) 
          C(2)          2717(2)        2160(1)        1840(2)        34(1) 
          C(3)          2054(2)        2159(1)        2052(2)        34(1) 
          C(4)          2210(2)        2109(2)        2854(2)        35(1) 
          C(5)          3035(2)        2066(1)        3410(2)        31(1) 
          C(6)          3322(2)        1903(1)        4291(2)        36(1) 
          C(7)          3523(2)        1234(2)        4321(2)        41(1) 
          C(8)          2992(3)         766(2)        4302(2)        49(1) 
          C(9)          3245(3)         178(2)        4226(2)        59(1) 
          C(10)         3982(3)          78(2)        4183(2)        60(1) 
          C(11)         4509(3)         568(2)        4220(2)        53(1) 
          C(12)         3728(2)        3426(1)        4866(2)        32(1) 
          C(13)         2875(2)        3496(1)        4389(2)        33(1) 
          C(14)         2574(2)        4052(2)        4047(2)        37(1) 
          C(15)         3120(3)        4551(2)        4176(2)        42(1) 
          C(16)         3958(3)        4461(2)        4640(3)        55(1) 
          C(17)         4273(3)        3907(2)        4993(3)        50(1) 
          C(18)         2759(3)        5173(2)        3818(2)        47(1) 
          C(19)         2199(4)        5398(2)        4185(3)        74(2) 
          C(20)         2309(3)        5137(2)        2918(2)        49(1) 
          C(21)         3482(4)        5646(2)        4025(4)        93(2) 
          C(22)         5916(2)        1734(2)        5224(2)        40(1) 
          C(23)         5864(2)        1579(2)        5924(2)        40(1) 
          C(24)         6601(2)        1401(2)        6588(2)        43(1) 
          C(25)         7374(2)        1374(2)        6545(2)        42(1) 
          C(26)         7397(2)        1515(2)        5818(2)        44(1) 
          C(27)         6672(2)        1698(2)        5156(2)        44(1) 
          C(28)         8168(2)        1214(2)        7262(2)        48(1) 
          C(29)         5364(2)        2767(2)        4179(2)        39(1) 
          N(4)          5405(5)        9481(4)        3613(5)        65(2) 
          C(30)         5247(6)        9883(4)        3180(5)        57(2) 
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          C(31)         5079(10)      10418(4)        2646(8)        69(3) 
          N(5)          5372(5)        9061(4)        3373(6)        76(2) 
          C(32)         5176(5)        8636(4)        2984(5)        58(2) 
          C(33)         4888(5)        8078(4)        2522(7)        53(3) 
          O(3)          4718(4)        4896(3)        8126(3)        50(1) 
          C(34)         5197(6)        5432(4)        8427(5)        54(2) 
          C(35)         5020(20)       4554(3)        7500(30)       72(3) 
          C(36)         4321(6)        4006(4)        7395(6)        56(2) 
          C(37)         4621(6)        4914(4)        6777(5)        59(2) 
          C(38)         5798(5)        4350(5)        7897(6)        56(2) 
______________________________________________________________________ 
  
 
X-ray structure determination for [(dpph)Pd
IV
(4-MeC6H4)(CF3)(NPhth)] 
(30). Colorless needles of 30 were grown from a chloroform solution at 23 deg. C.  A 
crystal of dimensions 0.14 x 0.12 x 0.08 mm was mounted on a Rigaku AFC10K Saturn 
944+ CCD-based X-ray diffractometer equipped with a low temperature device and 
Micromax-007HF Cu-target micro-focus rotating anode ( = 1.54187 A) operated at 0.3 
kW power (30 kV, 10 mA).  The X-ray intensities were measured at 85(1) K with the 
detector placed at a distance 42.00 mm from the crystal.  A total of 1239 images were 
collected with an oscillation width of 1.5 in  The exposure time was 15 sec. per image 
for low angle and 35 seconds for high angle images.   The integration of the data yielded 
a total of 53247 reflections to a maximum 2 value of 136.48 of which 7380 were 
independent and 6784 were greater than 2(I).  The final cell constants were based on the 
xyz centroids of 41264 reflections above 10(I).  Analysis of the data showed negligible 
decay during data collection; the data were processed with CrystalClear 2.0 and corrected 
for absorption.  The structure was solved and refined with the Bruker SHELXTL (version 
2008/4) software package, using the space group P2(1)/n with Z = 4 for the formula 
C34H26F3N3O2Pd, 3(CHCl3). All non-hydrogen atoms were refined anisotropically with 
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the hydrogen atoms placed in idealized positions. The dichloromethane solvate molecules 
are disordered and were modeled as diffuse scattering by use of the SQUEEZE 
subroutine of the PLATON program suite.  Full matrix least-squares refinement based on 
F2 converged at R1 = 0.0504 and wR2 = 0.1316 [based on I > 2sigma(I)], R1 = 0.0556 
and wR2 = 0.1331 for all data.  Additional details are presented in below. 
 
Crystal data and structure refinement for 30. 
  
  
      Identification code                am3201 
      Empirical formula                  C37 H29 Cl9 F3 N3 O2 Pd 
      Formula weight                     1030.08 
      Temperature                        85(2) K 
      Wavelength                         1.54178 A 
      Crystal system, space group        Monoclinic,  P 1 21/n 1 
      Unit cell dimensions               a = 9.8196(2) A   alpha = 90 deg. 
                                          b = 19.3578(4) A    beta = 98.596(7) deg. 
                                          c = 21.4850(15) A   gamma = 90 deg. 
      Volume                              4038.1(3) A^3 
      Z, Calculated density              4,  1.694 Mg/m^3 
      Absorption coefficient             9.641 mm^-1 
      F(000)                              2056 
      Crystal size                        0.14 x 0.12 x 0.08 mm 
      Theta range for data collection    3.09 to 68.24 deg. 
      Limiting indices                   -11<=h<=11, -23<=k<=22, -25<=l<=25 
      Reflections collected / unique     53247 / 7380 [R(int) = 0.0644] 
      Completeness to theta = 68.24      99.8% 
      Absorption correction              Semi-empirical from equivalents 
      Max. and min. transmission         0.726 and 0.423 
      Refinement method                  Full-matrix least-squares on F^2 
      Data / restraints / parameters     7380 / 0 / 391 
      Goodness-of-fit on F^2             1.097 
      Final R indices [I>2sigma(I)]      R1 = 0.0524, wR2 = 0.1316 
      R indices (all data)               R1 = 0.0556, wR2 = 0.1331 
      Largest diff. peak and hole        0.850 and -1.138 e.A^-3 
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Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 x 
10^3) for 30.U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________________ 
                   x                  y                  z            U(eq) 
_______________________________________________________________________ 
          Pd(1)         5488(1)        1266(1)        1998(1)        16(1) 
          F(1)           3657(2)        2041(2)        1109(1)        34(1) 
          F(2)          2718(3)        1101(2)        1404(1)        33(1) 
          F(3)          2874(3)        2003(2)        1996(1)        33(1) 
          O(1)          6875(3)        -184(2)        1484(2)        34(1) 
          O(2)          2914(4)          18(2)        2364(2)        43(1) 
          N(1)          7505(3)         959(2)        2347(2)        17(1) 
          N(2)          6042(3)        1181(2)        1072(2)        17(1) 
          N(3)          4951(3)         154(2)        1931(2)        22(1) 
          C(1)          7724(4)         491(2)        2812(2)        22(1) 
          C(2)          9024(4)         248(2)        3044(2)        25(1) 
          C(3)          10112(5)         482(3)        2748(2)        35(1) 
          C(4)          9893(4)         955(2)        2280(2)        28(1) 
          C(5)          8571(4)        1201(2)        2066(2)        20(1) 
          C(6)          8224(4)        1730(2)        1544(2)        17(1) 
          C(7)          7305(4)        1407(2)         976(2)        21(1) 
          C(8)          7706(5)        1349(2)         389(2)        30(1) 
          C(9)          6781(5)        1072(2)        -119(2)        28(1) 
          C(10)         5505(5)         848(2)         -12(2)        30(1) 
          C(11)         5179(5)         907(2)         588(2)        26(1) 
          C(12)         9585(4)        1989(2)        1336(2)        26(1) 
          C(13)         7452(4)        2345(2)        1797(2)        19(1) 
          C(14)         8009(5)        3005(2)        1820(2)        31(1) 
          C(15)         7340(5)        3557(2)        2072(3)        36(1) 
          C(16)         6131(6)        3457(2)        2283(3)        37(1) 
          C(17)         5544(5)        2797(2)        2259(2)        31(1) 
          C(18)         6220(4)        2250(2)        2027(2)        22(1) 
          C(19)         5115(5)        1427(2)        2915(2)        24(1) 
          C(20)         6158(6)        1682(3)        3353(2)        40(1) 
          C(21)         5928(7)        1784(3)        3982(3)        50(2) 
          C(22)         4667(8)        1655(3)        4156(3)        59(2) 
          C(23)         3577(8)        1389(3)        3704(3)        54(2) 
          C(24)         3844(6)        1277(3)        3093(2)        38(1) 
          C(25)         4351(11)       1798(4)        4817(4)        86(3) 
          C(26)         5797(4)        -308(2)        1684(2)        22(1) 
          C(27)         5238(5)       -1019(2)        1704(2)        31(1) 
          C(28)         5672(6)       -1660(3)        1513(2)        43(1) 
          C(29)         4883(7)       -2236(3)        1612(3)        51(2) 
          C(30)         3705(8)       -2169(4)        1890(3)        60(2) 
          C(31)         3244(7)       -1539(3)        2084(3)        50(2) 
          C(32)         4031(5)        -975(3)        1974(2)        34(1) 
          C(33)         3883(5)        -203(3)        2128(2)        28(1) 
          C(34)         3601(4)        1627(2)        1614(2)        25(1) 
 ______________________________________________________________________ 
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Chapter 3: Investigation of C–H Activation at Palladium(IV)
1
 
 
3.1 Introduction 
Synthesis of biaryls via traditional Pd
0/II
 catalyzed cross-coupling reactions (e.g., 
Suzuki, Kumada, Stille, Hiyama) require prefunctionalized starting materials. Oxidative 
C–H/C–H cross-coupling present a much more efficient process. Until now poor regio- 
and substrate chemo- slectivities have been considered a major limitation of the oxidative 
coupling approach. However, in 2011 Yu and coworkers reported regioselective 
oxidative C–H/C–H coupling of benzamides with monosubstituted arenes (Scheme 3.1).2 
Extremely high C–H activation regioselectivities and unusual substate selectivities were 
rationalized by the unique reactivity of [ArPd
IV
F] species.  
 
Scheme 3.1 para-Selective arylation of monosubstituted arenes 
 
 
C–H activation at PdIV has been proposed to be a key process in several other 
catalytic reactions.
3
 For example, mechanistic studies have provided evidence that 
palladium catalyzed oxidative dimerization of 2-arylpyridines
4
 (Scheme 3.2) and N-
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fluorobenzenesulfonimide (NFBS) promoted carboamination of olefins
5
 (Scheme 3.3) 
involve C–H cleavage at PdIV as important step in the catalytic turnover. This example 
demonstrates remarkable selectivity of Pd
IV
 towards C–H cleavage that potentially can be 
exploited to develop wide variety of very efficient C–H functionalization reactions.   
 
Scheme 3.2 Oxidative dimerization of 2-arylpyridines 
 
Scheme 3.3 Carboamination of alkenes 
 
 
In order to improve currently known C–H functionalization and oxidative cross-
coupling reactions and to develop new methodologies, a better understanding of 
processes occurring at Pd
IV
 is necessary. As such, stoichiometric studies of the 
mechanism, selectivity, and relative rates of such fundamental reactions at Pd
IV
 centers 
could provide key insights for designing, and improving catalytic processes. While 
numerous studies have been published on reductive elimination from Pd
IV
,
6
 C–H 
activation at isolated, high oxidation state Pd centers is not a thoroughly investigated and 
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understood process. This is mainly due to the highly reactive nature of the catalytically 
relevant intermediates. 
A recent communication from our group described the first example of C–H 
activation at a Pd
IV
 center (Scheme 3.4).
7
 In this system, the oxidation of Pd
II
 precursor 1 
with PhICl2 at –35 ºC afforded Pd
IV
 complex 2 as a transient intermediate. Warming a 
solution of 2 to 25 ºC resulted in rapid C–H activation to generate cyclopalladated 
product 3. Coordinatively unsaturated cationic Pd
IV
 species like 4 or 5 (Figure 3.1) are 
likely intermediates in the conversion of 2 to 3; however, the low stability of 2 hampered 
more detailed mechanistic investigations of this system. 
 
Scheme 3.4 Intramolecular C–H activation at a PdIV 
 
 
Figure 3.1 Possible intermediates  
 
 
We hypothesized that replacing the bidentate 4,4’-di-tert-butylbipyridine ligand 
with a tridentate supporting ligand would stabilize analogues of 4 and 5, thereby enabling 
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a thorough mechanistic investigation of the C–H activation reaction. Canty and co-
workers have previously reported several organometallic Pd
IV
 tris(2-pyridil)methane 
(Py3CH) complexes that are stable to reductive elimination at room temperature.
8
 This 
led us to propose that the third pyridine arm of Py3CH might impart an appropriate 
balance of stability and reactivity to enable C–H activation at PdIV. 
 
3.2 Synthesis of the [(Py3CH)Pd
IV
(biphenyl)Cl2]X Model System 
Initial synthetic efforts targeted Pd
IV
 complexes of the general structure 
[(Py3CH)Pd
IV
(biphenyl)Cl2]X (Scheme 3.5). The tris(2-pyridil)methane (Py3CH) ligand 
was prepared in 1 step from -picoline and 2-fluoropyridine (see Experimental Section 
for complete details). Pd
II
 precursor 6 was obtained via oxidative addition of 
iodobiphenyl to Pd(dba)2 and subsequent ligation of (4-
t
BuPy)2Pd
II
(biphenyl)(I) 
intermediate to Py3CH ligand. 
 
Scheme 3.5 Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][X] Complexes 
 
The treatment of (Py3CH)Pd
II
(biphenyl)(I) (6) with 2 equivalents of PhICl2 in 
CH2Cl2 at room temperature (Scheme 3.5, method A) afforded the desired cationic Pd
IV
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product 7 in 85% yield as the ICl2
–
 salt. The corresponding chloride salt (8) was obtained 
under slightly modified reaction conditions (Scheme 3.5, method B). Finally, the 
treatment of 7 with 2 equiv of AgOTf resulted in smooth conversion to the triflate salt 9. 
As predicted, complexes 7-9 are significantly more stable than 2, and they can be stored 
in the solid state at room temperature for at least 4 weeks without detectable 
decomposition. 
The solution stereochemistry and conformations of 7-9 were elucidated via 1D 
1
H 
NMR and 2D 
1
H/
1
H NOESY and ROESY NMR spectra. The ROESY NMR spectrum 
and peak assignments for 7 are shown in Figure 3.2.  
 
 
Figure 3.2 
1
H/
1
H ROESY spectrum of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][ICl2] 
 
(spectrum acquired at 500 MHz) 
 
The most notable feature of the structure 7 is the orientation of the phenyl ring of the 
biaryl ligand underneath two of the pyridine rings. This conformation was assigned on 
the basis of the shielding of the aromatic protons H-1 and H-2 (to 5.9 and 6.6 ppm, 
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respectively) as well as by NOE correlations between H-1 and H-10/H-11. This 
conformation is likely due to favorable π-π interactions between the biphenyl and 
tripyridylmethane ligands. 
The 
1
H NMR spectra of 7-9 are highly dependent on the counterion X. The spin-
lattice relaxation times (T1) for 7 and 8 in CDCl3 at 25 ºC show that the ICl2
–
 and Cl
–
 
counterions have close interactions with H(8), H(12), and H(16) of the Py3CH ligand 
(Table 3.1). This is likely due to equilibration of the counterion between three similar 
sites (Scheme 3.6). Remarkably, these interactions persist even in the highly polar 
CD3NO2. In contrast, the triflate counterion in complex 9 does not have strong 
interactions with the Py3CH ligand in either CDCl3 or CD3NO2. Related binding of halide 
counterions to the ligand periphery of cationic Pd
IV
 complexes has been documented by 
Kraft and Canty.
9
 
 
Table 3.1 Spin-lattice relaxation times (T1) for complexes 7, 8 and 9 
 
 
Position T1 (X = ICl2) T1 (X = Cl) T1 (X = TfO) 
1 1,336 1,206 1,948 
2 0,769 0,673 1,802 
3 0,592 0,542 1,888 
4 2,216 2,108 2,367 
5 1,783 1,627 1,575 
6 1,641 1,656 2,173 
7 1,926 1,765 2,027 
8 0,099 0,088 1,363 
9 0,589 0,493 1,782 
10 1,123 0,929 1,661 
11 1,679 1,546 2,146 
12 0,14 0,121 1,551 
13 0,836 0,7 1,848 
14 1,404 1,255 1,751 
15 2,091 1,917 2,576 
16 0,086 0,071 1,003 
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Scheme 3.6 Binding of chloride counterion to [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2] 
 
 
The structure of complex 7 was further confirmed by mass spectrometry and 
single crystal X-ray diffraction analysis. High resolution ESI mass spectrometric analysis 
of 7-9 showed an intense peak with m/z = 576.022 corresponding to the cationic Pd
IV
 
core. An ORTEP drawing of 7 is shown in Figure 3.3. This structure shows that, in the 
solid state, the ICl2
–
 counterion has short contacts with the methine hydrogen [Cl(3)–H(1) 
= 2.872 Å] as well as with pyridine proton H2 [Cl(3)–H(2) = 2.752 Å; I–H(2) = 3.354 Å]. 
 
Figure 3.3 ORTEP drawing of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][ICl2] 
 
Thermal ellipsoids are drawn at 50% probability. Only hydrogen atoms involved 
in bonding of ICl2
–
 are shown for clarity. 
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3.3 Reactivity of the Model Complexes 
On the basis of our previous work (Scheme 3.7), we expected that heating 
complexes 7-9 would result in C–H activation to form products like 12 (Scheme 3.7). 
However, instead, heating 8 at 90 ºC for 2 h in CDCl3 resulted in C–Cl bond-forming 
reductive elimination to afford Pd
II
 complex 10 along with chlorobiphenyl 11. 
 
Scheme 3.7 Thermal decomposition of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][Cl] 
 
 
We next hypothesized that base might be necessary to promote C–H activation in 
this system. However, the treatment of 8 with an excess of triethylamine or pyridine in 
CH2Cl2 at room temperature for 4 h returned only unreacted starting material (Scheme 
3.8). When this reaction was conducted at 60 ºC, complex 10 underwent decomposition 
to generate a complex mixture of unidentified products. The desired product 12 was not 
detected. Complex 8 did react with NaOD at 25 ºC to form a colorless D2O-soluble Pd
IV
 
product that we propose to be the deuteroxide complex 13. Attempts to isolate 13 resulted 
in decomposition; however, this complex was characterized in situ with 
13
C{
1
H}, 
1
H/
1
H 
gCOSY and NOESY NMR experiments as well as 
1
H/
13
C HSQC and HMBC correlation 
experiments. Notably, the chloride-to-deuteroxide ligand exchange was completely 
 69 
 
reversible. The acidification of D2O solutions of 14 with aqueous HCl resulted in rapid 
and near quantitative regeneration of 8. 
 
Scheme 3.8 Reactions of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][Cl] with bases 
 
 
The observation of facile, reversible chloride/deuteroxide ligand exchange 
prompted us to test the related ligand substitution reaction of chloride for acetate. We 
reasoned that incorporation of an acetate ligand might trigger C–H activation at PdIV via a 
concerted metallation deprotonation (CMD) mechanism. It is known that carboxylate 
plays an intimate role in the C–H actiavtion process at PdII. Numerous studies have 
implicated cyclic transition states for C–H activation at PdII, where the carbonyl group of 
the carboxylate ligand acts as an internal base (Scheme 3.9, 14).
10,11 
This pathway, often 
referred to as concerted metallation deprotonation (CMD), is supported by extensive 
experimental data as well as quantum-mechanical calculations.
12
  
 
Scheme 3.9 Concerted metallation-deprotonation (CMD) mechanism 
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Recent work has also shown that C–H cleavage via a CMD pathway can occur at 
Rh
III
, Ir
III
 and Ru
II
 centers as well.
13,14,15 
While CMD C–H activation at PdII centers has 
been well studied, the possibility of analogous pathways at high oxidation-state Pd 
centers remains unexplored. This gap in understanding is particularly noteworthy because 
palladium carboxylates are used as catalysts in oxidative C–H functionalization 
reactions
16
 (see Schemes 3.1-3.3 above), suggesting the possibility of CMD mechanism 
at Pd
IV
. 
 
Scheme 3.10 Acetate promoted C–H activation at PdIV 
 
 
 According to the reasoning above a CDCl3 solution of 8 was treated with 5% 
aqueous KOAc. This resulted in a rapid color change from orange to yellow within 5 min 
(Scheme 3.10). Gratifyingly, 
1
H NMR analysis of the separated CDCl3 layer showed 
clean conversion to the cyclometalated complex 12. When this reaction was performed 
on a preparative scale, complex 12 was isolated in only 39% yield. However, 
optimization of the reaction conditions (through the use of anhydrous CHCl3 as the 
solvent and substituting aqueous KOAc with AgOAc) led to the formation of 12 in high 
yield after 5 min at 25 ºC (78% isolated yield, Scheme 3.10). 
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Complex 12 is stable at room temperature in the solid state and in CDCl3 solution 
for at least two weeks. This cyclometalated compound was characterized by 1D and 2D 
NMR analysis as well as by single crystal X-ray diffraction. The X-ray structure of 12 is 
shown in Figure 3.4. In the solid-state, the chloride counterion is hydrogen-bonded to the 
methine hydrogen (Cl(2)-H(1) = 2.568Å) as well as to a co-crystalized water molecule. 
 
Figure 3.4 ORTEP drawing of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2,2’-diyl)(Cl)][Cl]. 
 
Thermal ellipsoids are drawn at 50% probability. Only hydrogen atom involved in 
hydrogen bonding is shown for clarity. Selected bond lengths (Å): Pd-C(1) 2.176, Pd-
Cl(1) 2.296, Pd-N(1) 2.176, Pd-N(2) 2.049. Selected bond angles (deg): N(1)-Pd-Cl(1) 
91.95, Cl(1)-Pd-C(1) 88.51, C(1)-Pd-N(2) 90.58, N(2)-Pd-N(1) 88.95, C(1)-Pd-C(1’) 
81.46, N(1)-Pd-C(1) 179.14. 
 
3.4 Proposed Mechanism of C–H Activation at Palladium(IV) 
We next sought to gain insights into the mechanism of this C–H activation 
reaction. As noted in Scheme 3.8 and Scheme 3.9, acetate was the only base examined 
that promoted this transformation. This strongly suggests that the carboxylate is not 
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simply serving as an external base in the reaction. Furthermore, the observation of facile 
replacement of chloride for hydroxide (Scheme 3.8) indicates the feasibility of ligand 
substitution to form a Pd
IV
 acetate complex prior to C–H activation. On the basis of these 
preliminary observations, we hypothesized that the observed C–H activation reaction 
could proceed via the pathway depicted in Scheme 3.11. This involves four distinct steps: 
(1) chloride to acetate ligand substitution, (2) rotation about the Pd–CAryl bond, (3) 
configurational isomerization via Berry pseudorotation, and (4) C–H cleavage with 
acetate acting as an internal base. With this working mechanism in mind, we have 
conducted a variety of experiments to gain insights into the feasibility of each of the 
proposed steps. These studies are described in detail in the sections below. 
 
Scheme 3.11 Proposed mechanism for acetate-assisted C–H activation at PdIV 
  
 73 
 
3.5 Ligand Substitution at Palladium(IV) 
The first step of the proposed mechanism involves chloride-to-acetate ligand 
exchange at cationic Pd
IV
 center 8. This most likely proceeds via reversible dissociation 
of one pyridine arm of the Py3CH ligand followed by binding of acetate to generate 
intermediate 18 (Scheme 3.12). Subsequent chloride dissociation and re-association of 
the pyridine arm would then yield 15. 
 
Scheme 3.12 Chloride-to-acetate ligand substitution at Pd
IV
 
 
 
We first sought to detect 15 at low temperature using 
1
H NMR spectroscopy. 
Treatment of a CD2Cl2 solution of 8 with 3 equiv of Bu4NOAc at –20 ºC resulted in the 
formation of a new species with spectroscopic features consistent with 15 (Scheme 3.13). 
This compound was unstable to isolation, and underwent rapid C–H activation to form 12 
upon warming to 0 ºC. As such, 15 could only be characterized in situ by 1D 
1
H NMR 
spectroscopy as well as 2D 
1
H/
1
H gCOSY and NOESY. Several diagnostic spectral 
features support the assignment of this species as a mono-acetate complex. Most 
importantly, the 
1
H NMR spectrum clearly shows that this intermediate lacks a plane of 
symmetry, suggesting that only one chloride ligand has undergone ligand exchange with 
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acetate. The observed exchange of only one of the chloride ligands is likely due to the 
possibility of 2 binding of the acetate to the cationic PdIV center (Scheme 3.13).17 This 
binding mode would inhibit association of a second acetate. 
 
Scheme 3.13 Detection of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)(OAc)]
+
 by NMR 
 
 
In order to gain further insights into ligand exchange processes at 8, we examined 
ligand substitution reactions with other nucleophilic anions. As shown in Scheme 3.14, 
complexes 7 and 8 also undergoes facile ligand exchange with both bromide and azide to 
generate stable products 19-21. 
 
Scheme 3.14 Preparation of Pd
IV
 bromide and azide complexes 
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Complexes 19-22 were characterized by conventional 1D and 2D NMR 
techniques and by HRMS. All of these compounds show CS symmetry, which indicates 
that both chloride ligands have been exchanged. Notably, the 
1
H NMR spectrum of 19 
shows several equilibrating species, suggesting that it exists as a mixture of 
conformational and configurational isomers (vide infra for further discussion). In 
contrast, the 
1
H NMR spectra of 20-22 are each consistent with the presence of a single 
major isomer in solution. These latter spectra are extremely similar to that of 8. The 
identity of dibromide complex 20 was further corroborated by a single crystal X-ray 
diffraction analysis, and the structure is shown in Figure 3.5. 
 
Figure 3.5 ORTEP drawing of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Br)2][IBr2] 
 
Thermal ellipsoids are drawn at 50% probability. Hydrogen atoms are omitted for clarity. 
Selected bond lengths (Å): Pd-C(1) 2.092(3), Pd-Br(1) 2.427, Pd-N(1) 2.198, Pd-N(2) 
2.070. Selected bond angles (deg): N(2)-Pd-Br(1) 88.75, Br(1)-Pd-Br(2) 89.71, Br(2)-Pd-
N(3) 89.16, N(3)-Pd-N(2) 91.87, N(1)-Pd-C(1) 177.51. 
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The chloride-to-bromide ligand exchange is readily reversible, and 20-21 reacted 
rapidly (within 5 min at 25 ºC) with aqueous NaCl to regenerate 7 or 8 (Scheme 3.14). 
The presence of bromide ligands did not alter the reactivity of Pd
IV
 center towards 
acetate-promoted C–H activation. For example, the reaction of 22 with 4 equiv of 
AgOAc resulted in clean C–H cleavage to afford cyclometalated product 23 in 53% 
isolated yield (Scheme 3.15). In contrast, the equilibrium for chloride-to-azide exchange 
appears to lie far to the right, as no reaction was observed upon treatment of 19 with a 
large excess of aqueous NaCl. In addition, the treatment of azide complex 19 with 
AgOAc returned only unchanged starting material (Scheme 3.15). 
 
Scheme 3.15 Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2,2’-diyl)(Br)][TfO] 
 
 
We noted that both the proposed ligand substitution (step 1 in Scheme 3.11) as 
well as the configurational isomerization (step 3 in Scheme 3.11) involve reversible 
dissociation of one arm of the Py3CH ligand. We thus hypothesized that these two steps 
(and thus the overall C–H activation process) would be slowed significantly by replacing 
the Py3CH ligand with Py3CCH3 (complex 24 in Scheme 3.16). The additional methyl 
group in Py3CCH3 is expected to render 24 more rigid than Py3CH, thus potentially 
slowing both ligand substitution and configurational isomerization. 
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Complex 24 was synthesized using a similar procedure to that for 9 (see 
Experimental Section for details). As predicted, this complex showed dramatically 
reduced reactivity towards acetate-assisted C–H activation. Indeed, as shown in Scheme 
3.16, the treatment of 24 with AgOAc or aqueous KOAc at room temperature did not 
lead to cyclometalation to form 25. Instead, these conditions resulted in slow (over 1 h) 
decomposition of 24 to generate a complex mixture of products. These results suggest 
that ligand substitution and/or configurational isomerization are likely greatly impeded in 
this system; as such, competing decomposition pathways predominate. 
 
Scheme 3.16 Reaction of [(Py3CCH3)Pd
IV
(biphenyl-2,2’-diyl)(Br)][TfO] with AgOAc 
 
 
To directly compare ligand substitution at 24 and 9, we studied the reaction of 
both complexes with KBr (Scheme 3.17). At room temperature, these reactions were too 
fast to be monitored by NMR spectroscopy, but they could be followed via UV-Vis 
spectroscopy based on the appearance of an absorbance band at 480 nm. Likely due to the 
presence of multiple steps with similar rate constants the kinetic behavior of these 
systems is complex. Despite this complexity, the experiments show that, under otherwise 
identical reaction conditions, ligand substitution of Cl for Br at 9 proceeds to completion 
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approximately 10-fold faster than the analogous transformation at 24. This is consistent 
with our predications about the increased rigidity of Py3CCH3 versus Py3CH. 
 
Scheme 3.17 Chloride-to-bromide ligand exchange rate at Pd
IV
 
 
 
3.6 Rotation about the PdIV–CAryl Bond 
As discussed above, complexes 7-9 were obtained as a single conformer with 
respect to rotation about the Pd-biphenyl bond. The favored conformation has the 
biphenyl ligand positioned under the Py3CH. We hypothesize that this conformation is 
stabilized by -stacking between the electron rich phenyl group of the biphenyl and the 
electron deficient pyridines. Thus, in an effort to disrupt this - interaction, we 
synthesized a complex with three electron withdrawing fluorine substituents on the 
biphenyl ligand (27). This perturbation has the predicted effect, and the 1D 
1
H NMR and 
2D 
1
H/
1
H ROESY NMR spectra of 27 show that this compound exists as a mixture of 
two CS symmetric conformational isomers 27a and 27b (27a:27b = 40:60 in CDCl3, 
Scheme 3.18) which interconvert on the EXSY time scale.
18 
Interestingly, the ratio of 
27a:27b is solvent dependent. While 27a is the major isomer in CD3NO2 (27a:27b = 
75:25), 27b predominates in less polar CDCl3 (27a:27b = 40:60). These results show that 
 79 
 
rotation around the Pd–aryl bond is fast in 27 and that both conformations are readily 
accessible at room temperature. The treatment of 27a/27b with AgOTf resulted in clean 
formation of the corresponding triflate complex 28 as a mixture of two isomers 28a and 
28b (28a:28b = 45:55 in CDCl3). Surprisingly, 28a and 28b do not interconvert on the 
NMR time scale (as determined by a 2D 
1
H/
1
H ROESY experiment in CDCl3 at 25 ºC). 
This observation indicates that the counterion can influence flexibility of the cationic 
Pd
IV
 core. 
 
Scheme 3.18 Rotation about the Pd
IV–CAryl bond  
 
 
As shown in Scheme 3.18, both complex 27 and its triflate counterpart 28 
participate in acetate-assisted C–H activation in a similar fashion to 7-9. For example, the 
treatment of 28a/b with 4 equiv of AgOAc in dry CHCl3 afforded complex 29 in 66% 
isolated yield. Overall this series of experiments demonstrates the feasibility of rotation 
about the Pd
IV–aryl bond in complexes that undergo acetate-assisted C–H activation (and 
that are closely related to the parent compounds 7-9). 
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3.7 Configurational Isomerization at PdIV via Berry Pseudorotation 
The viability of the proposed configurational isomerization process was first 
probed by EXSY NMR experiments in complexes of general structure 
[(Py3CH)Pd(biphenyl)Y2]
+
.
18
 Only one isomer was observed in the 
1
H and 
13
C NMR 
spectra of dichloride complexes 7-9; furthermore, 
1
H/
1
H ROESY and NOESY 
experiments show that 7-9 are configurationally stable on the NMR timescale.  In 
contrast, as shown in Figure 3.6, the 
1
H/
1
H ROESY spectrum of dibromide complex 20 
shows chemical exchange cross peaks between the two equivalent pyridine rings trans to 
the bromides and the one distinct pyridine ring trans to the carbon. 
 
Figure 3.6 
1
H/
1
H ROESY spectrum of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Br)2][IBr2] 
 
(spectrum acquired at 500 MHz) 
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Scheme 3.19 Isomerization of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Br)2][IBr2] 
 
It is well documented that six-coordinate complexes can undergo inversion of 
configuration at the metal by bond-rupture mechanism via formation of a 
configurationally labile five-coordinate intermediate.
19
 As such we propose that the 
observed exchange in complex 20 is the result of the pathway depicted in Scheme 3.19. 
Here, initial dissociation of one arm of the facial tridentate pyridine ligand (labeled N
2
 in 
Scheme 3.19) affords the 5-coordinate complex 30, which can undergo configurational 
isomerization to form 31 via Berry pseudorotation.
20
 N
2
 reassociation would then afford 
product 20a. Importantly, complexes 20 and 20a are chemically equivalent, with the sole 
difference that N
2 
has swapped places with one of the N
1
 groups. The configurational 
isomerization pathway proposed in Scheme 3.19 is further corroborated by the 
observation of broad, low intensity resonances in the 
1
H NMR and 
1
H/
1
H ROESY spectra 
of 20 (labeled with asterisks in Figure 3.6). This species is in exchange with 20 on the 
NMR timescale (based on 
1
H/
1
H ROESY analysis). Although the broad signals make it 
difficult to characterize definitively, we propose that this may be an intermediate like 30 
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or 31. We disfavor formulation of this species as an octahedral tribromide complex based 
on the fact that the addition of 2-4 equiv of NBu4Br did not increase the equilibrium 
population of this compound in solution. Interestingly, no chemical exchange crosspeaks 
were detected in 
1
H/
1
H ROESY spectrum for [(Py3CH)Pd(biphenyl)Br2][TfO] (22). This 
observation demonstrates the influence of the outer-sphere counterion on the binding 
properties of the Py3CH ligand. A possible explanation to this observation is that 
hydrogen bonding of IBr2
–
 to the Py3CH ligand in complex 20 promotes dissociation of 
one pyridine ring and stabilizes a pentacoordinate intermediate like 32 or 33. 
 
3.8 Acetate Assited C–H Cleavage at Palladium(IV) 
A series of isotope effect studies were conducted to (a) gain insights into the 
nature of the transition state for C–H cleavage and (b) establish whether C–H bond 
activation is involved in the rate-determining step of the overall transformation.
21
 Mono-
deuterated complex 32 was synthesized by analogy to the procedure shown in Scheme 
3.5.
22
 Complex 32 was then treated with various carboxylate sources to yield the 
cyclopalladated product 33 (Scheme 3.20). 
1
H NMR analysis of 33 showed that cleavage 
of the C–H bond occurred in preference to cleavage of the C–D bond with all of the 
carboxylates examined. Accurate values for the intramolecular KIE were obtained from 
ESI-MS mass spectrometric analysis. All of the carboxylate sources tested [KOAc 
(aqueous), AgOAc, AgOPiv, AgO2CCF3, and AgO2CC6H5] afforded product 33 with an 
intramolecular kH/kD between 9 and 12 at 25 ºC. Increasing the reaction temperature to 55 
ºC and lowering it to 0 ºC had a relatively small influence on the observed isotope effect. 
For example, with AgOAc, kH/kD = 10 at 0 
o
C and 7 at 55 
o
C. These latter results indicate 
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that quantum tunneling does not contribute significantly to the isotope effect in this 
system. 
 
Scheme 3.20 Determination of intramolecular KIE 
 
 
Overall, the observed large magnitude of the intramolecular isotope effect is 
indicative of central transition state for C–H cleavage, suggesting that the proton is 
transferred between two sites of similar basicity.
23
 These observed values are similar to 
those reported for CMD C–H cleavage at Pd(II)12d and Ir(III)14b centers (values in the 
literature vary from 5-7). An intermolecular KIE of 6 was determined also for benzene 
mercuration, which is proposed to proceed via a cyclic transition state with acetate acting 
as an intramolecular base.
24
 
The intermolecular KIE for this reaction was next determined using substrates 34 
and 37 (Scheme 3.21). The t-butyl group was introduced on the biphenyl ligand of 34 and 
37 in order to enhance solubility (essential for obtaining quantitative rate data). The 
fluorine substituent was added to enable monitoring of reaction rate by 
19
F NMR 
spectroscopy. The use of Bu4NOAc or AcOH/Et3N resulted in formation of 
cyclopalladated products 38 or 41 in only 65% and 35% NMR yield, respectively. 
Competitive formation of unidentified side products did not allow us to extract reliable 
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rate constants for CH activation under homogenous reaction conditions with Bu4NOAc 
therefore, for kinetic studies we switched to AgOPiv as carboxylate source. Thus, 
treatment of 34 and 37 with 3 equiv of AgOPiv resulted in smooth conversion to 
cyclopalladated products 36 and 39. 
 
Scheme 3.21 Determination of intermolecular KIE 
 
 
The progress of these reactions was monitored by 
19
F NMR spectroscopy. After 5 min, 
both substrates 34 and 37 underwent nearly quantitatively conversion to the mono-
pivalate intermediates 35 and 38. Both intermediates 35 and 38 then underwent relatively 
slow conversion to 36 and 39, respectively. The overall reaction rates for substrates 34 
and 37 under these conditions were the same within the error of measurement. These 
observations show that that the rate of the overall transformation is not limited by the rate 
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of the ligand exchange or the availability of the carboxylate ligand (due to low solubility 
of AgOPiv) and that conformational and configurational isomerization is likely the rate-
limiting step in this transformation. 
 
3.9 Regioselectivity of C–H Activation at Palladium(IV) 
So far we we have conducted a number of experiments to elucidate details of 
acetate-assisted C–H activation at PdIV (Scheme 3.11). It was discussed previously that 
some of the Pd
IV
 mediated C–H functionalization reactions proceed with remarkably high 
regioselectivities even when substrate does not contain directing groups. Such high 
regioselectivities are likely due either to unique electronic properties of Pd
IV
 or to steric 
requirements of octaheadral ligand environment at Pd
IV
 center. It must be noted that 
palladium carboxylates are typically used as catalysts in Pd
IV
 mediated C–H 
functionalization reactions therefore, it is plausible that the carboxylate ligand also plays 
role in ensuring high regioselectivities. In order to gain insight into the origin of this 
phenomenon, we decided to probe regioselectivity of C–H activation also in our system.  
 
Scheme 3.22 Regioselective acetate-assisted C–H activation at PdIV 
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We first chose to investigate the reactivity of complex 40 which contains two 
electronically similar sites for C–H cleavage but one of which is sterically hindered by a 
methyl group (Scheme 3.22). Treatment of 40 with AgOAc followed by workup with 
aqueous NaCl afforded complex 41 in 69% isolated yield. No regioisomer 42 was 
detected in crude reaction mixture or in isolated product 41. 
We next synthesized and investigated complex 43 which has both C–H activation 
sites hindered by methyl groups (Scheme 3.23). Treatment of 43 with AgOAc afforded 
only trace amounts of C–H activation product 44 which was detected by High-resolution 
Mass Spectrometry (HRMS). In this reaction, acetoxybiaryl 45 was isolated as major 
product in 63% yield. Compound 45 is likely a result of CAryl-OAcetyl bond forming 
reductive elimination from Pd
IV
 center. Interestingly, while the C–H activation reaction 
investigated in this chapter tolerates fluorine substituent next to the reaction site (Scheme 
3.18), methyl groups shut down C–H cleavage completely. 
 
Scheme 3.23 C–O bond forming reductive elimination process at PdIV center 
 
 
Experiments shown in Scheme 3.22 and Scheme 3.23 demonstrate that in Py3CH 
supported complexes high regioselectivity of C–H activation is a result of steric 
requirements set by the octaheadral ligand sphere of Pd
IV
. While it cannot be universally 
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generalized to all systems, it is highly likely that steric effects play a major role also in 
determining regioselectivity in many catalytic C–H functionalization reactions mediated 
by Pd
IV
. 
 
3.10 Conclusions 
A model system for investigation of C–H activation at a PdIV center was 
developed. As discussed above, C–H activation in this system likely proceeds through a 
pathway involving four key steps: (1) ligand exchange, (2) Pd–CAryl bond rotation, (3) 
configurational isomerization via Berry pseudorotation, and (4) C–H cleavage via a 
concerted metallation deprotonation (CMD) transition state with an acetate ligand serving 
as an internal base. The feasibility of each of these steps is supported by the experiments 
presented above. A key feature of the investigated [(Py3CH)Pd(biphenyl)Cl2]X system is 
the semilabile tridentate tris(2-pyridil)methane ligand. This ligand stabilizes octahedral 
cationic Pd
IV
 centers towards reductive elimination. However, coordinatively unsaturated 
species can be formed via dissociation of a pyridine arm of the ligand. This ligand 
dissociation is believed to facilitate both the ligand exchange as well as the 
configurational isomerization steps. Importantly, the extremely mild conditions necessary 
for acetate assisted C–H cleavage at PdIV centers renders this process attractive for 
applications in catalytic C–H functionalization processes mediated by high oxidation 
state palladium. 
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3.11 Experimental Section 
General Procedures. All syntheses were conducted under ambient atmosphere 
unless otherwise stated. All reagents were purchased from commercial sources and used 
as received. Tetrahydrofuran, dichloromethane and diethyl ether were purified using an 
Innovative Technologies (IT) solvent purification system consisting of a copper catalyst, 
activated alumina, and molecular sieves. NMR spectra were acquired using 400, 500 and 
700 MHz Varian spectrometers. All 
1
H/
1
H NOESY and 
1
H/
1
H ROESY correlation 
spectra were acquired on a 500 MHz instrument. 
1
H, 
19
F and 
13
C chemical shifts are 
reported in parts per million (ppm) relative to TMS. 
1
H
 
and 
19
F multiplicities are reported 
as follows: singlet (s), doublet (d), triplet (t), quartet (q) and multiplet (m). 
 
3.11.1 Synthesis and Characterization of Ligands and Organic Compounds 
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Preparation of tris(pyridin-2-yl)methane (S1). Under an atmosphere of 
nitrogen, butyllithium (2.5 M in hexanes, 68 mL, 170 mmol) was slowly added to a 
cooled (–78 oC) solution of 2-picoline (14.0 g; 150 mmol) in dry THF (250 mL). The 
resulting suspension was warmed to 0 
o
C over the period of 1 h, and then neat 2-
fluoropyridine (23.7 mL; 275 mmol) was slowly added over the period of 20 min. Next, 
the reaction was heated to 65 
o
C for 3 h and then it was poured into water (300 mL) and 
the resulting mixture was extracted with EtOAc (3 × 100 mL). The combined organic 
phases were washed with brine (200 mL) and dried over anhydrous MgSO4. The volatiles 
were removed under reduced pressure. Fractional vacuum distillation of the residue (180-
230 
o
C; ~ 0.05 mmHg) afforded di(pyridine-2-yl)methane (7.55 g; 30%) as a yellowish 
oil and tris(pyridine-2-yl)methane (5.23 g; 14%) as a pale brown solid. Mp = 92-93 ºC. 
1
H NMR (CDCl3): δ 8.58 (d, J = 4.9 Hz, 3H), 7.62 (td, J = 7.8 and 1.7 Hz, 3H), 7.31 (d, J 
= 7.8 Hz, 3H), 7.13 (m, 3H), 5.98 (s, 1H). 
13
C{
1
H} NMR (CDCl3): δ 161.07, 149.49, 
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136.54, 124.14, 121.73, 64.07. HRMS electrospray (m/z): [M + H]
+
 calcd for C16H14N3, 
248.1182; Found, 248.1185. 
Preparation of 1,1,1-tris(pyridin-2-yl)ethane (S2). Under an atmosphere of 
nitrogen, LDA (1.5 M solution in THF, 5.5 mL, 8.2 mmol) was slowly added to a cooled 
(–78 oC) solution of tris(pyridine-2-yl)methane (S1) ( 1.70 g;  6.9 mmol) in dry THF (50 
mL). The resulting solution was warmed to 20 
o
C over the period of 1 h, and then neat 
methyliodide (0.87 mL; 14 mmol) was added. Reaction mixture was stirred at 20 
o
C for 2 
h and then volatiles were removed under reduced pressure. The residue was purified by 
flash chromatography on a silica gel column (mobile phase: hexanes/EtOAc with 
gradient from 4/1 to 1/1) to yield 1.21g (67%) of a yellowish solid. Mp = 87-88 ºC. 
1
H 
NMR (CDCl3): δ 8.58 (m, 3H), 7.57 (td, J = 8.1 and 1.4 Hz, 3H), 7.01 (m, 6H), 2.33 (s, 
3H). 
13
C NMR (CDCl3): δ 165.88, 148.82, 135.99, 123.48, 121.22, 60.11, 27.33. HRMS 
electrospray (m/z): [M + H]
+
 calcd for C17H16N3, 262.1339; Found, 262.1339. 
 
Scheme 3.24 General procedure for the synthesis of iodobiphenyls 
 
 
 
 
General procedure 1: Synthesis of 2-arylanilines. A flask was charged with 
corresponding 2-bromoaniline (10.0 mmol), boronic acid (11.0 mmol), K2CO3 (40 mmol) 
and (PPh3)2PdCl2 (210 mg; 0.30 mmol). Dioxane (40 mL) and water (70 mL) were then 
added. Reaction mixture was heated to 70 
o
C for 3 h and then cooled to r.t. The product 
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was extracted from the biphasic mixture with EtOAc (3 × 50 mL). The combined organic 
phases were washed with brine (100 mL) and dried over anhydrous MgSO4. The solvent 
was removed under reduced pressure and the residue was purified by flash 
chromatography on a silica gel column (mobile phase: hexanes/EtOAc with gradient 
from 10/0 to 10/2) to yield product as a colorless oil or colorless crystals. 
Preparation of 3',4',5'-trifluoro-(1,1'-biphenyl)-2-amine (S3). S3 was obtained 
according to the general procedure 1 in 84% yield as colorless crystals.  Mp = 57-58 ºC. 
1
H NMR (CDCl3): δ 7.18 (td, J = 7.8 and 1.5 Hz, 1H), 7.10 (dd, J = 8.3 and 6.6 Hz 2H), 
7.06 (dd, J = 7.5 and 1.5 Hz, 1H), 6.82 (td, J =7.5 and 1.0 Hz, 1H), 6.76 (dd, J = 8.1 and 
0.9 Hz, 1H), 3.73 (bs, 2H). 
13
C NMR (CDCl3): δ 148.44 (ddd, J = 250.7, 19.5 and 4.1 
Hz), 140.35, 136.02 (dt, J = 252.0 and 15.3 Hz), 132.61 (td, J = 8.2 and 4.8 Hz), 127.24, 
126.55, 121.51, 116.00, 113.08, 110.31 (dd, J = 16.4 and 4.1 Hz). 
19
F NMR (CDCl3): δ -
133.99 (dd, J = 21.6 and 8.3 Hz, 2F), -162.35 (tt, J = 19.9 and 6.6 Hz, 1F). HRMS 
electrospray (m/z): [M + H]
+
 calcd for C12H8F3N, 224.0682; Found, 224.0679. 
Preparation of 4'-(tert-butyl)-5-fluoro-(1,1'-biphenyl)-2-amine (S4). S4 was 
obtained according to the general procedure 1 in 87% yield as a colorless oil. 
1
H NMR 
(CDCl3): δ 7.48 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 6.87 (m, 2H), 6.69 (dd, J = 
8.5 and 4.9 Hz, 1H), 3.67 (br, 2H), 1.37 (s, 9H). 
13
C NMR (CDCl3): δ 156.32 (d, J = 
236.4 Hz), 150.53, 139.68 (d, J = 2.0 Hz), 135.56, 128.69 (d, J = 6.9 Hz), 128.53, 125.83, 
116.65 (d, J = 22.5 Hz), 116.36 (d, J = 8.2 Hz), 114.60 (d, J = 22.5 Hz), 34.61, 31.34. 
19
F 
NMR (CDCl3): δ -127.06 (td, J = 8.2 and 4.1 Hz, 1F). HRMS electrospray (m/z): [M + 
H]
+
 calcd for C16H18FN, 244.1496; Found, 244.1501. 
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Preparation of 4,3'-dimethyl-(1,1'-biphenyl)-2-amine (S5). S5 was obtained 
according to the general procedure 1 in 88% yield as a colorless oil.  
1
H NMR (CDCl3 at 
25 
oC): δ 7.44 (td, J = 7.5 and 2.2 Hz, 1H), 7.41-7.36 (m, 2H), 7.27 (d, J = 7.3 Hz, 1H), 
7.10-7.07 (m, 2H), 6.77 (dd, J = 8.5 and 2.4 Hz, 1H), 3.73 (bs, 2H), 2.52 (s, 3H), 2.41 (s, 
3H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 141.14, 139.80, 138.47, 131.04, 129.94, 129.05, 
128.76, 127.96, 127.93, 127.80, 126.21, 115.90, 21.60, 20.57. HRMS electrospray (m/z): 
[M + H]
+
 calcd for C14H16N, 198.1277; Found, 198.1279. 
Preparation of 3',5'-dimethyl-(1,1'-biphenyl)-2-amine (S6). S6 was obtained 
according to the general procedure 1 in 94% yield as a colorless oil. 
1
H NMR (CDCl3 at 
25 
oC): δ 7.21-7.17 (m, 2H), 7.14 (s, 2H), 7.06 (s, 1H), 6.88 (t, J = 7.5 Hz, 1H), 6.80 (d, J 
= 7.8 Hz, 1H), 3.84 (bs, 2H), 2.43 (s, 6H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 143.54, 
139.50, 138.38, 130.41, 128.85, 128.36, 127.98, 126.88, 118.63, 115.59, 21.42. HRMS 
electrospray (m/z): [M + H]
+
 calcd for C14H16N, 198.1277; Found, 198.1285. 
General procedure 2: Synthesis of iodobiphenyls. Water (10 mL) and conc. aq. 
HCl (5 mL) were added to a solution of the corresponding 2-arylaniline (6.0 mmol) in 
MeOH (20 mL). The resulting solution was then cooled to 0 
o
C and NaNO2 (550 mg, 8.0 
mmol) in H2O (3 mL) was added slowly over the period of 5 minutes. The reaction 
mixture was stirred at 0
o
C for 15 minutes and KI (1.5 g; 9 mmol) in H2O (10 mL) was 
then added over the period of 5 minutes. Reaction mixture was stirred for 20 minutes at 
20 
o
C and then it was heated to 60 
o
C for 30 minutes. To the dark brown suspension was 
then added aqueous Na2SO3 (8 g in 40 mL H2O) and the resulting mixture was extracted 
with EtOAc (3 × 50 mL). The combined organic phases were washed with brine (100 
mL) and dried over anhydrous MgSO4. The volatiles were removed under reduced 
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pressure and the residue was purified by flash chromatography on a silica gel column 
(mobile phase: 100% hexanes) to yield product as a colorless oil. 
Preparation of 3',4',5'-trifluoro-2-iodo-1,1'-biphenyl (S7). S7 was obtained 
according to the general procedure 2 in 73% yield as a colorless oil. 
1
H NMR (CDCl3): δ 
7.94 (dd, J = 8.0 and 1.2 Hz, 1H), 7.39 (td, J = 7.5 and 1.2 Hz, 1H), 7.24 (dd, J = 7.5 and 
1.5 Hz, 1H), 7.07 (td, J = 7.8 and 1.7 Hz, 1H), 6.95 (dd, J = 8.2 and 6.5 Hz, 2H). 
13
C 
NMR (CDCl3): δ 150.66 (ddd, J = 250.0, 9.5 and 4.0 Hz), 143.64, 139.80 (multiplet 
overlapping with singlet at 139.75), 139.75, 139.40 (dt, J = 252.7 and 15.0 Hz), 129.81, 
129.71, 128.35, 113.80 (dd, J = 17.0 and 4.1 Hz), 97.79. 
19
F NMR (CDCl3): δ -134.44 
(dd, J = 21.5 and 8.3 Hz, 2F), 161.70 (tt, J = 21.5 and 6.6 Hz, 1F). HRMS electron 
impact (m/z): [M]
+
 calcd for C12H6F3I, 333.9466; Found, 333.9459. 
Preparation of 4-(tert-butyl)-5'-fluoro-2'-iodo-1,1'-biphenyl (S8). S8 was 
obtained according to the general procedure 2 in 73% yield as a colorless oil. 
1
H NMR 
(CDCl3): δ 7.88 (dd, J = 8.7 and 5.6 Hz, 1H), 7.45 (d, J = 8.3 Hz, 2H), 7.27 (d, J = 8.2 
Hz, 2H), 7.05 (dd, J = 9.6 and 3.1 Hz, 1H), 6.79 (td, J = 8.2 and 2.9 Hz, 1H), 1.38 (s, 
9H). 
13
C NMR (CDCl3): δ 162.83 (d, J = 248.0 Hz), 151.00, 148.42 (d, J = 7.5 Hz), 
140.63 (d, J = 7.5 Hz), 140.18, 128.70, 124.97, 117.47 (d, J = 22.5 Hz), 116.00 (d, J = 
21.8 Hz), 51.51 (d, J = 2.7 Hz), 34.67, 31.36. 
19
F NMR (CDCl3): δ - 114.70 (m, 1F). 
HRMS electron impact (m/z): [M]
+
 calcd for C16H16FI, 354.0280; Found, 354.0275. 
Preparation of 4,3'-dimethyl-2-iodo-1,1'-biphenyl (S9). S9 was obtained 
according to the general procedure 2 in 89% yield as a colorless oil. 
1
H NMR (CDCl3 at 
25 
oC): δ 7.87 (d, J = 8.2 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.26 (d. J = 7.5 Hz, 1H), 7.22-
7.19 (m, 3H), 6.91 (d, J = 8.2 Hz, 1H), 2.48 (s, 3H), 2.39 (s, 3H). 
13
C{
1
H} NMR (CDCl3 
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at 25 
oC): δ 146.57, 144.24, 139.28, 138.07, 137.54, 131.11, 130.01, 129.76, 128.32, 
127.85, 126.44, 94.60, 21.59, 21.00. HRMS electron impact ionization (m/z): [M]
+
 calcd 
for C14H13I, 308.0062; Found, 308.0057. 
Preparation of 3',5'-dimethyl-2-iodo-1,1'-biphenyl (S10). S10 was obtained 
according to the general procedure 2 in 81% yield as a colorless oil. 
1
H NMR (CDCl3 at 
25 
oC): δ 7.95 (d, J = 8.0 Hz, 1H), 7.38 (t, J = 7.4 Hz, 1H), 7.30 (d. J = 7.5 Hz, 1H), 7.05 
(s, 1H), 7.02 (t, J = 8.0 Hz, 1H), 6.97 (s, 2H), 2.39 (s, 6H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 146.86, 144.10, 139.42, 137.40, 130.04, 129.20, 128.59, 128.02, 127.08, 98.68, 
21.38. HRMS electron impact ionization (m/z): [M]
+
 calcd for C14H13I, 308.0062; 
Found, 308.0067. 
 
Scheme 3.25 Synthesis of 2,6-dideutero-4-(t-butyl)-5'-fluoro-2'-iodobiphenyl (S14) 
 
 
Preparation of 1,6-dideutero-4-(tert-butyl)-iodobenzene (S11). 4-tert-Butyl-
aniline (6.0 g; 39.7 mmol) was heated in 10% DCl/D2O (40 mL) to 100 
o
C under an inert 
atmosphere for 12 h. Volatiles were removed under reduced pressure and fresh portion of 
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DCl/D2O (40 mL) was added and heating was continued for another 12 h. Reaction 
mixture was then cooled to 0 
o
C and NaNO2 (3.45g; 50 mmol) in D2O (15 mL) was 
slowly added over the period of 15 minutes. Reaction mixture was stirred at 0 
o
C for 15 
minutes and KI (9.96 g; 60 mmol) in D2O (25 mL) was then added over the period of 10 
minutes. Reaction mixture was stirred for 20 minutes at 20 
o
C and then it was heated to 
60 
o
C for 30 minutes. Aqueous Na2SO3 (20 g in 200 mL H2O) was added to the resulting 
dark brown suspension and mixture was then extracted with EtOAc (3 × 100 mL). The 
combined organic phases were washed with brine (200 mL) and dried over anhydrous 
MgSO4. The solvent was removed under reduced pressure and the residue was purified 
by flash chromatography on a silica gel column (mobile phase: 100% hexanes) to yield 
9.80 g (94%) of a colorless oil.  
1
H NMR (CDCl3): δ 7.16 (s, 2H), 1.32 (s, 9H). 
13
C NMR 
(CDCl3): δ 150.86, 136.74 (t, J = 25.2 Hz), 127.46, 90.40, 34.60, 31.20. HRMS electron 
impact (m/z): [M]
+
 calcd for C10H11D2I, 262.0188; Found, 262.0194. 
Preparation of (2,6-dideutero-4-(tert-butyl)phenyl)boronic acid (S12). Under 
the atmosphere of nitrogen butyllithium (2.5 M in hexanes, 9 mL, 22.5 mmol) was slowly 
added to a cooled (–78 oC) solution of 2,6-dideutero-4-(tert-butyl)-iodobenzene (S11) 
(5.5 g;  21 mmol) in dry THF (150 mL). Neat trimethylborate (5.6 mL; 50 mmol) was 
next slowly added over the period of 5 min. Reaction mixture was stirred at -78 
o
C for 2 h 
and then it was slowly warmed to 20 
o
C and kept at this temperature for 2 hours. 
Saturated aq NH4Cl (100 mL) was then added and the resulting biphasic mixture was 
intensively stirred at r.t. for 2 hours. The reaction mixture was then extracted with Et2O 
(3 × 100 mL). The combined organic phases were washed with brine (200 mL), dried 
over anhydrous MgSO4 and the volatiles were removed under reduced pressure. The 
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resulting white solid (2.76 g; 73%) was used in the next step as is without 
characterization or further purification. 
Preparation of 2',6'-dideutero-4'-(tert-butyl)-5-fluoro-(1,1'-biphenyl)-2-amine 
(S13). S13 was synthesized from (2,6-dideutero-4-(tert-butyl)phenyl)boronic acid (S12) 
according to the general procedure 1 in 96% yield (colorless oil). 
1
H NMR (CDCl3): δ 
7.49 (br, 2H), 6.88 (m, 2H), 6.70 (dd, J = 8.5 and 4.7 Hz, 1H), 3.70 (br, 2H), 1.38 (s, 9H). 
13
C NMR (CDCl3): δ 156.37 (d, J = 235.6 Hz), 150.56, 139.64 (d, J = 2.0 Hz), 135.38, 
128.70 (d, J = 6.8 Hz), 128.22 (t, J = 24.5 Hz), 125.73, 116.67 (d, J = 22.5 Hz), 116.43 
(d, J = 8.2 Hz), 114.61 (d, J = 21.8 Hz), 34.62, 31.35. 
19
F NMR (CDCl3): δ -126.92 (m, 
1F). HRMS electrospray (m/z): [M + H]
+
 calcd for C16H16D2FN, 246.1622; Found, 
246.1621. 
Preparation of 2,6-dideutero-4-(tert-butyl)-5'-fluoro-2'-iodo-1,1'-biphenyl 
(S14). S14 was obtained according to the general procedure 2 in 68% yield (colorless 
oil). 
1
H NMR (CDCl3): δ 7.88 (dd, J = 8.7 and 5.6 Hz, 1H), 7.45 (d, J = 8.3 Hz, 2H), 7.05 
(dd, J = 9.6 and 3.1 Hz, 1H), 6.79 (td, J = 8.2 and 2.9 Hz, 1H), 1.38 (s, 9H). 
13
C NMR 
(CDCl3): δ 162.83 (d, J = 248.0 Hz), 151.00, 148.42 (d, J = 7.5 Hz), 140.63 (d, J = 7.5 
Hz), 140.18, 128.70, 124.97, 117.47 (d, J = 22.5 Hz), 116.00 (d, J = 21.8 Hz), 51.51 (d, J 
= 2.7 Hz), 34.67, 31.36. 
19
F NMR (CDCl3): δ - 114.70 (m, 1F). HRMS electron impact 
(m/z): [M]
+
 calcd for C16H16FI, 354.0280; Found, 354.0275. 
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Scheme 3.26 Synthesis of 2-deutero-2'-iodo-1,1'-biphenyl (S15) 
 
 
2,2'-Diiodo-1,1'-biphenyl was synthesized according to a published procedure.
25
 
Preparation of 2-deutero-2'-iodo-1,1'-biphenyl (S15). Under an atmosphere of 
nitrogen iPr gCl•LiCl (1.3  in THF  3.3 mL  4.3 mmol) was added to a cooled (-78 oC) 
solution of 2,2'-diiodo-1,1'-biphenyl (1.35g, 3.33 mmol) in dry THF (30 mL). The 
reaction mixture was warmed to 0 
o
C and stirred at this temperature for 2 h. D2O (0.2 
mL; 10 mmol) was added to the solution in one portion. The reaction mixture was then 
partitioned between Et2O (100 mL) and brine (100 mL). The organic phase was dried 
over MgSO4 and the solvent was then removed under reduced pressure to yield colorless 
oil. The obtained crude product (890 mg; 95%) contained approximately 10% of 
unreacted starting material which was removed on a silica gel column (mobile phase: 
100% hexanes) to afford 765 mg (82%) of a pure product as a colorless oil. The extent of 
D incorporation (99%) was calculated from the mass spectrometry data according to a 
published procedure.
26
 For mass spectrometry data see pages 33-36. 
1
H NMR (CDCl3): δ 
7.98 (dd, J = 8.0 and 0.9 Hz, 1H), 7.40 (m, 2H), 7.41 (m, 2H), 7.37 (d, J = 8.3 Hz, 1H), 
7.33 (d, J = 7.5 Hz, 1H), 7.05 (t, J = 7.3 Hz, 1H). 
13
C NMR (CDCl3): δ 146.63, 144.14, 
139.52, 130.11, 129.28, 128.99 (t, J = 24.5 Hz), 128.80, 128.14, 127.98, 127.87, 127.66, 
98.67. HRMS electron impact (m/z): [M]
+
 calcd for C12H8DI, 280.9812; Found, 
280.9820.  
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3.11.2 PdII Precursors of (Py3CH)Pd
II
([1,1'-biphenyl]-2-yl)(I) General Structure 
 
 
 
General procedure 3: Preparation of Pd
II
 complexes with 
(Py3CH)Pd
II
(biphen-2-yl)(I)  general structure. A 20 mL vial was charged with 4-tert-
butylpyridine (300 mg, 2.2 mmol), the corresponding iodobiphenyl (1.3 mmol) and THF 
(15 mL). Pd(dba)2 (600mg; 1.0 mmol) was then added and the vial was sealed with a 
teflon lined cap. The reaction mixture was heated to 50 
o
C until the color of the solution 
changed from dark red to yellow (usually 5-10 min). Tris(pyridine-2-yl)methane (S1) 
(284 mg; 1.15 mmol) was added to the reaction mixture and the resulting solution was 
then filtered through a plug of diatomaceous earth. The volatiles were removed under 
reduced pressure and the residue was suspended in hexanes (100 mL). The solid was 
filtered, redissolved in CH2Cl2 (15 mL) and then precipitated again with hexanes (100 
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mL). The product was filtered and then washed with 50/50 mixture of Et2O and hexanes 
(3 × 30 mL) and dried under reduced pressure.  
Pd
II
 complexes with the (Py3CH)Pd
II
(biphen-2-yl)(I) general structure exist as a 
mixture of equilibrating isomers as shown in Scheme 3.27. NMR specttra for the 
obtained Pd
II
 complexes are very broad at 25 
o
C indicating that the isomerization is 
facile. Upon cooling to -20 
o
C the broad resonances resolved into sharp signals. However, 
as it is evident from 2D 
1
H/
1
H ROESY or NOESY spectra, both isomers are still in 
equilibrium at -20
o
C. Because of extensive overlap between the peaks of the two isomers, 
1
H and 
13
C{
1
H} NMR data for these Pd
II
 complexes is not reported in detail. The 
structure of Pd
II
 complex 6 was confirmed by a single crystal X-ray diffraction analysis 
(Figure 3.7). 
 
Scheme 3.27 Equilibrium between conformers of (Py3CH)Pd
II
(biphen-2-yl)(I) 
 
 
Preparation of (Py3CH)Pd
II
([1,1'-biphenyl]-2-yl)(I) (6). 6 was was obtained 
according to the general procedure 3 in 67% yield as a yellow powder. X-ray quality 
crystals of 6 were obtained by slow vapor diffusion of Et2O into CH2Cl2 solution of 6. In 
CDCl3 at 25 
o
C complex 6 exists as a mixture of two equilibrating isomers 6a and 6b in 
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approximately 1:2 ratio, however, isomer 6a crystallized in preference to 6b (Figure 3.7). 
HRMS electrospray (m/z): [M – I]+ calcd for C28H22N3Pd, 506.0854; Found, 506.0859. 
 
Figure 3.7 Ortep drawing of (Py3CH)Pd
II
([1,1'-biphenyl]-2-yl)(I) (6) 
 
Thermal ellipsoids are drawn at 50% probability. Hydrogen atoms are omitted for 
clarity. There is rotational disorder in a portion of the free pyridine ring that results in 
N3/C13 sites being mixed occupancy at 0.5 ratio. 
 
Preparation of (Py3CCH3)Pd
II
([1,1'-biphenyl]-2-yl)(I) (S16). S16 was obtained 
according to the general procedure 3 in 77% yield as a yellow powder. Only one 
stereoisomer was detected in the 
1
H and 
13
C{
1
H} NMR spectra of S16. Stereochemistry 
of S16 was determined from the 
1
H/
1
H NOESY NMR experiment. 
1
H NMR (CDCl3 at 
25
o
C): δ 9.41 (d, J = 4.8 Hz, 1H), 8.64 (d, J = 4.1 Hz, 1H), 8.38 (d, J = 7.5 Hz, 2H), 7.98 
(d, J = 5.9 Hz, 1H), 7.85 (t, J = 6.5 Hz, 1H), 7.76 (m, 3H), 7.70 (d, J = 5.9 Hz, 1H), 7.39 
(t, J = 7.6 Hz, 2H), 7.34 (dd, J = 6.7 and 5.0 Hz, 1H), 7.30 (t, J = 6.2 Hz, 1H), 7.24 (t, J = 
7.4 Hz, 1H), 7.20 (dd, J = 7.4 and 1.0 Hz, 1H), 6.98 (dd, J = 8.9 and 5.3 Hz, 1H), 6.88 (d, 
J = 8.1 Hz, 1H), 6.85 (t, J = 7.6 Hz, 1H), 6.66 (t, J = 6.7 Hz, 1H), 6.51 (d, J = 7.2 Hz, 
1H), (s, 3H). 
13
C NMR (CDCl3 at 25
o
C): δ 165.84, 161.58, 159.12, 154.91, 152.64, 
 101 
 
149.61, 145.76, 145.04, 143.21, 138.20, 138.02, 137.74, 137.54, 130.52, 129.32, 127.40, 
126.06, 124.69, 124.01, 123.60, 123.23, 123.21, 123.18, 122.52, 122.31, 60.01, 28.05. 
HRMS electrospray (m/z): [M – I]+ calcd for C29H24N3Pd, 520.1000; Found, 520.1009. 
Preparation of (Py3CH)Pd
II
(3',4',5'-trifluoro-[1,1'-biphenyl]-2-yl)(I) (S17). 
S17 was obtained according to the general procedure 3 in 73% yield as a yellow powder. 
19
F NMR (CD2Cl2 at -25 
oC) of the major isomer: δ -136.92 (dd, J = 20.0 and 10.0 Hz, 
2F), -165.43 (tt, J = 21.6 and 6.6 Hz, 1F). 
19
F NMR (CD2Cl2 at -25 
o
C) of the minor 
isomer: δ -136.96 (dd, J = 21.6 and 8.3 Hz, 2F), -165.27 (tt, J = 21.6 and 6.6 Hz, 1F). 
HRMS electrospray (m/z): [M – I]+ calcd for C28H19F3N3Pd, 560.0560; Found, 560.0571. 
Preparation of (Py3CH)Pd
II(2’-deutero-[1,1'-biphenyl]-2-yl)(I) (S18). S18 was 
obtained according to the general procedure 3 in 79% yield as a yellow powder. HRMS 
electrospray (m/z): [M – I]+ calcd for C28H21DN3Pd, 507.0906; Found, 507.0916. 
Preparation of (Py3CH)Pd
II
(5-fluoro-4'-tert-butyl-[1,1'-biphenyl]-2-yl)(I) 
(S19). S19 was obtained according to the general procedure 3 in 74% yield as a yellow 
powder. 
19
F NMR (CDCl3 at -25
o
C): δ -124.24 (q, J = 8.3 Hz, isomer S19a), -123.45 (q, J 
= 9.4 Hz, isomer S19b). HRMS electrospray (m/z): [M – I]+ calcd for C32H29FN3Pd, 
580.1375; Found, 580.1391. 
Preparation of (Py3CH)Pd
II
(4'-tert-butyl-2',6'-dideutero-5-fluoro-[1,1'-
biphenyl]-2-yl)(I) (S20). S20 was obtained according to the general procedure 3 in 83% 
yield as a yellow powder. 
19
F NMR (CDCl3 at -25
o
C): δ -124.24 (q, J = 10.0 Hz, isomer 
S20a), -123.46 (q, J = 8.2 Hz, isomer S20b). HRMS electrospray (m/z): [M – I]+ calcd 
for C32H27D2FN3Pd, 582.1500; Found, 582.1515. 
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Preparation of (Py3CH)Pd
II
(4,3'-dimethyl-[1,1'-biphenyl]-2-yl)(I) (S21). S21 
was obtained according to the general procedure 3 in 73% yield as a yellow powder.  
HRMS electrospray (m/z): [M – I]+ calcd for C30H26N3Pd, 534.1156; Found, 534.1153. 
Preparation of (Py3CH)Pd
II
(3',5'-dimethyl-[1,1'-biphenyl]-2-yl)(I) (S22). S22 
was obtained according to the general procedure 3 in 51% yield as a yellow powder.   
HRMS electrospray (m/z): [M – I]+ calcd for C30H26N3Pd, 534.1156; Found, 534.1168. 
 
X-ray structure determination for (Py3CH)Pd
II
([1,1'-biphenyl]-2-yl)(I) (6). 
Orange blocks of 6 were grown from a dichloromethane/diethyl ether solution of the 
compound at 4 deg. C.  A crystal of dimensions 0.06 x 0.03 x 0.03 mm was mounted on a 
Rigaku AFC10K Saturn 944+ CCD-based X-ray diffractometer equipped with a low 
temperature device and Micromax-007HF Cu-target micro-focus rotating anode ( = 
1.54187 A) operated at 1.2 kW power (40 kV, 30 mA).  The X-ray intensities were 
measured at 85(1) K with the detector placed at a distance 42.00 mm from the crystal.  A 
total of 3718 images were collected with an oscillation width of 1.0 in  The exposure 
time was 1 sec. for the low angle images, 4 sec. for high angle.  The integration of the 
data yielded a total of 60719 reflections to a maximum 2 value of 136.46 of which 
4344 were independent and 4154 were greater than 2(I).  The final cell constants were 
based on the xyz centroids of 46120 reflections above 10(I).  Analysis of the data 
showed negligible decay during data collection; the data were processed with 
CrystalClear 2.0 and corrected for absorption.  The structure was solved and refined with 
the Bruker SHELXTL (version 2008/4) software package, using the space group P2(1)/n 
with Z = 4 for the formula C28H22N3PdI.  Full matrix least-squares refinement based on 
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F2 converged at R1 = 0.0320 and wR2 = 0.0825 [based on I > 2sigma(I)], R1 = 0.0329 
and wR2 = 0.0832 for all data.  There is rotational disorder in a portion of one ligand that 
results in N3/C13 sites being mixed occupancy at 0.5 ratio. Additional details are 
presented in below. 
 
Crystal data and structure refinement for am5379 (complex 6). 
  
      Identification code                am5379 
      Empirical formula                  C28 H22 I N3 Pd 
      Formula weight                     633.79 
      Temperature                        85(2) K 
      Wavelength                         1.54178 A 
      Crystal system, space group        Monoclinic,  P2(1)/n 
      Unit cell dimensions               a = 9.3934(2) A   alpha = 90 deg. 
                                          b = 14.7202(3) A  beta = 101.232(7) deg. 
                                          c = 17.5207(12) A  gamma = 90 deg. 
      Volume                              2376.23(18) A^3 
      Z, Calculated density              1.772 Mg/m^3 
      Absorption coefficient             16.657 mm^-1 
      F(000)                              1240 
      Crystal size                        0.06 x 0.03 x 0.03 mm 
      Theta range for data collection    5.15 to 68.23 deg. 
      Limiting indices                   -11<=h<=11, -17<=k<=17, -21<=l<=20 
      Reflections collected / unique     60719 / 4344 [R(int) = 0.0687] 
      Completeness to theta = 68.23      99.9% 
      Absorption correction              Semi-empirical from equivalents 
      Max. and min. transmission         0.6349 and 0.4348 
  
      Refinement method                  Full-matrix least-squares on F^2 
  
      Data / restraints / parameters     4344 / 0 / 298 
      Goodness-of-fit on F^2             1.063 
      Final R indices [I>2sigma(I)]      R1 = 0.0320, wR2 = 0.0825 
      R indices (all data)               R1 = 0.0329, wR2 = 0.0832 
      Largest diff. peak and hole        1.392 and -0.984 e.A^-3 
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Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 x 
10^3) for complex 6. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 __________________________________________________________________________________ 
  
                                x                  y                   z            U(eq) 
__________________________________________________________________________________ 
  
          I(1)          4030(1)        2258(1)        1980(1)        26(1) 
          Pd(1)         1358(1)        2255(1)        1197(1)        21(1) 
          C(1)         -1923(4)        2424(3)         827(2)        25(1) 
          C(2)         -3297(4)        2533(3)         379(2)        27(1) 
          C(3)         -3443(4)        2640(3)        -417(2)        30(1) 
          C(4)         -2217(4)        2601(2)        -745(2)        26(1) 
          C(5)          -869(4)        2480(2)        -272(2)        23(1) 
          C(6)           493(4)        2442(3)        -617(2)        25(1) 
          C(7)          1249(4)        1538(3)        -442(2)        28(1) 
          C(8)          1355(5)         930(3)       -1038(3)        35(1) 
          C(9)          1987(6)          88(3)        -849(3)        43(1) 
          C(10)         2492(6)        -123(3)         -71(3)        45(1) 
          C(11)         2344(5)         508(3)         487(3)        35(1) 
          C(12)         1439(4)        3284(3)        -389(2)        26(1) 
          C(13)         2871(4)        3215(3)         -58(2)        34(1) 
          N(3A)         2871(4)        3215(3)         -58(2)        34(1) 
          C(14)         3616(5)        4007(3)         164(3)        36(1) 
          C(15)         2952(5)        4835(3)          34(3)        37(1) 
          C(16)         1529(5)        4862(3)        -344(3)        43(1) 
          C(17)          865(4)        3114(2)        1978(2)        24(1) 
          C(18)         1193(4)        4028(3)        1887(2)        29(1) 
          C(19)          775(4)        4699(3)        2354(3)        33(1) 
          C(20)           17(4)        4464(3)        2924(2)        33(1) 
          C(21)         -321(4)        3563(3)        3024(2)        28(1) 
          C(22)           97(4)        2873(3)        2561(2)        24(1) 
          C(23)         -331(4)        1919(3)        2693(2)        26(1) 
          C(24)        -1712(4)        1734(3)        2845(2)        30(1) 
          C(25)        -2150(4)         862(3)        2980(2)        34(1) 
          C(26)        -1200(5)         140(3)        2981(2)        36(1) 
          C(27)          187(4)         297(3)        2834(2)        30(1) 
          C(28)          603(4)        1179(3)        2690(2)        27(1) 
          N(1)          -717(3)        2400(2)         515(2)        21(1) 
          N(2)          1737(4)        1325(2)         310(2)        29(1) 
          N(3)           755(4)        4085(3)        -551(2)        34(1) 
          C(13A)         755(4)        4085(3)        -551(2)        34(1) 
________________________________________________________________ 
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3.11.3 Complexes with [(Py3CH)Pd
IV
(biaryl)(Cl)2][ICl2] General Structure 
 
 
 
General procedure 4: Preparation of Pd
IV
 complexes with 
[(Py3CH)Pd
IV
(biphen-2-yl)(Cl)2][ICl2]  general structure. Iodobenzene dichloride 
(1.24g; 4.5 mmol) was added to a solution of the corresponding Pd
II
 complex (2.1 mmol) 
in CH2Cl2 (25 mL). The reaction mixture was stirred at ambient temperature for 5 
minutes. If any precipitate had formed during this period, nitromethane (~ 5 mL) was 
then added to dissolve it. The resulting bright orange solution was washed with water (3 
× 40 mL) and then with brine (2 × 40 mL). The organic phase was dried over anhydrous 
Na2SO4 and evaporated under reduced pressure. Et2O (80 mL) was added to the 
amorphous residue and the resulting suspension was sonicated for 15 minutes at 20 
o
C. 
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The crystalline product was filtered and washed with several portions of Et2O (3 × 30 
mL) and then with EtOAc (3 × 10 mL). Thus obtained orange powder was dried under 
high vacuum. 
Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][ICl2] (7). 7 was 
obtained according to the general procedure 4 in 85% yield. X-ray quality crystals of 
were obtained by slow vapor diffusion of Et2O into CD3NO2 solution of 7 at 4 
o
C. 
1
H 
NMR (CD3NO2): δ 9.14 (d, J = 5.1 Hz, 1H), 9.00 (d, J = 6.1 Hz, 2H), 8.53 (d, J = 8.8 Hz, 
1H), 8.30 (t, J = 7.5 Hz, 2H), 8.09 (t, J = 7.6 Hz, 1H), 7.97 (m, 3H), 7.78 (t, J = 6.9 Hz, 
2H), 7.65 (t, J = 6.4 Hz, 1H), 7.35 (m, 2H), 6.85 (t, J = 7.3 Hz, 1H), 6.79 (d, J = 6.8 Hz, 
1H), 6.55 (t, J = 7.6 Hz, 2H), 6.44 (s, 1H), 5.94 (d, J = 7.3 Hz, 2H). 
13
C NMR (CD3NO2): 
δ 155.61, 154.24, 150.29, 149.28, 148.67, 144.20, 143.56, 142.00, 141.15, 140.94, 
135.60, 128.11, 127.92, 127.76, 127.68, 127.08, 125.78, 125.68, 125.57, 61.98. HRMS 
electrospray (m/z): [M – ICl2]
+
 calcd for C28H22Cl2N3Pd, 576.0220; Found, 576.0211. 
Preparation of [(Py3CCH3)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][ICl2] (S23). S23 
was obtained according to the general procedure 4 in 79% yield. 
1
H NMR (CD3NO2): δ 
9.29 (d, J = 5.3 Hz, 1H), 9.10 (d, J = 5.4 Hz, 2H), 8.57 (d, J = 8.6 Hz, 1H), 8.32 (t, J = 
7.4 Hz, 2H), 8.11 (m, 3H), 8.00 (d, J = 8.3 Hz, 1H), 7.77 (t, J = 6.4 Hz, 2H), 7.77 (t, J = 
6.4 Hz, 1H), 7.37 (td, J = 8.9 and 1.9 Hz, 1H), 7.32 (t, J = 6.9 Hz, 1H), 7.23 (t, J = 7.4 
Hz, 1H), 6.77 (dd, J = 6.9 and 2.1 Hz, 1H), 6.53 (t, J = 7.6 Hz, 2H), 5.84 (d, J = 7.2 Hz, 
2H), 2.77 (s, 3H). 
13
C NMR (CD3NO2): δ 156.24, 154.94, 151.70, 151.20, 150.59, 
144.01, 143.55, 141.75, 141.10, 140.96, 135.64, 127.79, 127.72 (two overlapping peaks 
as determined by 2D 
1
H/
13
C ASAPHMQC), 127.65, 127.11, 126.16, 125.63, 125.45, 
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123.21, 57.87, 21.40. HRMS electrospray (m/z): [M – ICl2]
+
 calcd for C29H24Cl2N3Pd, 
592.0382; Found, 592.0370. 
Preparation of [(Py3CH)Pd
IV
(3',4',5'-trifluoro-[1,1'-biphenyl]-2-yl)(Cl)2] 
[ICl2] (27). 27 was obtained according to the general procedure 4 in 77% yield. Complex 
27 exist as a mixture of two equilibrating isomers 27a and 27b. The ratio between 
isomers 27a and 27b is ~ 40/60 in CDCl3 and ~ 75/25 in CD3NO2 at 25
o
C. Because of the 
overlap between the peaks of the two isomers 
1
H and 
13
C{
1
H} NMR data for 27a/b is not 
reported in detail. 
19
F NMR (CDCl3 at 25
o
C) of the major isomer: δ - 137.88 (dd, J = 18.4 
and 11.7 Hz, 2F), -162.93 (t, J = 21.6 Hz, 1F). 
19
F NMR (CDCl3 at 25
o
C) of the minor 
isomer: δ -132.61 (dd, J = 19.9 and 7.5 Hz, 2F), -158.61 (t, J = 19.9 Hz, 1F). 19F NMR 
(CD3NO2 at 25
o
C) of the major isomer: δ -136.62 (m, 2F), -164.26 (m, 1F). 19F NMR 
(CD3NO2 at 25
o
C) of the minor isomer: δ - 141.34 (dd, J = 18.3 and 8.3 Hz, 2F), -166.93 
(tt, J = 20.1 and 6.7 Hz, 1F). HRMS electrospray (m/z): [M – ICl2]
+
 calcd for 
C28H19Cl2F3N3Pd, 629.9937; Found, 629.9938. 
Preparation of [(Py3CH)Pd
IV(2’-deutero-[1,1'-biphenyl]-2-yl)(Cl)2][ICl2] 
(S24). S24 was obtained according to the general procedure 4 in 46% yield. 
1
H NMR 
(CD3NO2): δ 9.13 (d, J = 5.3 Hz, 1H), 8.99 (d, J = 6.0 Hz, 2H), 8.52 (d, J = 9.0 Hz, 1H), 
8.29 (t, J = 7.5 Hz, 2H), 8.08 (t, J = 7.7 Hz, 1H), 7.98 (d, J = 7.9 Hz, 2H), 7.95 (d, J = 7.7 
Hz, 1H), 7.77 (t, J = 6.4 Hz, 2H), 7.64 (t, J = 6.4 Hz, 1H), 7.36 (td, J = 7.3 and 1.5 Hz, 
1H), 7.32 (t, J = 7.0 Hz, 1H), 6.84 (t, J = 7.5 Hz, 1H), 6.78 (dd, J = 7.0 and 1.7 Hz, 1H), 
6.54 (m, 2H), 6.44 (s, 1H), 5.94 (d, J = 7.9 Hz, 1H). 
13
C NMR (CD3NO2): δ 155.61, 
154.22, 150.28, 149.27, 148.66, 144.20, 143.52, 141.99, 141.14, 140.84, 135.59, 128.11, 
127.91, 127.74, 127.69, 127.62, 127.08, 126.96 125.77, 125.68, 125.56, 61.96 (Signal of 
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the carbon attached to the deuterium was not observed presumably because it is a triplet 
of low intensity that overlaps with other more intense nearby peaks). HRMS electrospray 
(m/z): [M – ICl2]
+
 calcd for C28H21DCl2N3Pd, 577.0283; Found, 577.0283. 
Preparation of [(Py3CH)Pd
IV
(5-fluoro-4'-tert-butyl-[1,1'-biphenyl]-2-yl)(Cl)2] 
[ICl2] (S25). S25 was obtained according to the general procedure 4 in 60% yield. 
1
H 
NMR (CD3NO2): δ 9.12 (d, J = 4.9 Hz, 1H), 8.98 (d, J = 6.0 Hz, 2H), 8.55 (dd, J = 9.2 
and 5.8 Hz, 1H), 8.32 (t, J = 7.5 Hz, 2H), 8.09 (t, J = 7.5 Hz, 1H), 8.02 (d, J = 7.2 Hz, 
2H), 7.95 (d, J = 7.6 Hz, 1H), 7.80 (t, J = 6.4 Hz, 2H), 7.64 (t, J = 6.4 Hz, 1H), 7.18 (td, J 
= 8.6 and 3.2 Hz, 1H), 6.61 (dd, J = 9.6 and 3.4 Hz, 1H), 6.56 (d, J = 8.1 Hz, 2H), 6.53 
(s, 1H), 5.89 (d, J = 8.3 Hz, 2H), 1.19 (s, 9H). 
13
C NMR (CD3NO2): δ 161.15 (d, J = 
246.6 Hz), 154.24, 150.31, 149.11, 148.54, 148.22, 145.20 (d, J = 7.5 Hz), 144.34, 
142.27 (d, J = 7.5 Hz), 142.15, 137.42, 137.14, 127.98, 127.81, 127.21, 125.87, 125.79, 
123.97, 120.54 (d, J = 21.8 Hz), 113.79 (d, J = 21.1 Hz), 61.77, 33.64, 29.96. 
19
F NMR 
(CD3NO2): δ -118.74 (q, J = 7.3 Hz). 
1
H NMR (CDCl3): δ 9.10 (d, J = 5.4 Hz, 1H), 8.92 
(d, J = 6.0 Hz, 2H), 8.52 (dd, J = 9.5 and 5.7 Hz, 1H), 8.39 (d, J = 7.5 Hz, 2H), 8.35 (d, J 
= 7.7 Hz, 1H), 8.19 (t, J = 7.5 Hz, 2H), 8.01 (t, J = 7.5 Hz, 1H), 7.64 (t, J = 6.4 Hz, 1H), 
7.53 (t, J = 6.9 Hz, 1H), 7.23 (s, 1H), 7.09 (td, J = 7.4 and 3.4 Hz, 1H), 6.54 (dd, J = 9.2 
and 3.4 Hz, 1H), 6.47 (d, J = 8.1 Hz, 2H), 5.67 (d, J = 8.1 Hz, 2H), 1.20 (s, 9H). 
13
C 
NMR (CDCl3): δ 161.21 (d, J = 249 Hz), 153.78, 150.53, 149.35 (two overlapping 
resonances as revealed by 2D 
1
H/
13
C HSQC and HMBC), 149.14, 147.56, 144.64 (d, J = 
6.8 Hz), 143.63, 142.58 (d, J = 6.8 Hz), 142.06, 136.87, 129.01, 127.18, 126.96, 126.91, 
125.81, 124.21, 121.12 (d, J = 21.5 Hz), 114.66 (d, J = 20.5 Hz), 60.40, 34.27, 31.17. 
19
F 
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NMR (CDCl3): δ -115.80 (q, J = 16.6 Hz). HRMS electrospray (m/z): [M – ICl2]
+
 calcd 
for C32H29Cl2FN3Pd, 650.0752; Found, 650.0757. 
Preparation of [(Py3CH)Pd
IV
(4'-tert-butyl-2',6'-dideutero-5-fluoro-[1,1'-
biphenyl]-2-yl)(Cl)2][ICl2] (S26). S26 was obtained according to the general procedure 4 
in 81% yield. 
1
H NMR (CD3NO2): δ 9.12 (d, J = 5.1 Hz, 1H), 8.98 (d, J = 6.4 Hz, 2H), 
8.55 (td, J = 7.7 and 3.6 Hz, 1H), 8.32 (t, J = 7.3 Hz, 2H), 8.09 (t, J = 7.2 Hz, 1H), 8.01 
(d, J = 7.5 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.80 (t, J = 6.4 Hz, 2H), 7.64 (t, J  =6.3 Hz, 
1H), 7.18 (td, J = 8.9 and 3.2 Hz, 1H), 6.61 (dd, J = 9.4 and 3.1 Hz, 1H), 6.56 (br, 2H), 
6.51 (s, 1H), 1.19 (s, 3H). 
13
C NMR (CD3NO2): δ 161.15 (d, J = 246.6 Hz), 154.24, 
150.31, 149.09, 148.53, 148.24, 145.14 (d, J = 6.8 Hz), 144.36, 142.27 (d, J = 7.5 Hz), 
142.15, 137.42, 136.96, 128.00, 127.81, 126.89 (t, J = 23.8 Hz), 125.88, 125.81, 123.86, 
120.54 (d, J = 21.8 Hz), 113.79 (d, J = 21.1 Hz), 61.80, 33.64, 29.98. 
19
F NMR 
(CD3NO2): δ -118.73 (q, J = 6.7 Hz). HRMS electrospray (m/z): [M – ICl2]
+
 calcd for 
C32H27D2Cl2FN3Pd, 652.0877; Found, 652.0878. 
Preparation of [(Py3CH)Pd
IV
(4,3'-dimethyl-[1,1'-biphenyl]-2-yl)(Cl)2][ICl2] 
(40). 40 was obtained according to the general procedure 4 in 74% yield. 
1
H NMR 
(CDCl3 at 25 
oC): δ 9.11 (d, J = 5.1 Hz, 1H), 8.97 (d, J = 5.4 Hz, 1H), 8.91 (d, J = 4.4 Hz, 
1H), 8.50 (d, J = 7.6 Hz, 1H), 8.40-8.35 (m, 3H), 8.18 (t, J = 7.3 Hz, 1H), 8.12 (t, J = 7.3 
Hz, 1H), 7.96 (td, J = 7.6 and 1.2 Hz, 1H), 7.58 (t, J = 6.4 Hz, 1H), 7.53 (t, J = 6.6 Hz, 
1H), 7.49 (t, J = 6.4 Hz, 1H), 7.41 (s, 1H), 7.12 (dd, J = 8.9 and 2.5 Hz, 1H), 6.77 (d, J = 
7.6 Hz, 1H), 6.52 (d, J = 2.2 Hz, 1H), 6.37 (t, J = 7.8 Hz, 1H), 5.68 (s, 1H), 5.36 (d, J = 
7.3 Hz, 1H), 2.35 (s, 3H), 1.89 (s, 3H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 153.80, 
153.74, 153.14, 150.38, 149.86, 149.60, 143.38, 143.05, 142.71, 141.71, 140.85, 140.69, 
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137.74, 136.38 (two overlapping peaks as revealed by 
1
H/
13
C HMBC), 136.08, 129.33, 
129.26, 128.97, 128.84, 127.68, 127.20, 126.89, 126.68, 126.13, 125.60, 124.09, 59.99, 
21.35, 19.98. HRMS electrospray (m/z): [M – ICl2]
+
 calcd for C30H26Cl2N3Pd, 
604.0533; Found, 604.0518. 
Preparation of [(Py3CH)Pd
IV
(3',5'-dimethyl-[1,1'-biphenyl]-2-yl)(Cl)2][ICl2] (43). 
40 was obtained according to the general procedure 4 in 53% yield. 
1
H NMR (CD3NO2 at 
25 
oC): δ 9.13 (d, J = 5.1 Hz, 1H), 8.97 (d, J = 5.9 Hz, 2H), 8.52 (d, J = 8.6 Hz, 1H), 8.34 
(t, J = 7.6 Hz, 2H), 8.09 (t, J = 7.6 Hz, 1H), 8.05 (d, J = 7.6 Hz, 2H), 8.00 (d, J = 7.6 Hz, 
1H), 7.79 (t, J = 6.6 Hz, 2H), 7.64 (t, J = 6.1 Hz, 1H), 7.35 (t, J = 6.1 Hz, 1H), 7.30 (t, J = 
7.1 Hz, 1H), 6.72 (d, J = 6.6 Hz, 1H), 6.56 (s, 1H), 6.53 (s, 1H), 5.51 (s, 2H), 1.84 (s 6H). 
13
C{
1
H} NMR (CD3NO2 at 25 
oC): δ 155.68, 154.31, 150.30, 149.40, 148.96, 144.02, 
143.73, 142.03, 141.11, 140.94, 136.33, 135.91, 128.21, 127.79, 127.68 (two overlapping 
signals as revealed by 
1
H/
13
C ASAPHMQC, see below), 127.26, 125.97, 125.78, 125.69, 
61.98, 19.95. HRMS electrospray (m/z): [M – ICl2]
+
 calcd for C30H26Cl2N3Pd, 
604.0533; Found, 604.0541.  
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X-ray structure determination for [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][ICl2] (7). 
Orange blocks of 7 were grown from a diethyl ether/nitromethane solution of the 
compound at 4 deg. C.  A crystal of dimensions 0.08 x 0.06 x 0.06 mm was mounted on a 
Rigaku AFC10K Saturn 944+ CCD-based X-ray diffractometer equipped with a low 
temperature device and Micromax-007HF Cu-target micro-focus rotating anode ( = 
1.54187 A) operated at 1.2 kW power (40 kV, 30 mA).  The X-ray intensities were 
measured at 85(1) K with the detector placed at a distance 42.00 mm from the crystal.  A 
total of 3580 images were collected with an oscillation width of 1.0 in  The exposure 
time was 2 sec. for the low angle images, 6 sec. for high angle.  The integration of the 
data yielded a total of 67413 reflections to a maximum 2 value of 136.48 of which 
5115 were independent and 5056 were greater than 2(I).  The final cell constants were 
based on the xyz centroids of 49398 reflections above 10(I).  Analysis of the data 
showed negligible decay during data collection; the data were processed with 
CrystalClear 2.0 and corrected for absorption.  The structure was solved and refined with 
the Bruker SHELXTL (version 2008/4) software package, using the space group P2(1)/c 
with Z = 4 for the formula C28H22N3Cl4IPd.  Full matrix least-squares refinement based 
on F2 converged at R1 = 0.0253 and wR2 = 0.0592 [based on I > 2sigma(I)], R1 = 0.0257 
and wR2 = 0.0603 for all data.  Additional details are presented below. 
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Crystal data and structure refinement for complex 7. 
  
      Identification code                am5380 
      Empirical formula                  C28 H22 Cl4 I N3 Pd 
      Formula weight                     775.59 
      Temperature                        85(2) K 
      Wavelength                         1.54178 A 
      Crystal system, space group        Monoclinic,  P 2(1)/c  
      Unit cell dimensions               a = 13.9340(3) A   alpha = 90 deg. 
                                          b = 12.6639(2) A    beta = 92.745(7) deg. 
                                          c = 15.8661(11) A   gamma = 90 deg. 
      Volume                              2796.5(2) A^3 
      Z, Calculated density              4,1842 Mg/m^3 
      Absorption coefficient             17.724 mm^-1 
      F(000)                              1512 
      Crystal size                        0.08 x 0.06 x 0.06 mm 
      Theta range for data collection    3.18 to 68.24 deg. 
      Limiting indices                   -16<=h<=16, -15<=k<=15, -19<=l<=19 
      Reflections collected / unique     67413 / 5115 [R(int) = 0.0543] 
      Completeness to theta = 68.24     99.9% 
      Absorption correction              Semi-empirical from equivalents 
      Max. and min. transmission        0.4161 and 0.3313 
      Refinement method                  Full-matrix least-squares on F^2 
      Data / restraints / parameters     5115 / 0 / 334 
      Goodness-of-fit on F^2             1.105 
      Final R indices [I>2sigma(I)]      R1 = 0.0253, wR2 = 0.0592 
      R indices (all data)               R1 = 0.0257, wR2 = 0.0603 
      Largest diff. peak and hole        1.280 and -0.901 e.A^-3 
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Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 x 
10^3) for complex 7. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 _____________________________________________________________________________ 
  
                              x                    y                   z            U(eq) 
___________________________________________________________________ 
  
          I(1)           5485(1)        6869(1)        1107(1)        18(1) 
          Pd(1)          1004(1)        5737(1)        3082(1)         9(1) 
          Cl(1)             9(1)        4361(1)        3391(1)        16(1) 
          Cl(2)           284(1)        6771(1)        4054(1)        19(1) 
          Cl(3)          5827(1)        6118(1)        2622(1)        20(1) 
          Cl(4)          5109(1)        7599(1)        -337(1)        26(1) 
          C(1)           1754(2)        4960(3)        4866(2)        18(1) 
          C(2)           2419(3)        4688(3)        5497(2)        21(1) 
          C(3)           3385(2)        4685(3)        5328(2)        21(1) 
          C(4)           3658(2)        4960(3)        4525(2)        18(1) 
          C(5)           2952(2)        5243(2)        3926(2)        12(1) 
          C(6)           3184(2)        5585(2)        3034(2)        12(1) 
          C(7)           2881(2)        6721(2)        2897(2)        12(1) 
          C(8)           3558(2)        7513(3)        2822(2)        16(1) 
          C(9)           3255(3)        8558(3)        2760(2)        22(1) 
          C(10)          2286(3)        8778(3)        2775(2)        22(1) 
          C(11)          1642(2)        7961(3)        2840(2)        17(1) 
          C(12)          1342(2)        4005(3)        1837(2)        15(1) 
          C(13)          1879(2)        3303(3)        1391(2)        16(1) 
          C(14)          2870(2)        3377(3)        1430(2)        18(1) 
          C(15)          3293(2)        4152(3)        1940(2)        17(1) 
          C(16)          2734(2)        4821(2)        2398(2)        12(1) 
          C(17)            26(2)        6239(2)        2128(2)        12(1) 
          C(18)          -915(2)        6326(3)        2384(2)        16(1) 
          C(19)         -1648(2)        6686(2)        1841(2)        16(1) 
          C(20)         -1450(2)        6954(2)        1021(2)        17(1) 
          C(21)          -517(2)        6848(2)         765(2)        17(1) 
          C(22)           247(2)        6493(2)        1298(2)        12(1) 
          C(23)          1190(2)        6437(2)         889(2)        14(1) 
          C(24)          1386(2)        5570(3)         379(2)        17(1) 
          C(25)          2235(3)        5521(3)         -49(2)        23(1) 
          C(26)          2883(2)        6352(3)           6(2)        20(1) 
          C(27)          2674(2)        7235(3)         476(2)        18(1) 
          C(28)          1834(2)        7283(3)         910(2)        16(1) 
          N(1)           2020(2)        5238(2)        4096(2)        13(1) 
          N(2)           1936(2)        6950(2)        2894(2)        12(1) 
          N(3)           1763(2)        4753(2)        2327(2)        11(1) 
 ____________________________________________________________________________ 
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3.11.4 Complexes with [(Py3CH)Pd
IV
(biaryl)(Z)(Y)][X] General Structure (Z, Y = 
OD, OAc, Cl, Br, N3) 
 
 
Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][Cl] (8). AgOOCCF3 
(265 mg; 1.2 mmol) was added to the solution of the corresponding Pd
II
 iodide complex 6 
(645 mg; 1.0 mmol) in CH2Cl2 (25 mL). The resulting suspension was sonicated at 20 
o
C 
for 5 min and then it was filtered through a pad of diatomaceous earth. Iodobenzene 
dichloride (470 mg; 1.7 mmol) was then added and the solution was stirred at 20 
o
C for 5 
min. The resulting bright orange solution was washed with water (3 × 40 mL) and then 
with brine (2 × 40 mL). The organic phase was dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. Et2O (80 mL) was added to the amorphous residue 
and the resulting suspension was sonicated for 15 minutes at 20 
o
C. The crystalline 
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product was filtered and washed with several portions of Et2O (3 × 30 mL) and then with 
EtOAc (3 × 5 mL). After drying under vacuum 515 mg (83%) of 8 was obtained as an 
orange powder. 
1
H NMR (CDCl3): δ 9.07 (dd, J = 5.5 and 1.3 Hz, 1H), 8.99 (s, 1H), 8.88 
(dd, J = 6.0 and 1.0 Hz, 2H), 8.83 (d, J = 7.6 Hz, 1H), 8.72 (d, J = 7.4 Hz, 2H), 8.55 (dd, 
J = 8.8 and 0.6 Hz, 1H), 8.03 (t, J = 6.9 Hz, 2H), 7.89 (td, J = 7.6 and 1.2 Hz, 1H), 7.49 
(t, J = 6.5 Hz, 2H), 7.43 (t, J = 6.0 Hz, 1H), 7.30 (td, J = 7.0 and 2.0 Hz, 1H), 7.22 (td, J 
= 7.2 and 0.7 Hz, 1H), 6.81 (t, J 7.6 = Hz, 1H), 6.69 (dd, J = 7.2 and 2.2 Hz), 6.42 (t, J = 
7.7 Hz, 2H), 5.74 (d, J = 7.1 Hz, 2H). 
13
C NMR (CDCl3): δ 154.84, 153.36, 150.60, 
150.27, 149.92, 143.21, 142.89, 141.72, 141.36, 140.69, 135.52, 129.58, 128.25, 127.77, 
127.60, 127.56, 127.08, 126.33, 126.20, 125.29, 57.84. HRMS electrospray (m/z): [M – 
Cl]
+
 calcd for C28H22Cl2N3Pd, 576.0220; Found, 576.0211. 
Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(OD)2][OD] (13). The 
corresponding Pd
IV
 dichloride complex 8 (20.0 mg; 0.03 mmol) was dissolved in CDCl3 
(0.7 mL). NaOD (~8 mg; 0.2 mmol) in D2O (1.0 mL) was added to the CDCl3 solution 
and the resulting biphasic mixture was shaken intensively for two minutes. Then D2O and 
CDCl3 layers were separated and analyzed by NMR spectroscopy. 
1
H NMR spectrum of 
the CDCl3 layer did not contain any resonances of significant intensity. The 
 1
H NMR (of 
the D2O layer): δ 8.71 (d, J = 5.3 Hz, 1H), 8.35 (d, J = 5.8 Hz, 2H), 8.06 (t, J = 7.5 Hz, 
2H), 7.90 (t, J = 7.7 Hz, 1H), 7.81 (dd, J = 8.6 and 0.9 Hz, 1H), 7.75 (m, 3H), 7.52 (t, J = 
6.4 Hz, 2H), 7.47 (td, J = 6.5 and 1.0 Hz, 1H), 7.38 (td, J = 8.4 and 1.2 Hz, 1H), 7.24 (td, 
J = 7.2 and 0.9 Hz, 1H), 6.68 (m, 2H), 6.35 (t, J = 7.4 Hz, 2H), 5.74 (d, J = 7.2 Hz, 2H). 
13
C NMR (D2O): δ 153.12, 151.44, 149.91, 149.72, 148.32, 143.81, 143.52, 142.04, 
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140.43, 134.38, 133.38, 128.94, 127.73, 127.66, 127.65, 127.22, 127.02, 125.77, 125.75, 
125.49, 60.72. 
Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)(OAc)][OAc] (15). 
Bu4NOAc (11.7 mg; 0.04 mmol) was added to a cooled (-30 
o
C) NMR tube containing a 
solution of complex 8 (10 mg; 0.013 mmol) in CD2Cl2 (0.5 mL). The NMR tube was 
inserted into the NMR spectrometer (precooled to -20 
o
C) and the progress of the reaction 
was monitored by 
1
H NMR. With ~3 equivalents of Bu4NOAc only ~50% conversion of 
8 to 15 was observed. Upon the addition of ~3 more equivalents of Bu4NOAc conversion 
reached 80%. Further addition of Bu4NOAc resulted only in formation of complex 
mixture of products. 
Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(N3)2][N3] (19). The solution 
of Pd
IV
 dichloride complex 8 (115 mg; 0.15 mmol) in CH2Cl2 (15 mL) was washed with 
4% aq NaN3 (4×10 mL). The organic phase was dried over anhydrous Na2SO4 and the 
solvent was removed under reduced pressure. The amorphous residue was suspended in 
Et2O (10 mL) and sonicated for 15 minutes at 20 
o
C. The Precipitate was collected by 
filtration, washed with EtOAc (2×3 mL) and dried under vacuum. 88 mg (94%) of 19 
was obtained as a dark red powder. Complex 19 exist as a mixture of two equilibrating 
isomers 19a and 19b. The ratio between isomers 19a and 19b is ~70/30 in CD2Cl2 at 
25
o
C. Because of the overlap between the peaks of the two isomers 
1
H and 
13
C{
1
H} 
NMR data for 19a/b is not reported in detail. 
1
H NMR of the isomer 19a (CD2Cl2): δ 8.81 
(d, J = 5.2 Hz, 1H), 8.59 (d, J = 5.7 Hz, 2H), 8.20 (t, J = 7.2 Hz, 2H), 8.14 (m, 3H), 8.06 
(t, J = 7.5 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.65 (t, J = 6.5 Hz, 2H), 7.61 (m, 1H), 7.50 
(m, 1H), 7.33 (t, J = 7.0 Hz, 1H), 6.92 (t, J = 7.5 Hz, 1H), 6.79 (d, J = 5.4 Hz, 1H), 6.62 
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(s, 1H), 6.51 (t, J = 7.4 Hz, 2H), 5.77 (d, J = 7.2 Hz, 2H). HRMS electrospray (m/z): [M 
– N3]
+
 calcd for C28H22N9Pd, 590.1028; Found, 590.1032. 
[(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Br)2][IBr2] (20). The solution of Pd
IV
 
dichloride complex 7 (100.0 mg; 0.13 mmol) in CH2Cl2 (25 mL) was washed with 10% 
aq KBr (6 × 30 mL). The organic phase was dried over anhydrous Na2SO4 and solvent 
was removed under reduced pressure. The amorphous residue was suspended in Et2O (10 
mL) and sonicated for 15 minutes at 20 
o
C. Precipitate was collected by filtration, washed 
with EtOAc (2 × 3 mL) and dried under vacuum. 89 mg (72%) of 20 was obtained as a 
dark red powder. X-ray quality crystals of 20 were grown by slow vapor diffusion of 
MTBE into CD3NO2 solution at 4 
o
C. 
1
H NMR (CD3NO2): δ 9.37 (d, J = 5.0 Hz, 1H), 
9.20 (d, J = 5.3 Hz, 2H), 8.95 (d, J = 6.4 Hz, 1H), 8.27 (t, J = 7.4 Hz, 2H), 8.06 (t, J = 7.5 
Hz, 1H), 7.95 (m, 3H), 7.73 (t, J = 6.4 Hz, 2H), 7.57 (t, J = 6.2 Hz, 1H), 7.29 (t, J = 7.1 
Hz, 1H), 7.23 (t, J = 7.2 Hz, 1H), 6.83 (t, J = 7.4 Hz, 1H), 6.76 (d, J = 5.3 Hz, 1H), 6.53 
(t, J = 7.0 Hz, 2H), 6.41 (s, 1H), 5.91 (br, 2H). 
13
C NMR (CD3NO2): δ 155.56, 152.10, 
151.14, 149.87, 148.98, 146.63, 144.53, 143.97, 141.88, 141.39, 135.91, 127.89, 127.68, 
127.54, 127.41 (two overlapping resonances as determined by 2D 
1
H/
13
C HSQC), 127.00, 
125.85, 125.70, 125.44, 62.24. HRMS electrospray (m/z): [M – IBr2]
+
 calcd for 
C28H22Br2N3Pd, 663.9210; Found, 663.9194. 
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X-ray structure determination for [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-
yl)(Br)2][IBr2] (20). Orange plates of am5390 (complex 20) were grown from a methyl-
t-butyl ether/nitromethane solution of the compound at 4 deg. C.  A crystal of dimensions 
0.13 x 0.10 x 0.06 mm was mounted on a Rigaku AFC10K Saturn 944+ CCD-based X-
ray diffractometer equipped with a low temperature device and Micromax-007HF Cu-
target micro-focus rotating anode ( = 1.54187 A) operated at 1.2 kW power (40 kV, 30 
mA).  The X-ray intensities were measured at 85(1) K with the detector placed at a 
distance 42.00 mm from the crystal.  A total of 4081 images were collected with an 
oscillation width of 1.0 in  The exposure time was 1 sec. for the low angle images, 4 
sec. for high angle.  The integration of the data yielded a total of 80397 reflections to a 
maximum 2 value of 136.44 of which 5317 were independent and 5271 were greater 
than 2(I).  The final cell constants were based on the xyz centroids of 48097 reflections 
above 10(I).  Analysis of the data showed negligible decay during data collection; the 
data were processed with CrystalClear 2.0 and corrected for absorption.  The structure 
was solved and refined with the Bruker SHELXTL (version 2008/4) software package, 
using the space group P2(1)/c with Z = 4 for the formula C28H22N3Br3IPd.  Full matrix 
least-squares refinement based on F2 converged at R1 = 0.0251 and wR2 = 0.0588 [based 
on I > 2sigma(I)], R1 = 0.0253 and wR2 = 0.0589 for all data.  Additional details are 
presented below. 
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Crystal data and structure refinement for am5390 (complex 20). 
  
  
      Identification code                am5390 
      Empirical formula                  C28 H22 Br4 I N3 Pd 
      Formula weight                     953.43 
      Temperature                        85(2) K 
      Wavelength                         1.54178 A 
      Crystal system, space group        Monoclinic,  P2(1)/c 
      Unit cell dimensions               a = 13.5583(3) A   alpha = 90 deg. 
                                          b = 12.5698(2) A   beta = 103.335(7) deg. 
                                          c = 17.5426(12) A  gamma = 90 deg. 
      Volume                              2909.1(2) A^3 
      Z, Calculated density              4,  2.177 Mg/m^3 
      Absorption coefficient             20.096 mm^-1 
      F(000)                              1800 
      Crystal size                        0.13 x 0.10 x 0.06 mm 
      Theta range for data collection    4.37 to 68.22 deg. 
      Limiting indices                   -16<=h<=16, -15<=k<=15, -21<=l<=21 
      Reflections collected / unique     80357 / 5317 [R(int) = 0.0581] 
      Completeness to theta = 68.22      100.0% 
      Absorption correction              Semi-empirical from equivalents 
      Max. and min. transmission         0.545 and 0.287 
      Refinement method                  Full-matrix least-squares on F^2 
      Data / restraints / parameters     5317 / 0 / 334 
      Goodness-of-fit on F^2             1.126 
      Final R indices [I>2sigma(I)]      R1 = 0.0251, wR2 = 0.0588 
      R indices (all data)               R1 = 0.0253, wR2 = 0.0589 
      Largest diff. peak and hole        0.708 and -0.777 e.A^-3 
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Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 x 
10^3) for am5390 (complex 20).U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
________________________________________________________________ 
 
                               x                  y                  z            U(eq) 
________________________________________________________________ 
          Pd(1)         3964(1)        1372(1)        8289(1)         8(1) 
          I(1)          8708(1)        2890(1)        2363(1)        12(1) 
          Br(1)         4910(1)        -248(1)        8713(1)        14(1) 
          Br(2)         5268(1)        1925(1)        7630(1)        16(1) 
          Br(3)         8444(1)        3029(1)        3824(1)        19(1) 
          Br(4)         9136(1)        2879(1)         916(1)        14(1) 
          N(1)          3163(2)         537(2)        7225(2)        12(1) 
          N(2)          2812(2)         815(2)       8778(2)         9(1) 
          N(3)          3108(2)        2670(2)        7802(2)        10(1) 
          C(1)          3624(3)         -73(3)        6785(2)        18(1) 
          C(2)          3098(3)        -540(3)        6104(3)        22(1) 
          C(3)          2061(3)        -385(3)        5870(2)        21(1) 
          C(4)          1583(3)         232(3)        6329(2)        17(1) 
          C(5)          2156(3)         683(3)        7007(2)        11(1) 
          C(6)          1693(2)        1389(3)        7535(2)        10(1) 
          C(7)          1859(3)         906(3)        8340(2)        11(1) 
          C(8)          1054(3)         490(3)        8616(2)        16(1) 
          C(9)          1241(3)         -46(3)        9321(3)        19(1) 
          C(10)         2230(3)        -146(3)        9748(2)        17(1) 
          C(11)         3003(3)         303(3)        9464(2)        14(1) 
          C(12)         2109(3)        2506(3)        7504(2)         9(1) 
          C(13)         1505(3)        3308(3)        7107(2)        12(1) 
          C(14)         1928(3)        4281(3)        6997(2)        15(1) 
          C(15)         2954(3)        4438(3)        7302(2)        15(1) 
          C(16)         3522(3)        3620(3)        7710(2)        12(1) 
          C(17)         4666(3)        2182(3)        9313(2)        11(1) 
          C(18)         5715(3)        2048(3)        9536(2)        14(1) 
          C(19)         6276(3)        2497(3)       10218(2)        15(1) 
          C(20)         5803(3)        3085(3)       10689(2)        20(1) 
          C(21)         4760(3)        3223(3)       10468(2)        18(1) 
          C(22)         4163(3)        2790(3)        9777(2)        13(1) 
          C(23)         3048(3)        3027(3)        9649(2)        14(1) 
          C(24)         2461(3)        2464(3)       10074(2)        17(1) 
          C(25)         1433(3)        2673(4)        9966(3)        24(1) 
          C(26)          978(3)        3473(4)        9459(3)        25(1) 
          C(27)         1568(3)        4087(4)        9077(3)        24(1) 
          C(28)         2601(3)        3870(3)        9185(2)        18(1) 
________________________________________________________________ 
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3.11.5 Complexes with [(Py3CH)Pd
IV
(biaryl)(Y) 2][OTf] General Structure  
 
 
 
General procedure 5: Preparation of Pd
IV
 complexes with 
[(Py3CH)Pd
IV
(biphen-2-yl)(Y)2][OTf]  general structure. AgOTf (82 mg; 0.32 mmol) 
was added to the solution of the corresponding Pd
IV
 complex (0.15 mmol) in CHCl3 (15 
mL). Resulting suspension was sonicated at 20 
o
C for 5 min and then it was filtered 
through a pad of diatomaceous earth. Volatiles were removed under reduced pressure and 
the residue was suspended in EtOAc (3 mL). EtOAc suspension was cooled to -25 
o
C for 
30 min and then the product was collected by filtration, washed with EtOAc (2 mL) and 
finally with Et2O (10 mL). The obtained orange powder was dried under high vacuum. 
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Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][OTf] (9). 9 was 
obtained according to the general procedure 5 in 90% yield. 
1
H NMR (CDCl3): δ 9.09 (d, 
J = 5.2 Hz, 1H), 8.91 (d, J = 5.7 Hz, 2H), 8.53 (d, J = 8.8 Hz, 1H), 8.40 (d, J = 7.7 Hz, 
2H), 8.31 (d, J = 7.7 Hz, 1H), 8.09 (t, J = 7.6 Hz, 2H), 7.92 (t, J = 7.6 Hz, 1H), 7.53 (t, J 
= 6.2 Hz, 2H), 7.46 (t, J = 6.4 Hz, 1H), 7.31 (m, 2H), 7.23 (t, J = 6.9 Hz, 1H), 6.84 (t, J = 
7.5 Hz, 1H), 6.71 (dd, J = 7.0 and 2.1 Hz, 1H), 6.43 (t, J = 7.7 Hz, 2H), 5.73 (d, J = 7.2 
Hz, 2H). 
13
C NMR (CDCl3): δ 155.10, 153.58, 150.26, 149.97, 149.78, 143.35, 143.14, 
141.69, 141.61, 140.60, 135.55, 129.08, 128.35, 127.89, 127.50, 127.14, 126.41, 126.26, 
125.45, 120.87 (q, J = 319.8 Hz), 59.67. 
19
F NMR (CDCl3): δ -78.20 (s). HRMS 
electrospray (m/z): [M – OTf]+ calcd for C28H22Cl2N3Pd, 576.0220; Found, 576.0217. 
Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2-yl)(Br)2][OTf] (22). 22 was 
obtained according to the general procedure 5 in 73% yield. 
1
H NMR (CDCl3): δ 9.33 (d, 
J = 4.8 Hz, 1H), 9.09 (dd, J = 5.8 and 1.0 Hz, 2H), 8.94 (d, J = 8.8 Hz, 1H), 8.34 (d, J = 
7.5 Hz, 2H), 8.28 (d, J = 7.7 Hz, 1H), 8.08 (t, J = 7.5 Hz, 2H), 7.90 (td, J = 7.8 and 1.7 
Hz, 1H), 7.51 (t, J = 6.8 Hz, 2H), 7.39 (t, J = 7.2 Hz, 1H), 7.18 (m, 3H), 6.81 (t, J = 7.5 
Hz, 1H), 6.69 (dd, J = 7.2 and 2.7 Hz, 1H), 6.41 (t, J = 7.8 Hz, 2H), 5.71 (d, J = 7.8 Hz, 
2H). 
13
C NMR (CDCl3): δ 154.88, 152.03, 150.53, 150.36, 150.18, 147.09, 144.16, 
143.19, 141.55, 141.07, 135.88, 128.78, 127.76, 127.64, 127.51, 127.05, 126.82, 126.27, 
126.06, 125.35, 120.88 (q, J = 320.2 Hz), 60.04. 
19
F NMR (CDCl3): δ -78.14 (s). HRMS 
electrospray (m/z): [M – TfO]+ calcd for C28H22Br2N3Pd, 663.9215; Found, 663.9205. 
Preparation of [(Py3CCH3)Pd
IV
([1,1'-biphenyl]-2-yl)(Cl)2][OTf] (24). 24 was 
obtained according to the general procedure 5 in 58% yield. 
1
H NMR (CD3NO2): δ 9.29 
(d, J = 4.9 Hz, 1H), 9.12 (d, J = 5.7 Hz, 2H), 8.57 (d, J = 8.6 Hz, 1H), 8.33 (t, J = 8.1 Hz, 
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2H), 8.10 (m, 3H), 8.01 (d, J = 8.1 Hz, 1H), 7.78 (t, J = 6.6 Hz, 2H), 7.67 (t, J = 6.4 Hz, 
1H), 7.38 (td, J = 7.1 and 2.2 Hz, 1H), 7.33 (t, J = 7.1 Hz, 1H), 6.83 (t, J = 7.6 Hz, 1H), 
6.78 (dd, J = 6.9 and 2.2 Hz, 1H), 6.53 (t, J = 7.6 Hz, 2H), 5.85 (d, J = 7.3 Hz, 2H), 2.75 
(s, 3H). 
13
C NMR (CD3NO2): δ 156.24, 154.93, 151.71, 151.20, 150.58, 144.02, 143.56, 
141.76, 141.09, 140.96, 135.64, 127.79, 127.73 (two overlapping peaks as determined by 
2D 
1
H/
13
C ASAPHMQC), 127.64, 127.10, 126.17, 125.65, 125.43, 123.22, 120.93 (q, J = 
320.4 Hz), 57.88, 21.36. 
19
F NMR (CD3NO2): δ -79.68 (s). HRMS electrospray (m/z): [M 
– TfO]+ calcd for C29H24Cl2N3Pd, 592.0382; Found, 592.0376. 
Preparation of [(Py3CH)Pd
IV
(3',4',5'-trifluoro-[1,1'-biphenyl]-2-yl)(Cl)2] 
[OTf] (28). 28 was obtained according to the general procedure 5 in 77% yield. The ratio 
between isomers 28a and 28b is approximately 50/50 in CDCl3 at 25 
o
C. Because of the 
overlap between the peaks of the two isomers 
1
H and 
13
C{
1
H} NMR data for 28a/b is not 
reported in detail. 
19
F NMR (CDCl3 at 25
o
C): δ -78.28 (s, 6F), - 133.05 (dd, J = 19.9 and 
6.7 Hz, 2F), - 137.94 (dd, J = 19.9 and 8.3 Hz, 2F), -159.42 (tt, J = 19.9 and 6.6 Hz, 1F), 
-163.01 (tt, J = 21.6 and 7.4 Hz, 1F). HRMS electrospray (m/z): [M – TfO]+ calcd for 
C28H19Cl2F3N3Pd, 629.9937; Found, 629.9939. 
Preparation of [(Py3CH)Pd
IV(2’-deutero-[1,1'-biphenyl]-2-yl)(Cl)2][OTf] (32). 
32 was obtained according to the general procedure 5 in 77% yield. 
1
H NMR (CDCl3): δ 
9.12 (d, J = 5.5 Hz, 1H), 8.94 (d, J = 6.0 Hz, 2H), 8.55 (d, J = 8.8 Hz, 1H), 8.42 (d, J = 
7.4 Hz, 2H), 8.33 (d, J = 7.6 Hz, 1H), 8.11 (t, J = 7.4 Hz, 2H), 7.94 (dt, J = 7.7 and 1.4 
Hz, 1H), 7.56 (t, J = 7.1 Hz, 2H), 7.49 (t, J = 6.5 Hz, 1H), 7.34 (m, 2H), 7.25 (t, J = 7.0 
Hz, 1H), 6.87 (t, J = 7.6 Hz, 1H), 6.73 (dd, J = 7.1 and 2.2 Hz, 1H), 6.46 (m, 2H), 5.75 
(d, J = 7.3 Hz, 1H). 
13
C NMR (CDCl3): δ 155.14, 153.60, 150.27, 149.86, 149.74, 
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143.46, 143.12, 141.72, 141.56, 140.51, 135.56, 129.01, 128.32, 127.89, 127.54, 127.16, 
127.03, 126.63, 126.54, 126.21, 125.49, 120.86 (q, J = 320.2 Hz), 59.80. 
19
F NMR 
(CDCl3 at 25
oC): δ -78.20 (s). HRMS electrospray (m/z): [M – TfO]+ calcd for 
C28H21DCl2N3Pd, 577.0283; Found, 577.0283. 
Preparatipon of [(Py3CCH3)Pd
IV
(5-fluoro-4'-tert-butyl-[1,1'-biphenyl]-2-
yl)(Cl)2][OTf] (34). 34 was obtained as an orange powder in 73% yield according to the 
general procedure 5 only using Et2O for crystallization instead of EtOAc. 
1
H NMR 
(CDCl3): δ 9.09 (d, J = 4.8 Hz, 1H), 8.89 (d, J = 5.9 Hz, 1H), 8.54 (dd, J = 9.5 and 6.1 
Hz, 1H), 8.44 (d, J = 7.7 Hz, 2H), 8.35 (d, J = 7.7 Hz, 1H), 8.11 (td, J = 7.7 and 1.1 Hz, 
2H), 7.94 (td, J = 7.7 and 1.5 Hz, 1H), 7.57 (td, J = 7.3 and 1.5 Hz, 2H), 7.47 (t, J = 7.0 
Hz, 1H), 7.39 (s, 1H), 7.09 (m, 1H),  6.53 (dd, J = 9.2 and 3.7 Hz, 1H), 6.43 (d, J = 8.1 
Hz, 2H), 5.65 (d, J = 8.4 Hz, 2H), 1.17 (s, 9H). 
13
C NMR (CDCl3): δ 161.19 (d, J = 249.9 
Hz), 153.48, 150.27, 149.93, 149.64, 149.44, 147.53, 144.72 (d, J = 7.6 Hz), 143.39, 
142.57 (d, J = 7.7 Hz), 141.89, 136.84, 129.01, 127.09, 126.84, 126.54, 125.52, 124.12, 
121.02 (d, J = 21.9 Hz), 120.83 (q, J = 319.5 Hz), 114.59 (d, J = 20.1 Hz), 59.52, 34.15, 
30.88. 
19
F NMR (CDCl3): δ -78.13 (s, 3F), -115.97 (q, J = 7.7 Hz, 1F). HRMS 
electrospray (m/z): [M – TfO]+ calcd for C32H29Cl2FN3Pd, 650.0752; Found, 650.0758. 
Preparation of [(Py3CH)Pd
IV
(4'-tert-butyl-2',6'-dideutero-5-fluoro-[1,1'-
biphenyl]-2-yl)(Cl)2][OTf] (37). 37 was obtained as an orange powder in 91% yield 
according to the general procedure 5 only using Et2O for crystallization instead of 
EtOAc. 
1
H NMR (CDCl3): δ 9.08 (dd, J = 5.7 and 1.2 Hz, 1H), 8.88 (dd, J = 5. and 1.2 
Hz, 1H), 8.53 (dd, J = 9.7 and 5.8 Hz, 1H), 8.44 (dd, J = 7.7 and 1.4 Hz, 2H), 8.35 (d, J = 
7.7 Hz, 1H), 8.10 (td, J = 7.7 and 1.4 Hz, 2H), 7.92 (td, J = 7.7 and 1.3 Hz, 1H), 7.57 (m, 
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2H), 7.47 (m, 1H), 7.39 (s, 1H), 7.09 (m, 1H),  6.52 (dd, J = 9.0 and 3.4 Hz, 1H), 6.42 (s, 
2H), 1.16 (s, 9H). 
13
C NMR (CDCl3): δ 161.19 (d, J = 249.7 Hz), 153.45, 150.26, 149.95, 
149.65, 149.46, 147.55, 144.65 (d, J = 7.2 Hz), 143.37, 142.56 (d, J = 7.5 Hz), 141.87, 
136.66, 129.01, 126.85, 126.76 (broad signal of low intensity overlapping with 126.85), 
126.51, 125.51, 124.00, 121.01 (d, J = 21.2 Hz), 120.84 (q, J = 320.2 Hz), 114.57 (d, J = 
20.4 Hz), 59.48, 34.14, 30.88. 
19
F NMR (CDCl3): δ -78.15 (s, 3F), -115.97 (q, J = 7.9 Hz, 
1F). HRMS electrospray (m/z): [M – TfO]+ calcd for C32H27D2Cl2FN3Pd, 652.0877; 
Found, 652.0881. 
 
3.11.6 Complexes with [(Py3CH)Pd
IV
([1,1'-biphenyl]-2,2’-diyl)(X)][Y] General 
Structure 
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Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2,2’-diyl)(Cl)][Cl] (12). Method 
A: with aq KOAc as the acetate source. Solution of Pd
IV
 dichloride 9 (200 mg; 0.33 
mmol) in CH2Cl2 (10 mL) was washed with 5% aq KOAc (4×15 mL) then with water 
(2×15 mL) and finally with brine (2×15 mL). The organic phase was dried over 
anhydrous Na2SO4 and volatiles were evaporated under reduced pressure. The residue 
was suspended in Et2O (20 mL) and sonicated for 5 minutes at 20 
o
C. The product was 
collected by filtration, washed with EtOAc (3×2 mL) and dried under vacuum. Yield: 73 
mg (39%) of a pale yellow powder.  
Method B: with AgOAc as the acetate source. AgOAc (167 mg; 1.0 mmol) was 
added to the solution of the Pd
IV
 dichloride 9 (200.0 mg; 0.33 mmol) in CHCl3 (20 mL). 
The resulting suspension was sonicated for 5 min at 20 
o
C and then filtered through a pad 
of diatomaceous earth. The mother liquor was then washed with brine (4×10 mL). 
Organic layer was dried over anhydrous Na2SO4 and evaporated under reduced pressure. 
The residue was suspended in Et2O (10 mL) and sonicated for 5 minutes at 20 
o
C. The 
fine powder was collected by filtration, washed with Et2O (3×3 mL) then with EtOAc 
(3×3 mL) and dried under vacuum. Yield: 148 mg (78%) of a pale yellow powder. X-ray 
quality crystals of 12 were grown by slow vapor diffusion of MTBE into CD3NO2 
solution of 12 at 4 
o
C. 
1
H NMR (CDCl3): δ 9.22 (d, J = 7.2 Hz, 1H), 9.11 (m, 3H), 8.96 
(d, J = 7.6 Hz, 2H), 8.06 (t, J = 6.9 Hz, 2H), 7.95 (t, J = 7.4 Hz, 1H), 7.77 (d, J = 6.2 Hz, 
2H), 7.61 (t, J = 6.2 Hz, 3H), 7.50 (d, J = 5.3 Hz, 1H), 7.31 (t, J = 7.1 Hz, 2H), 7.04 (t, J 
= 6.2 Hz, 1H), 6.96 (t, J = 7.0 Hz, 2H), 6.87 (d, J = 7.9 Hz, 2H). 
13
C NMR (CDCl3): δ 
161.47, 153.06, 152.89, 150.44, 150.04, 146.21, 142.19, 141.42, 130.47, 130.36, 128.87, 
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128.00, 127.67, 125.51, 125.48, 124.88, 57.23. HRMS electrospray (m/z): [M – Cl]+ 
calcd for C28H21ClN3Pd, 540.0453; Found, 540.0462. 
General procedure 6: Preparation of Pd
IV
 complexes with 
[(Py3CH)Pd
IV
([1,1'-biphenyl]-2,2’-diyl)(X)][OTf]  general structure. 4Å Molecular 
sieves were added to the solution of the corresponding [(Py3CH)Pd
IV
(aryl)(X)2][OTf] 
complex (0.06 mmol) in CHCl3 (7 mL). The solution was stirred 5 minutes at ambient 
temperature and then AgOAc (45 mg; 0.27 mmol) was added. The resulting suspension 
was stirred for 40 min at ambient temperature and then filtered through a pad of 
diatomaceous earth. The mother liquor was washed with water (2×5 mL), organic layer 
was dried over anhydrous Na2SO4 and evaporated under reduced pressure. The residue 
was suspended in Et2O (5 mL) and sonicated for 5 minutes at 20
o
C. The product was 
collected by filtration, washed with EtOAc (3×2 mL) and dried under vacuum. 
Preparation of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2,2’-diyl)(Br)][OTf] (23). 23 was 
obtained according to the general procedure 6 in 53% yield as a pale yellow powder. 
1
H 
NMR (CD2Cl2): δ 9.29 (d, J = 5.5 Hz, 2H), 8.60 (d, J = 8.9 Hz, 1H), 8.46 (d, J = 7.9 Hz, 
2H), 8.15 (td, J = 7.9 and 1.7 Hz, 2H), 8.00 (td, J = 7.5 and 1.4 Hz, 1H), 7.80 (dd, J = 7.5 
and 1.4 Hz, 2H), 7.67 (td, J = 6.7 and 1.4 Hz, 2H), 7.49 (d, J = 5.9 Hz, 1H), 7.33 (m, 3H), 
7.10 (td, J = 7.5 and 1.4 Hz, 1H), 7.00 (td, J = 7.7 and 1.7 Hz, 2H), 6.91 (d, J = 8.2  Hz, 
2H).  
13
C NMR (CD2Cl2): δ 157.35, 152.47, 151.77, 151.21, 150.07, 147.19, 142.45, 
141.71, 130.96, 129.00, 128.90, 127.46, 127.04, 125.89, 125.64, 124.64, 121.04 (q, J = 
320.8 Hz), 59.83. 
19
F NMR (CD2Cl2): δ -79.20 (s). HRMS electrospray (m/z): [M – 
TfO]
+
 calcd for C28H21BrN3Pd, 583.9954; Found, 583.9958. 
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Preparation of [(Py3CH)Pd
IV
(3,4,5-trifluoro-[1,1'-biphenyl]-2,2’-
diyl)(Cl)][OTf] (28). 28 was obtained according to the general procedure 6 in 66% yield 
as a pale yellow powder. 
1
H NMR (~1/2 mixture of CD3NO2 and CDCl3): δ 9.16 (m, 2H), 
8.38 (d, J = 7.8 Hz, 1H), 8.27 (m, 2H), 8.21 (m, 3H), 7.83 (ddd, J = 7.3, 5.7 and 2.0 Hz, 
1H), 7.77 (dd, J = 7.7 and 1.7 Hz, 1H), 7.65 (m, 2H), 7.62 (m, 1H), 7.41 (t, J = 7.1 Hz, 
1H), 7.33 (ddd, J = 7.5, 6.1and 1.5 Hz, 1H), 7.07 (ddd, J = 7.7, 6.1 and 1.7 Hz, 1H), 6.91 
(s, 1H), 6.86 (d, J = 8.2 Hz, 1H). 
13
C NMR (~1/2 mixture of CD3NO2 and CDCl3): δ 
161.92, 152.25, 152.21, 151.63, 151.26 (ddd, J = 250.0, 64.8 and 3.4 Hz), 151.22, 
151.10, 150.88, 150.41, 146.47 (m), 143.58, 143.00 (m), 142.66, 142.02, 138.10 (ddd, J = 
255.5, 19.8 and 15.8 Hz), 135.63 (dt, J = 23.8 and 3.0 Hz), 130.53, 130.04, 129.05, 
128.10, 126.78, 126.59, 126.57, 126.37, 125.66, 124.54, 121.00 (q, J = 320.8 Hz), 107.66 
(dd, J = 20.4 and 1.4 Hz), 61.22. 
19
F NMR (~1/2 mixture of CD3NO2 and CDCl3): δ -
79.03 (s, 3F), -123.44 (m, 1F), -137.92 (m, 1F), -158.36 (m, 1F). HRMS electrospray 
(m/z): [M – TfO]+ calcd for C28H18ClF3N3Pd, 594.0171; Found, 594.0183. 
Preparation of [(Py3CH)Pd
IV
(6-deutero-[1,1'-biphenyl]-2,2’-diyl)(Cl)][OTf] 
(33). 33 was obtained according to the general procedure 6 in 84% yield as a pale yellow 
powder. 
1
H NMR (CDCl3): δ 9.14 (d, J = 5.1 Hz, 2H), 8.75 (d, J = 7.8 Hz, 1H), 8.57 (d, J 
= 7.8 Hz, 2H), 8.10 (td, J = 7.8 and 1.4 Hz, 2H), 7.99 (td, J = 7.8 and 1.3 Hz, 1H), 7.77 
(dd, J = 7.5 and 1.2 Hz, 1H), 7.64 (t, J = 6.4 Hz, 1H), 7.53 (m, 2H), 7.32 (m, 2H), 7.08 (t, 
J = 6.0 Hz, 1H), 6.97 (t, J = 7.3 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H). 
13
C NMR (CDCl3): δ 
161.49, 161.43, 152.38, 152.06, 150.81, 150.34, 146.13, 146.09, 142.68, 141.84, 130.28, 
129.75, 128.96, 127.78, 127.67, 127.30, 125.84, 125.76, 124.99, 120.91 (q, J = 320.2 
Hz), 59.27. (Signal of the carbon attached to deuterium was not observed presumably 
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because it is a triplet of low intensity that overlaps with nearby more intense signals.) 
19
F 
NMR (CDCl3): δ -78.02. HRMS electrospray (m/z): [M – TfO]
+
 calcd for 
C28H20DClN3Pd, 541.0516; Found, 541.0523. 
Preparation of [(Py3CH)Pd
IV
(4'-tert-butyl-5-fluoro-[1,1'-biphenyl]-2,2’-
diyl)(Cl)][OTf] (36). 36 was obtained according to the general procedure 6 in 70% yield 
as a pale yellow powder. 
1
H NMR (CDCl3): δ 9.14 (d, J = 5.6 Hz, 1H), 9.10 (d, J = 5.6 
Hz, 1H), 8.76 (d, J = 7.8 Hz, 1H), 8.61 (d, J = 7.8 Hz, 1H), 8.54 (d, J = 8.0 Hz, 1H), 8.14 
(td, J = 7.7 and 1.5 Hz, 1H), 8.11 (td, J = 7.8 and 1.5 Hz, 1H), 8.03 (td, J = 7.7 and 1.4 
Hz, 1H), 7.64 (m, 3H), 7.52 (m, 2H), 7.46 (dd, J = 9.0 and 2.9 Hz, 1H), 7.36 (dd, J = 8.0 
and 1.4 Hz, 1H), 7.12 (td, J = 6.8 and 1.4 Hz, 1H), 6.83 (d, J = 1.4 Hz, 1H), 6.80 (dd, J = 
8.7 and 4.8 Hz, 1H), 6.70 (td, J = 7.8 and 2.9 Hz, 1H), 1.17 (s, 9H). 
13
C NMR (CDCl3): δ 
162.78 (d, J = 245.9 Hz), 161.53, 153.76, 153.50, 152.45, 152.43, 152.08, 150.73, 
150.30, 150.18, 147.29 (d, J = 6.8 Hz), 142.78, 142.31 (d, J = 2.7 Hz), 142.09, 141.88, 
130.79 (d, J = 7.5 Hz), 130.00, 127.63, 127.39, 126.81, 125.83, 125.81, 125.28, 125.08, 
124.68, 120.91 (q, J = 320.2 Hz), 114.64 (d, J = 22.5 Hz), 111.51 (d, J = 23.2 Hz), 59.18, 
35.84, 31.21. 
19
F NMR (CDCl3): δ -78.12 (s, 3F), -115.40 (m, 1F). HRMS electrospray 
(m/z): [M – TfO]+ calcd for C32H28CFlN3Pd, 614.0985; Found, 614.0995. 
Preparation of [(Py3CH)Pd
IV
(4'-t-Bu-2'-deutero-5-fluoro-[1,1'-biphenyl]-2,2’-
diyl)(Cl)][OTf] (35). 35 was obtained according to the general procedure 6 in 63% yield 
as a pale yellow powder. 
1
H NMR (CDCl3): δ 9.15 (d, J = 4.9 Hz, 1H), 9.11 (d, J = 4.8 
Hz, 1H), 8.82 (d, J = 7.8 Hz, 1H), 8.65 (d, J = 7.8 Hz, 1H), 8.58 (d, J = 7.8 Hz, 1H), 8.14 
(td, J = 7.8 and 1.1 Hz, 1H), 8.11 (td, J = 7.8 and 1.4 Hz, 1H), 8.02 (t, J = 7.5 Hz, 1H), 
7.64 (m, 2H), 7.60 (s, 1H), 7.53 (d, J = 5.3 Hz, 1H), 7.47 (dd, J = 9.0 and 2.9 Hz, 1H), 
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7.37 (s, 1H), 7.12 (t, J = 6.1 Hz, 1H), 6.84 (d, J = 1.0 Hz, 1H), 6.80 (dd, J = 8.7 and 4.7 
Hz, 1H), 6.71 (td, J = 8.7 and 2.9 Hz, 1H), 1.18 (s, 9H). 
13
C NMR (CDCl3): δ 162.79 (d, 
J = 245.9 Hz), 161.51, 153.75, 153.51 (d, J = 1.5 Hz), 152.45, 152.43, 152.08, 150.74, 
150.31, 150.19, 147.27 (d, J = 7.5 Hz), 142.77, 142.25 (d, J = 2.7 Hz), 142.09, 141.89, 
130.79 (d, J = 7.5 Hz), 130.01, 127.64, 127.40, 126.81, 125.83, 125.81, 125.28, 124.98, 
124.39 (broad multiplet), 120.92 (q, J = 320.2 Hz), 114.64 (d, J = 21.8 Hz), 111.52 (d, J 
= 23.2 Hz), 59.16, 35.85, 31.21. 
19
F NMR (CDCl3): δ -78.12 (s, 3F), -115.35 (m, 1F). 
HRMS electrospray (m/z): [M – TfO]+ calcd for C32H27DCFlN3Pd, 615.1048; Found, 
615.1064. 
Preparation of [(Py3CH)Pd
IV
(5,5'-dimethyl-[1,1'-biphenyl]-2,2’-diyl)(Cl)](Cl) 
(41). AgOAc (134 mg; 0.80 mmol) was added to the solution of the Pd
IV
 complex 40 
(150 mg; 0.187 mmol) in CHCl3 (20 mL). The resulting suspension was sonicated for 5 
min at 20 
o
C and then filtered through a pad of diatomaceous earth. Mother liquor was 
washed with brine (4×10 mL). Organic layer was dried over anhydrous MgSO4 and 
evaporated under reduced pressure. The residue was suspended in MTBE (10 mL) and 
sonicated for 5 minutes at 20 
o
C. The fine powder was collected by filtration, washed 
with MTBE (3×3 mL) and dried under vacuum. Yield: 78 mg (69%) of a pale yellow 
powder. Analytical sample was obtained by dissolving the crude product in minimal 
amount of CH2Cl2 and consecutive precipitation with ethanol. 
 1
H NMR (acetone-d6 at 25 
oC): δ 9.19 (dd, J = 5.4 and 1.0 Hz, 2H), 8.70 (d, J = 7.5 Hz, 1H), 8.58 (d, J = 7.5 Hz, 
2H), 8.33 (t, J = 7.5 Hz, 2H), 8.24 (t, J = 7.1 Hz, 1H), 7.93 (bs, 1H), 7.89 (dd, J = 5.8 and 
7.2 Hz, 2H), 7.75 (d, J = 1.9 Hz, 2H), 7.71 (dd, J = 5.1 and 1.0 Hz, 1H), 7.41 (t, J = 6.6 
Hz, 1H), 6.91 (d, J = 8.3 Hz, 2H), 6.82 (dd, J = 8.3 and 1.5 Hz, 2H), 2.41 (s, 6H). 
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13
C{
1
H} NMR (acetone-d6 at 25 
oC): δ 158.61, 152.36, 151.93, 151.40, 150.84, 146.17, 
142.96, 142.04, 136.98, 130.22, 129.13, 128.98, 126.55, 126.37, 126.19, 125.39, 59.90, 
19.91. HRMS electrospray (m/z): [M – Cl]+ calcd for C30H25ClN3Pd, 568.0772; Found, 
568.0763. 
X-ray structure determination for [(Py3CH)Pd
IV
([1,1'-biphenyl]-2,2’-
diyl)(Cl)][Cl] (12). Orange needles of complex 12 were grown from a methyl-t-butyl 
ether /nitromethane solution of the compound at 4 deg. C.  A crystal of dimensions 0.11 x 
0.03 x 0.03 mm was mounted on a Rigaku AFC10K Saturn 944+ CCD-based X-ray 
diffractometer equipped with a low temperature device and Micromax-007HF Cu-target 
micro-focus rotating anode ( = 1.54187 A) operated at 1.2 kW power (40 kV, 30 mA).  
The X-ray intensities were measured at 85(1) K with the detector placed at a distance 
42.00 mm from the crystal.  A total of 3890 images were collected with an oscillation 
width of 1.0 in  The exposure time was 2 sec. for the low angle images, 8 sec. for 
high angle.  The integration of the data yielded a total of 61924 reflections to a maximum 
2 value of 136.48 of which 2289 were independent and 270 were greater than 2(I).  
The final cell constants were based on the xyz centroids of 46351 reflections above 
10(I).  Analysis of the data showed negligible decay during data collection; the data 
were processed with CrystalClear 2.0 and corrected for absorption.  The structure was 
solved and refined with the Bruker SHELXTL (version 2008/4) software package, using 
the space group Pnma with Z = 4 for the formula C28H21N3Cl2Pd•(H2O)0.5.  Full matrix 
least-squares refinement based on F2 converged at R1 = 0.0219 and wR2 = 0.0548 [based 
on I > 2sigma(I)], R1 = 0.0221 and wR2 = 0.0549 for all data.  The Pd-complex lies on a 
mirror plane in the crystal lattice.  Additional details are presented in below. 
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Crystal data and structure refinement for complex 12. 
  
  
      Identification code                am5405 (complex 12) 
      Empirical formula                  C28 H22 Cl2 N3 O0.50 Pd 
      Formula weight                     585.79 
      Temperature                        85(2) K 
      Wavelength                         1.54178 A 
      Crystal system, space group        Orthorhombic,  P n m a 
      Unit cell dimensions               a = 13.9621(10) A   alpha = 90 deg. 
                                          b = 12.8717(2) A    beta = 90 deg. 
                                          c = 13.3016(2) A   gamma = 90 deg. 
      Volume                              2390.51(18) A^3 
      Z, Calculated density              4,  1.628 Mg/m^3 
      Absorption coefficient             8.514 mm^-1 
      F(000)                              1180 
      Crystal size                        0.11 x 0.03 x 0.03 mm 
      Theta range for data collection    4.59 to 68.24 deg. 
      Limiting indices                   -16<=h<=16, -15<=k<=15, -16<=l<=16 
      Reflections collected / unique     61924 / 2289 [R(int) = 0.0440] 
      Completeness to theta = 68.24     100.0% 
      Absorption correction              Semi-empirical from equivalents 
      Max. and min. transmission         0.7843 and 0.4544 
      Refinement method                  Full-matrix least-squares on F^2 
      Data / restraints / parameters     2289 / 3 / 182 
      Goodness-of-fit on F^2             1.051 
      Final R indices [I>2sigma(I)]      R1 = 0.0219, wR2 = 0.0548 
      R indices (all data)               R1 = 0.0221, wR2 = 0.0549 
      Largest diff. peak and hole        0.461 and -0.376 e.A^-3 
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Atomic coordinates ( x 10^4) and equivalent isotropic displacement 
parameters (A^2 x 10^3) for am5405 (complex 12). U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________ 
  
                                 x                  y                  z          U(eq) 
________________________________________________________________ 
  
          Pd(1)         3727(1)        2500           3816(1)       10(1) 
          Cl(1)         2373(1)        2500           2835(1)       16(1) 
          Cl(2)         3989(1)        2500           8797(1)       19(1) 
          N(1)          3107(1)        1381(1)        4856(1)       13(1) 
          N(2)         4952(1)        2500           4664(1)       12(1) 
          C(1)          2569(1)         572(1)        4570(1)       15(1) 
          C(2)          2238(1)        -160(1)        5252(1)       18(1) 
          C(3)          2465(1)         -35(1)        6262(1)       19(1) 
          C(4)          2988(1)         829(1)        6563(1)       17(1) 
          C(5)          3299(1)        1527(1)        5837(1)       14(1) 
          C(6)          3856(2)        2500           6119(2)       14(1) 
          C(7)          4854(2)        2500           5673(2)       14(1) 
          C(8)          5656(2)        2500           6284(2)       16(1) 
          C(9)          6564(2)        2500           5862(2)       19(1) 
          C(10)         6647(2)        2500           4825(2)       17(1) 
          C(11)         5830(2)        2500           4243(2)       15(1) 
          C(12)         4319(1)        1474(1)        2845(1)       13(1) 
          C(13)         4410(1)         419(1)        3028(1)       15(1) 
          C(15)         5120(1)         230(1)        1379(1)       17(1) 
          C(16)         5048(1)        1295(1)        1215(1)       17(1) 
          C(17)         4657(1)        1930(1)        1963(1)       14(1) 
          C(14)         4819(1)        -198(1)        2279(1)       17(1) 
          O(1)          6181(2)        2500           8864(3)       20(1) 
________________________________________________________________ 
 
Hydrogen bonds for am5405 (complex 12) [A and deg.]. 
________________________________________________________________________ 
 D-H...A                      d(D-H)       d(H...A)     d(D...A)     <(DHA) 
  
 O(1)-H(1)...Cl(2)    0.824(17)    2.238(17)    3.061(4)     179(6) 
 _______________________________________________________________________ 
  
 Symmetry transformations used to generate equivalent atoms: #1 x,-y+1/2,z     
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3.11.7 Chloride-to-bromide ligand exchange rates for complexes 9 and 24 
Experimental procedures. First, 9 and 24 were titrated with potassium bromide 
(0-50 equivalents) and progress of the reaction was monitored with UV-VIS 
spectroscopy. Both reactions of 9 and 24 yielded very similar UV-VIS spectra and those 
of compound 24 are shown in Figure 3.8. Growing absorbance band centered at ~ 480 nm 
is likely due to a bromide-to-palladium charge transfer in the corresponding mono 
bromide intermediates and in final products 22 and 26. From this absorbance band at 480 
nm it was determined that for both complexes ~10 equivalents of bromide are necessary 
to drive the reaction to completion. 
 
Figure 3.8 Absorbance of complex 24 as a function of added bromide (0 - 50 equiv) 
 
 
Next, rate experiments were performed under pseudo first order conditions in 
bromide (10-200 equiv). Reactions were monitored at 480 nm and in all cases even and 
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reproducible reaction traces were obtained (Figure 3.9 and Figure 3.10). However, these 
reaction traces were not fitted to an exponential or two exponentials because the overall 
transformations shown in the scheme above are multi step processes that involve several 
ligand dissociation and association events and the relative rates of these elementary steps 
are unknown.  Even though accurate rate constants were not extracted from the 
performed rate experiments, nevertheless, two important qualitative observations were 
made. First, it was determined that under identical conditions reaction of 9 with KBr 
reached completion in more than 10 times shorter time than the reaction of 24 with KBr. 
Second, for both complexes 10 and 24, the reaction rate was dependent on the bromide 
concentration in a wide concentration range from 5-100 mM (10 to 200 equiv). These 
two observations support the hypothesis of reversible dissociation of one pyridine arm of 
the Py3CH ligand and the proposed ligand exchange mechanism. 
 
Figure 3.9 UV-Vis traces (480 nm) of reaction between complex 9 and bromide 
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Figure 3.10 UV-Vis traces (480 nm) of reaction between complex 24 and bromide 
 
 
3.11.8 Determination of Intramolecular Kinetic Isotope Effect 
Experimental procedure for determination of intramolecular KIE: Complex 
32 (9.8 mg; 0.015 mmol) was dissolved in CDCl3 (0.5 mL) and 4Å molecular sieves were 
added to this solution. The solution was equilibrated to a set temperature and then the 
corresponding silver carboxylate (0.06 mmol) was added in one portion. The resulting 
suspension was stirred intensively for 20 minutes and then filtered through a plug of 
celite. The solution was first analyzed by 
1
H NMR to ensure a complete consumption of 
the starting material and to verify that complex 33 is the main reaction product. CDCl3 
solution was then evaporated and the residue was analyzed by mass spectrometry in low 
resolution ESI+ mode. The MS data is provided in Table 3.3. 
Calculation of KIE: KIEs were calculated from MS data (Table 3.3) according to 
the published method.
26
 The MS data of 12 (showed in Table 3.2) was used as a standard 
from which extent of deuterium incorporation for compound 31 was calculated. The use 
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of theoretical isotope distribution pattern as standard yielded slightly different results, 
however, the discrepancies were negligible. 
 
Table 3.2 MS data of [(Py3CH)Pd
IV
([1,1'-biphenyl]-2,2’-diyl)(Cl)]+ (12) 
m/z 538 539 540 541 542 543 544 545 546 547 548 
 Relative intensity 
Complex 12 27.1 64.51 98.01 45.07 100 29.11 54.75 16.09 11.63 3.33 0 
 
Table 3.3 MS data for intramolecular KIE determination 
 
m/z 538 539 540 541 542 543 544 545 546 547 548   
 Relative intensity KIE 
AgOAc, 25 
o
C 3.86 34.38 73.82 99.24 55.04 100 34.33 54.69 17.11 11.47 2.99 9.4 
AgOAc, 0 
o
C 3.47 32.99 72.96 97.61 53.39 100 32.91 54.53 16.68 11.28 3.23 10.34 
AgOAc, 55 
o
C 4.83 36.42 75.53 100 58.74 98.53 35.64 55.83 16.8 11.24 3.16 6.93 
AgOPiv, 25 
o
C 3.52 32.36 73.06 100 52.5 99.37 30.92 51.81 14.5 9.99 2.61 9.73 
AgOOCCF3, 25 
o
C 3.21 31.31 71.66 99.58 51.58 100.00 30.93 52.12 14.46 9.84 2.67 11.49 
AgOOCC6H5, 25 
o
C 3.57 33.29 72.19 100.00 51.82 99.40 32.22 53.14 16.15 10.81 2.65 9.96 
aq KOAc, 25 
o
C 3.40 32.43 71.90 100.00 51.16 99.41 30.48 51.46 14.67 10.02 2.73 10.89 
AgOTf, 25 
o
C 11.66 49.67 95.74 100.00 78.06 95.29 43.14 49.61 16.11 9.59 2.41 1.97 
 
3.11.9 Determination of Intermolecular Kinetic Isotope Effect 
Experimental procedure: Complex 34 (12.3 mg; 0.015 mmol) was dissolved in 
dry CDCl3 (0.6 mL) and the solution was cooled to -30 
o
C. Silver pivalate (9.4 mg; 
0.045) was then added and the resulting suspension was sonicated at -30 
o
C for 3 
minutes. 
19
F NMR and 
1
H NMR analysis of this reaction mixture at -30 
o
C showed 
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almost complete conversion of 34 to the intermediate 35. The kinetics of conversion of 
35 into the final product 36 was monitored by 
19
F NMR at 0 
o
C and spectra were 
recorded with 1 minute intervals (Figure 3.11 and Figure 3.12). Kinetics of conversion of 
the deuterated complex 37 into the final product 39 was monitored in the exactly same 
manner (Figure 3.13 and Figure 3.14). Complexes 36 and 39 were also synthesized on a 
preparative scale and fully characterized by NMR and MS (see above). The obtained 
reaction traces could not be fitted to a simple mathematical functions, however, it can be 
qualitatively estimated that 35 and 38 decays to the corresponding products 36 and 39 at 
approximately the same rate. The most likely explanation of why reaction traces could 
not be fitted to simple mathematical functions is that conversion of 35 to 36 (and 38 to 
39) is a multistep process. 
 
Figure 3.11 Array of 
19
F NMR spectra showing conversion of 34 to the product 35  
 
(intermediate 34 at approximately -116.0 ppm and product 35 ~ -115.3 ppm, spectra 
acquired at 500 MHz) 
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Figure 3.12 Plot of 35 formed and 34 consumed as a function of time 
 
 
Figure 3.13 Array of 
19
F NMR spectra showing conversion of 38 to the product 39  
 
(intermediate 38 at approximately -116.0 ppm and product 39 ~ -115.3 ppm, 
spectra acquired at 500 MHz) 
 
 
Figure 3.14 Plot of 39 formed and 38 consumed as a function of time 
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Chapter 4: Synthesis of Trifluoromethyl Complexes Using 
TFAA as CF3 Source 
 
4.1 Introduction 
Swarts reaction is the oldest method for the preparation of trifluoromethylated 
arenes (Scheme 4.1).
1
 Originally SbF3 was used as a fluorinating reagent in the presence 
of a SbF5 catalyst; however, a modern version of Swarts reaction involves use of HF in 
the presence of a Lewis acid catalyst to convert trichloromethylated starting material into 
the desired trifluoromethylated product. Even though the Swarts reaction requires highly 
corrosive reagents and generates three equivalents of HCl byproduct, it is still the only 
method for the synthesis of trifluoromethylated compounds that is used on industrial 
scale. It is even more surprising, considering that trichloromethylated starting material is 
usually synthesized via chlorination with Cl2 thus generating three more equivalents of 
HCl. In addition, the Swarts reaction can be applied only to very simple building blocks 
since the harsh reaction conditions would degrade complex pharmaceutical and 
agrochemical intermediates containing acid or oxidant sensitive functional groups. 
 
Scheme 4.1. Swarts reaction 
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Transition metal catalyzed cross-couplings typically allow very efficient and 
completely regioselective formation of the C–C bond. Therefore, over the last several 
decades many attempts have been made to apply transition metal catalysis to the 
development of trifluoromethylation reactions.
2
 Several practically useful 
trifluoromethylation methodologies have been discovered.
2,3,4
 For instance, treatment of 
aryl iodides with trifluoromethyliodide (CF3I) in the presence of superstoichiometric 
amounts of copper powder affords corresponding benzotrifluorides. Scheme 4.2 shows an 
example of such a reaction.
5
 Aryl iodides can be converted into benzotrifluorides also in 
copper(I) iodide mediated cross-coupling reactions with Ruppert’s reagent (CF3SiMe3) 
(Scheme 4.3).
2,6
 
  
Scheme 4.2. McLoughlin-Thrower reaction 
 
 
Scheme 4.3. Cross coupling of aryl iodides with Ruppert’s reagent 
 
 
R o-CH3 m-CH3 p-CH3 p-CH3O p-Cl p-CH3CH2O2C p-CH3CO 
Yield (%) 86 78 82 48 35 94 45 
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Most compounds that are used as a CF3 source for transition metal 
catalyzed/mediated C–CF3 bond formation (e.g., CF3I, CF3-SiMe3, CF3-SiEt3, Togni 
reagent) are expensive and/or toxic and volatile. Trifluoroacetate can be used as a cheap 
CF3 source, however, super-stoichiometric amounts of transition metal catalyst and very 
harsh reaction conditions are typically required in decarboxylative trifluoromethylation 
reactions (Scheme 4.4).
2,7,8
 Therefore a mild and regioselective trifluoromethylation 
method that would employ cheap bulk chemicals such as trifluoroacetic anhydride 
(TFAA) or trifluoroacetic esters (TFA  esters) as a CF3 source is still highly desirable. 
 
Scheme 4.4. Copper mediated decarboxylative trifluoromethylation 
 
 
R m-CH3 p-NO2 p-Cl p-CH3O 
Yield (%) 88 47 68 59 
 
Nickel and palladium are the most commonly used catalysts for traditional cross-
coupling reactions. Ni and Pd are efficient catalysts also for decarbonylative coupling 
reactions.
9,10,11,12
 This prompted us to investigate nickel and palladium as catalysts for 
decarbonylative trifluoromethylation reactions with TFAA or TFA esters as cheap and 
available CF3 donors. Scheme 4.5 shows the general mechanism for transition metal 
catalyzed decarbonylative C–C bond forming reactions. Oxidative addition of an ester to 
low valent transition metal species [M
0
] and consecutive CO deinsertion 
(decarbonylation) are the key steps in the catalytic turnover. After decarbonylation, a 
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second coupling partner (R
2
) is transferred to the Pd
II
 center via transmetallation, C–H 
activation, or 1,2-insertion. Finally, reductive elimination or β-elimination affords the 
product and returns [M
0
] species into the catalytic cycle. 
 
Scheme 4.5 General mechanism of decarbonylative coupling reactions 
 
 
Scheme 4.6 shows an example of a palladium catalyzed decarbonylative coupling 
reaction. Only 0.5-1% of Pd(OAc)2 is necessary for efficient decarbonylative coupling of 
aroyl chlorides with activated alkenes.
13
 
 
Scheme 4.6. Palladium catalyzed decarbonylative coupling 
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Our proposal that TFAA or TFA esters could also be used as reagents for 
decarbonylative trifluoromethylation reactions is supported by the fact that 
decarbonylation is a common method for the synthesis of transition metal CF3 complexes 
(Scheme 4.7).
14,15,16,17
 It has been applied to first, second, and even third row metals such 
as iridium and platinum. 
 
Scheme 4.7 Preparation of transition metal CF3 complexes 
 
 
 Surprisingly, TFAA and TFA esters have never been used for the synthesis of 
nickel and palladium trifluoromethyl complexes.18,19 In some cases CO deinsertion from 
M–COCF3 complexes is a very difficult process, requiring heating to high temperatures. 
For example, transformation of CF3COPt(Cl)(PPh3)2 to CF3Pt(Cl)(PPh3)2 requires heating 
to 210 
o
C for 4 hours.20 Therefore, at the outset of this project it was our concern that CO 
deinsertion could be a limiting process in the proposed nickel and palladium catalyzed 
decarbonylative trifluoromethylation reactions. Therefore, before attempting catalytic 
turnover, we decided to investigate TFAA and TFA esters as reagents for the 
decarbonylative synthesis of nickel and palladium trifluoromethyl complexes. 
 
4.2 Decarbonylative Synthesis of Nickel Trifluoromethyl Complexes 
Decarbonylation is generally a more facile process at first row metal centers; 
therefore, we decided to investigate decarbonylation at Ni first.  For the investigation of 
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decarbonylation we chose Ni(COD)2 as an available nickel(0) source and PPh3 as a 
simple supporting ligand. Somewhat unexpectedly, treatment of Ni(COD)2 with two 
equivalents of PPh3 followed by the addition of a slight excess of TFAA afforded 
(PPh3)2Ni(CF3)(OOCCF3) (2) directly in 70% isolated yield (Scheme 4.8). The 
temperature of the reaction medium never exceeded 25 
o
C. Complex 2 was characterized 
by NMR and IR spectroscopies and composition of 2 was confirmed also by elemental 
analysis. 
19
F-NMR spectrum of 2 exhibits two resonances at -20 and 75 ppm in a 1:1 
integral ratio and 
31
P{
1
H}-NMR spectrum contains one resonance at 40 ppm. NMR 
signals of 2 are broad and 
3
JF-P coupling is not resolved even at -50 
o
C which is likely a 
result of the highly fluxional nature of 2. 
 
Scheme 4.8 Preparation of (PPh3)2Ni(CF3)(OOCCF3) 
 
 
Complex 2 undergoes facile ligand exchange with bidentate phosphine ligands. 
For example, treatment of 2 with slight excess of diphenylphosphinoethane (dppe) 
afforded 3 in 96% isolated yield (Scheme 4.9). Interestingly, treatment of Ni(COD)2 with 
one equivalent of dppe, folowed by TFAA did not afford 3, but (dppe)Ni(OCOCF3)2 
instead. Complex 3 was characterized by NMR, IR, and elemental analysis. 
3
J F-P 
coupling observed in both 
19
F- and 
31
P-NMR spectra lend a strong support to the 
proposed structure (see Figure 4.1 and Figure 4.2 for spectra). Specifically, 
31
P-NMR 
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spectrum of 3 exhibits an apparent quintet at 45 ppm (
2
JP-P ≈ 
3
JP-F ≈ 45 Hz) and a doublet 
of quartets at 56 ppm (
2
JP-P = 46 Hz and 
3
JP-F = 10 Hz) in 1:1 integral ratio. In addition, 
19
F-NMR spectrum of 3 exhibits two characteristic resonances in 1:1 integral ratio: 
doublet of doublets at -29 ppm (
3
J(F-P) = 43.1 Hz and 10.0 Hz) and a singlet at 75 ppm. 
 
Scheme 4.9 Preparation of (dppe)Ni(CF3)(OOCCF3) 
 
 
Figure 4.1 
19
F NMR spectrum of (dppe)Ni(CF3)(OOCCF3) 
 
(spectrum acquired at 500 MHz) 
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Figure 4.2 
31
P{
1
H} NMR spectrum of (dppe)Ni(CF3)(OOCCF3) 
 
(spectrum acquired at 500 MHz) 
 
Next, we investigated oxidative addition and decarbonylation of other carboxylic 
anhydrides and chloroanhydrides to Ni
0
. A convenient one pot procedure was developed 
(Scheme 4.10). First, Ni(COD)2 was treated with two equivalents of PPh3 followed by 
slight excess of corresponding carboxylic anhydride or chloride. Next, to facilitate 
purification and characterization, in situ generated fluoroalkylnickel species were trapped 
with dppe. This approach proved successful for a number of complexes.  For example, 
with simple higher analogues of TFAA, products 4 and 5 were isolated in 48% and 52% 
yields, respectively. Cyclic carboxylic anhydrides could also be used in this reaction. 
Thus, products 6 and 7 were isolated in 52% and 36% yield. Finally, with carboxylic 
chlorides, complexes 8 and 9 were obtained in 47% and 65% isolated yields. Moderate 
isolated yields of 4-9 are a result of losses during isolation and purification. 
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Scheme 4.10 Preparation of (dppe)Ni(Rf)(X) complexes 
 
 
4.3 Decarbonylative Synthesis of PdII Trifluoromethyl Complexes 
While decarbonylation at nickel is fast at or below room temperature, this is not 
the case for palladium. Treatment of Pd(PPh3)4 with TFAA resulted in formation of 
trifluoroacetyl complex 10 in 90% isolated yield (Scheme 4.11). Complex 10 is stable at 
room temperature in CDCl3 solution and no decomposition was detected over the course 
of three days. Pentafluorophenyl trifluoroacetate also undergoes oxidative addition to 
Pd(PPh3)4. Unexpectedly, with C6F5OCOCF3, the oxidative addition product was isolated 
as trifluoroacetate complex 10 and not as pentafluorophenoxide complex 11. It is likely 
that initially formed 11 reacts with trifluoroacetic acid generated in situ during workup 
from excess C6F5OCOCF3. 
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Scheme 4.11 Synthesis of (PPh3)2Pd(COCF3)(OCOCF3) 
 
 
Decarbonylation at Pd
II
 was investigated next (Scheme 4.12). In order to promote 
CO deinsertion, 10 was heated in CDCl3 solution to 110 
o
C and decarbonylation progress 
was monitored by 
19
F- and 
31
P-NMR spectroscopy. 10 underwent slow conversion to 12 
as evidenced by the appearance of a triplet at -20 ppm in 
19
F-NMR spectrum and a 
quartet at 40 ppm in 
31
P-NMR spectrum (
3
JF-P ≈ 30 Hz in both spectra). After 3 hours at 
110 
o
C approximately 30% of 12 and 70% of 10 was detected in the reaction mixture. 
Unfortunately, 12 could not be isolated in pure form because after prolonged heating to 
110 
o
C both starting material 10 and product 12 had decomposed to a complex mixture of 
unidentified side products. 
 
Scheme 4.12 Reactivity of (PPh3)2Pd(COCF3)(OCOCF3) 
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After unsuccessful but somewhat encouraging results with Pd(PPh3)4 as a Pd
0
 
source, a number of other  palladium starting complexes were screened (Figure 4.3). 
Unfortunately, none of the complexes shown in Figure 4.3 gave significant improvement 
over Pd(PPh3)4. 
 
Figure 4.3 Screened Pd
0
(L)n complexes 
 
 
CO insertion/deinsertion is generally accepted to proceed via a three-center 
transition state (Scheme 4.13).
19a,21
 The very facile decarbonylation at nickel can be 
rationalized with the fact that square planar tetracoordinate Ni
II
 centers easily expand 
coordination number to five and thus the three-center transition state such as 13  is 
reached without prior dissociation of the spectator ligands (Scheme 4.13).
19a,21
 In 
contrast, CO insertion/deinsertion at  square planar tetracoordinate Pd
II 
center via a 
pentacoordinate transition state analogous to 13 is feasible but it is a high energy 
pathway. For palladium, CO insertion/deinsertion via a tetracoordinate transition state 
such as 14 is, in general, a much more facile process (Scheme 4.14).
21
 We envisioned that 
substitution of PPh3 supporting ligands with more labile analogues would accelerate the 
rate of decarbonylation at the Pd
II
 center via a transition state 14. 
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Scheme 4.13 Viable mechanism for decarbonylation at Ni
II
 
  
 
Scheme 4.14 Viable mechanism for decarbonylation at Pd
II
 
 
Based to the reasoning above, we chose to substitute PPh3 with sterically more 
bulky and thus more labile P(o-Tol)3 ligands. Treatment of Pd[P(o-Tol)3]2 with TFAA in 
THF at room temperature afforded complex 15 in 91% isolated yield (Scheme 4.15). 
Reaction of Pd[P(o-Tol)3]2 with C6F5OCOCF3 also afforded 15, only in this case 2 h at 50 
o
C was required for complete conversion. 
19
F- and 
31
P-NMR spectra of 15 are similar to 
those of 10; however, peaks are much broader which is likely due to reversible 
dissociation of the phosphine ligand. 
 
Scheme 4.15 Synthesis of (P(o-Tol)3)2Pd(COCF3)(OCOCF3) 
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Decarbonylation of the synthesized complex 15 was investigated next (Scheme 
4.16). We found that simply refluxing 15 in benzene for 20 minutes leads to complete 
decarbonylation. Pure 16 was isolated as a crystalline solid in 61% yield. Although 
isolated 16 passed elemental analyses, NMR spectra of complex 16 are broad and show 
the presence of several species. We explain this with a reversible dissociation of the P(o-
Tol)3 ligand. In order to definitely confirm the structure of 16, it was treated with dppe 
(Scheme 4.16). The resulting complex 17 was isolated in high purity. 17 passed elemental 
analyses and very distinctive 
19
F-, 
31
P- and 
13
C-NMR spectral data provides substantial 
evidence for the proposed structure. 
 
Scheme 4.16 Decarbonylative decomposition of (P(o-Tol)3)2Pd(COCF3)(OCOCF3) 
 
 
In order to test our theory that dissociation of the supporting ligand from Pd
II
 is 
necessary for facile decarbonylation, the reaction of 15 with excess ligand was carried 
out. 3 equivalents of P(o-Tol)3 were added to the benzene solution of 15 and the resulting 
mixture was refluxed for 1 hour. P(o-Tol)3 completely inhibited decarbonylation and pure 
15 was recovered in 63% yield. 
After we had determined appropriate spectator ligands for decarbonylation at Pd
II
, 
preparation of palladium complexes with other fluoroalkyl groups was targeted next. A 
convenient one-pot procedure starting from Pd[P(o-Tol)3]2 was developed (Scheme 4.17). 
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In order to facilitate purification and characterization, all products were isolated as dppe 
complexes. We found that higher analogues of TFAA are effective reagents in this 
reaction and thus complexes 18 and 19 were isolated in 87% and 50% yield, respectively. 
In contrast, use of cyclic anhydrides was not successful for the preparation of palladium 
complexes. 20 was obtained only in 16% isolated yield and attempted preparation of 21 
resulted in the formation of an insoluble precipitate. 
 
Scheme 4.17 Preparation of (dppe)Pd(Rf)(OCORf) complexes 
 
 
We investigated the oxidative addition-decarbonylation sequence also with 
difluoroacetic anhydride (Scheme 4.18). We were unable to find appropriate solvent and 
conditions for the crystallization and purification of the initially targeted compound 22. 
However, we found that treatment of the crude 22 with aqueous NaCl resulted in facile 
ligand exchange and chloride complex 23 was successfully isolated via crystallization in 
72% yield starting from Pd[P(o-Tol)3]2. 
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Scheme 4.18 Preparation of (dppe)Pd(CHF2)(Cl) 
 
 
4.4 Reactivity of the Perfluoroalkyl Nickel and Palladium Complexes 
We have shown that with selection of appropriate phosphine ligands 
decarbonylation of fluoroacyl ligands at Ni
II
 and Pd
II
 occurs under mild conditions. Next, 
we aimed to investigate the reactivity of the obtained Ni and Pd trifluoromethyl 
complexes towards transmetallation. Reaction of 2, 3 and 12 with phenyllithium, 
phenylmagnesium bromide or diphenylzinc afforded inseparable mixture of products. 
Biphenyl was isolated as the organic product in all cases. It has been reported that 
complexes with (phosphine)Ni(CF3)(aryl) and (phosphine)Pd(CF3)(aryl) general structure 
decompose with concomitant formation of the corresponding biaryl.
22,23
 It is possible that 
arylnickel and arylpalladium species generated from 2, 3 and 12 also undergo rapid 
decomposition in accordance with the literature precedents. 
We also investigated transmetallation to perfluoroalkylpalladium complexes 17-
19 anticipating that bidentate dppe ligand should stabilize the targeted arylpalladium 
species (Scheme 4.19). Gratifyingly, treatment of 17-19 with diphenylzinc afforded 24-
26 in good isolated yields. Complexes 24-26 are stable under ambient conditions and 
their structures were confirmed unequivocally by NMR spectroscopy and elemental 
analyses. 
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Scheme 4.19 Preparation of (dppe)Pd(Rf)(C6H5) complexes 
 
 
We found that dimethylzinc is also an appropriate transmetallating reagent. 
Treatment of complex 17 with Zn(CH3)2 in anhydrous THF resulted in formation of air 
stable complex 27 in 80% isolated yield (Scheme 4.20). 
 
Scheme 4.20 Preparation of (dppe)Pd(CF3)(CH3) 
 
 
4.5 Conclusions 
This chapter describes the investigation of decarbonylation of –CORf ligands at 
Ni
II
 and Pd
II
 centers. It was found that facile decarbonylation of 
(PPh3)2Ni(COCF3)(CO2CF3) occurs at or below room temperature. In contrast, the 
analogous palladium complex (PPh3)2Pd(COCF3)(CO2CF3) undergoes very slow 
decarbonylation when heated to 110 
o
C. However, acylpalladium complexes supported 
by sterically bulky and therefore more labile P(o-Tol)3 ligands decarbonylate under 
milder reaction conditions. For example, complete decarbonylative decomposition of 
[P(o-Tol)3]2Pd(CF3CO)(CO2CF3) in boiling benzene was achieved in only 20 minutes. 
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Performed experiments indicate that decarbonylation at nickel proceed without ligand 
dissociation via a pentacoordinate transition state. In contrast, decarbonylation at Pd
II
 
most likely proceeds through a tetracoordinate transition state. This mechanism requires 
prior dissociation of the supporting phosphine ligand.  
The results described in this chapter support the viability of decarbonylative 
trifluoromethylation methodology with TFAA or TFA esters as a CF3 source. The fact 
that facile decarbonylation at Ni
II
 and Pd
II
 proceeds under mild conditions encouraged 
further investigation of processes relevant to the proposed trifluoromethylation reaction. 
The results of these investigations are described in the following chapter. 
 
4.6 Experimental Section 
General Procedures. All syntheses were conducted under nitrogen unless 
otherwise stated. All reagents were purchased from commercial sources and used as 
received. Pd[P(o-Tol)3]2 was obtained according to literature procedure.
24
 
Tetrahydrofuran, dichloromethane and diethyl ether were purified using an Innovative 
Technologies (IT) solvent purification system consisting of a copper catalyst, activated 
alumina, and molecular sieves. NMR spectra were acquired using 400, 500 and 700 MHz 
Varian spectrometers. All 
1
H/
1
H NOESY and 
1
H/
1
H ROESY correlation spectra were 
acquired on a 500 MHz instrument. 
1
H, 
19
F and 
13
C chemical shifts are reported in parts 
per million (ppm) relative to TMS, with the residual solvent peak used as an internal 
reference. 
1
H
 
and 
19
F multiplicities are reported as follows: singlet (s), doublet (d), triplet 
(t), quartet (q), broad resonance (br) and multiplet (m). Overlapping signals in 
1
H-NMR 
spectra were also reported as (m). 
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Preparation of (PPh3)2Ni(CF3)(OOCCF3) (2). In a nitrogen filled glovebox a 
Schlenk flask was charged with a teflon coated stirbar, triphenylphosphine (4.20 g; 16 
mmol) and Ni(cod)2 (2.00 g; 7.27 mmol). The flask was sealed with septum and then 
taken out of the glovebox. Dry THF (150 mL) was added via cannula and the resulting 
dark red mixture was stirred at r.t. for 15 minutes. The solution was then cooled to -78 
o
C 
and trifluoroacetic anhydride (TFAA) (1.70 ml; 12 mmol) was added dropwise. Solution 
was slowly warmed to rt and volatiles were then removed under reduced pressure via the 
sidearm of the reaction flask. Diethylether (200 ml) was added to the residue and product 
then precipitated in a form of yellow crystals. The product was collected by filtration and 
washed with several portions of diethyl ether. After drying in vacuum 4.04 g (70%) of 
yellow crystalline powder was obtained. 
1
H NMR (CDCl3 at 23 
oC): δ 7.90-7.78 (m, 
12H), 7.52-7.37 (m, 18H). 
13
C{H} NMR (CDCl3 at 23 
oC): δ 160.11 (q, 2J(C-F) = 37.5 
Hz), 134.39 (br), 130.49 (br), 130.07 (br), 128.40 (br), 123.28 (broad quartet, 
1
J(C-F) = 
361.7 Hz), 113.88 (q, 
1
J(C-F) = 290.9 Hz). 
19
F NMR (CDCl3 at 23 
oC): δ 75.54 (s, 3F), -
8.83 (br, 3F). 
31
P{
1
H} NMR (CDCl3 at 23 
oC): δ 22.62 (br). 19F/13C HSQC NMR (CDCl3 
at 25 
oC): δF/δC -8.95/123.34, -75.67/114.03.  IR (ATR): cm
-1
 3058 (w), 1675 (s), 1482 
(s), 1434 (s), 1415 (s), 1190 (s). Elemental analysis: Calculated for NiC39H30F6O2P2 C 
= 61.21%, H = 3.95%, F = 14.90%; Found: C = 61.12%, H = 3.95%, F = 14.81%. 
Preparation of (dppe)Ni(CF3)(OOCCF3) (3). A 20 mL vial was charged with 
(PPh3)2Ni(CF3)(OOCCF3) (1) (153 mg; 0.20 mmol), 1,2-bis(diphenylphosphino)ethane 
(dppe) (105 mg; 0.26 mmol) and dry dichloromethane (10 ml). The resulting solution was 
stirred at rt for 5 minutes and then the reaction mixture was filtered through a pad of 
celite. Volatiles were removed under reduced pressure and residue was dissolved in 
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diisopropyl ether. Product slowly separated in a form of yellow crystals. The product was 
collected by filtration, washed with several portions of diisopropyl ether and dried under 
reduced pressure. The yield of the product was 123 mg (96%). Analytical sample was 
obtained after crystallization (3 times) from dichloromethane/diisopropyl ether. 
1
H NMR 
(CD2Cl2 at 23 
oC): δ 8.07-8.00 (m, 4H), 7.82-7.75 (m, 4H), 7.67-7.51 (m, 12H), 2.31-2.19 
(m, 4H), 2.12-2.00 (m, 4H).
 13
C{
1
H} NMR (CD2Cl2 at 23 
oC): δ 160.73 (d, 2J(C-F) = 36.1 
Hz), 133.48 (d, 
3
J(C-P) = 10.9 Hz), 133.42 (qdd, 
1
J(C-F) = 234.3 Hz, 
3
J(C-P) = 137.6 Hz, 
3
J(C-
P) = 39.5 Hz) 133.07 (d, 
3
J(C-P) = 11.6 Hz), 132.05 (d, 
4
J(C-P) = 2.7 Hz), 131.82 (d, 
4
J(C-P) = 
2.0 Hz), 129.24 (d, 
2
J(C-P) = 10.2 Hz), 129.14 (d, 
2
J(C-P) = 10.9 Hz), 127.84 (d, 
1
J(C-P) = 50.4 
Hz), 127.00 (d, 
1
J(C-P) = 40.9 Hz), 114.94 (q, 
1
J(C-F) = 290.2 Hz), 29.40 (dd, 
1
J(C-P) = 33.4 
Hz, 
2
J(C-P) = 17.0 Hz), 22.28 (dd, 
1
J(C-P) = 30.0 Hz, 
2
J(C-P) = 7.9 Hz). 
19
F NMR (CD2Cl2 at 
23 
oC): δ -29.02 (dd, 3J(F-P) = 43.1 Hz and 10.0 Hz, 3F), -75.12 (s, 3F). 
31
P{
1
H} NMR 
(CD2Cl2 at 23 
oC): δ 56.54 (dq, 2J(P-P) = 45.8 Hz, 
3
J(P-F) = 10.7 Hz), 45.76 (apparent 
quintet, 
2
J(P-P) = 
3
J(P-F) = 44.7 Hz). 
19
F/
13
C HSQC NMR (CD2Cl2 at 25 
oC): δF/ δC -
29.16/133.48, -75.24/114.98. 
19
F/
13
C HMBC NMR (CD2Cl2 at 25 
oC): δF/ δC -
75.14/160.71. IR (ATR): cm
-1
 3054 (w), 1685 (s), 1573 (w), 1485 (m), 1436 (s), 1421 (s), 
1313 (m), 1183 (s). Elemental analysis: Calculated for NiC29H24F6O2P2 C = 54.50%, 
H = 3.78%, F = 17.84%; Found: C = 54.53%, H = 3.69%, F = 17.97%. 
General procedure 1: Synthesis of dppe supported perfluoroalkylnickel 
complexes 4-9. In a nitrogen filled glovebox a Schlenk flask was charged with 
triphenylphosphine (1.00 g; 3.81 mmol) and Ni(cod)2 (500 mg;  1.82 mmol). The flask 
was sealed with septum and then taken out of the glovebox. Dry THF (50 mL) was added 
via cannula and the resulting dark red mixture was stirred at r.t. for 15 minutes. The 
 161 
 
solution was then cooled to -78 
o
C and corresponding carboxylic anhydride or carboxylic 
chloride (3 mmol) was added dropwise. Solution was slowly warmed to rt over the period 
of 1 hour and then dppe (876 mg; 2.20 mmol) was added. Resulting solution was stirred 
at rt for 5 minutes and then filtered through a pad of celite. Volatiles were removed under 
reduced pressure and the residue was suspended in diisopropyl ether (50 mL). Product 
separated in a form of yellow crystalls. Product was collected by filtration, washed with 
several portions of diisopropyl ether and dried under reduced pressure. Analytical sample 
was obtained after crystallization (3 times) from DCM/diisopropyl ether. 
Preparation of (dppe)Ni(C2F5)(OOCC2F5) (4). 4 was obtained according to the 
general procedure 1 in 640 mg (48%) yield. 
1
H NMR (CD2Cl2 at 23 
oC): δ 8.06-8.00 (m, 
4H), 7.82-7.76 (m, 4H), 7.66-7.59 (m, 4H), 7.59-7.50 (m, 8H), 2.21-2.12 (m, 4H), 2.10-
2.00 (m, 4H).
 13
C{
1
H} NMR (CD2Cl2 at 25 
o
C): δ 160.89 (t, 2J(C-F) = 26.0 Hz), 133.60 (d, 
3
J(C-P) = 10.2 Hz), 133.20 (d, 
3
J(C-P) = 10.9 Hz), 131.97 (d, 
4
J(C-P) = 2.7 Hz), 131.85 (d, 
4
J(C-
P) = 2.0 Hz), 129.19 (d, 
2
J(C-P) = 10.2 Hz), 129.03 (d, 
2
J(C-P) = 10.9 Hz), 128.47 (m, Ni-
CF2-CF3 resonance not observed in 
13
C spectrum but shift extracted from 
19
F/
13
C HSQC 
and HMBC experiments), 127.62 (d, 
1
J(C-P) = 50.4 Hz), 126.67 (d, 
1
J(C-P) = 40.9 Hz), 
120.63 (qtd, 
1
J(C-F) = 285.4 Hz, 
2
J(C-F) = 32.0 Hz, 
3
J(C-P) = 8.2 Hz, Ni-CF2-CF3), 118.26 
(qt, 
1
J(C-F) = 286.1  Hz, 
2
J(C-F) = 35.4 Hz, CO-CF2-CF3), 105.49 (tq, 
1
J(C-F) = 263.0  Hz, 
2
J(C-F) = 38.1 Hz, CO-CF2-CF3), 28.98 (dd, 
1
J(C-P) = 35.4 Hz, 
2
J(C-P) = 16.4 Hz), 22.30 (dd, 
1
J(C-P) = 30.0 Hz, 
2
J(C-P) = 8.9 Hz). 
19
F NMR (CD2Cl2 at 23 
oC): δ -80.31 (s, 3F, Ni-CF2-
CF3), -83.56 (br, 3F, CO-CF2-CF3), -102.07 (broad triplet, 
3
J(F-P) = 24.9 Hz, 2F, Ni-CF2-
CF3), -119.83 (br, 2F, CO-CF2-CF3). 
31
P{
1
H} NMR (CD2Cl2 at 23 
oC): δ 54.91 (dt, 2J(P-P) 
= 48.5 Hz, 
3
J(P-F) = 25.9 Hz), 45.27 (dt, 
2
J(P-P) = 48.5 Hz, 
3
J(P-F) = 27.5 Hz). 
19
F/
13
C HSQC 
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NMR (CD2Cl2 at 25 
oC): δF/ δC -80.43/120.72, -83.68/118.48, -102.19/128.47, -
119.91/105.56. 
19
F/
13
C HMBC NMR (CD2Cl2 at 25 
oC): δF/ δC -80.31/128.36, -
80.31/120.82 (
1
J correlation), -83.58/105.41, -83.58/118.32 (
1
J correlation), -
102.08/120.73, -119.78/105.41 (
1
J correlation),-119.78/118.32, -119.78/161.00. IR 
(ATR): cm
-1
 1696 (s), 1485 (w), 1439 (s), 1393 (m), 1319 (s), 1296 (s), 1225 (m), 1154 
(s). Elemental analysis: Calculated for NiC31H24F10O2P2 C = 50.37%, H = 3.27%, F = 
25.70%; Found: C = 50.23%, H = 3.32%, F = 25.76%. 
Preparation of (dppe)Ni(C3F7)(OOCC3F7) (5). 5 was obtained according to the 
general procedure 1 in 790 mg (52%) yield. 
1
H NMR (CDCl3 at 23 
oC): δ 8.06-7.97 (m, 
4H), 7.80-7.74 (m, 4H), 7.60-7.43 (m, 12H), 2.17-2.07 (m, 2H), 2.06-1.96 (m, 2H). 
13
C{H} NMR (CDCl3 at 23 
o
C; resonances of fluoroalkyl groups are assigned from 
19
F/
13C HSQC spectrum): δ 161.06 (br), 133.65 (d, 3J(C-P) = 10.9 Hz), 133.18 (d, 
3
J(C-P) = 
10.9 Hz), 131.87, 131.83, 131.09 (m, Ni-CF2-), 129.25 (d, 
2
J(C-P) = 10.2 Hz), 129.05 (d, 
2
J(C-P) = 10.9 Hz), 127.73 (d, 
1
J(C-P) = 50.4 Hz), 126.56 (d, 
1
J(C-P) = 40.2 Hz), 118.17 (m, -
CF3), 117.81 (m, -CF3), 110.98 (m, -CF2-), 108.21 (m, -CF2-), 107.38 (m, -CF2-), 28.95 
(dd, 
1
J(C-P) = 34.1 Hz, 
2
J(C-P) = 16.4 Hz), 22.32 (dd, 
1
J(C-P) = 29.3 Hz, 
2
J(C-P) = 8.9 Hz). 
19
F 
NMR (CDCl3 at 23 
oC): δ -80.51 (s, 3F), -80.81 (s, 3F), -98.43 (br, 2F), -116.88 (br, 2F), 
-118.28 (s, 2F), -127.07 (s, 2F). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 54.15 (dt, 2J(P-P) = 
43.5 Hz, 
3
J(P-F) = 25.4 Hz, 1P), 44.33 (dt, 
2
J(P-P) = 43.5  Hz, 
3
J(P-F) = 28.6 Hz, 1P). 
19
F/
13
C 
HSQC NMR (CDCl3 at 25 
oC): δF/δC -80.63/118.17, -80.94/117.81, -98.54/131.09, -
117.02/107.38, -118.40/110.98, -127.19/108.21. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
o
C): 
δF/δC -80.53/110.96, -80.83/108.17, -118.32/111.19 (
1
J correlation), -118.32/118.14, -
127.08/107.57, -127.08/117.96. IR (ATR): cm
-1
 1698 (s), 1486 (w), 1437 (m), 1385 (w), 
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1330 (s), 1210 (s), 1174 (s), 1119 (s), 1078 (s). Elemental analysis: Calculated for 
NiC33H24F14O2P2 C = 47.23%, H = 2.88%, F = 31.70%; Found: C = 47.37%, H = 
2.92%, F = 31.70%. 
Preparation of (dppe)Ni(CF2CF2COO) (6). 6 was obtained according to the 
general procedure 1 in 572 mg (52%) yield. 
1
H NMR (CD2Cl2 at 25 
oC): δ 8.87-7.78 (m, 
8), 7.63-7.48 (m, 12H), 2.44-2.34 (m, 2H), 2.21-2.10 (m, 2H). 
13
C{H} NMR (CD2Cl2 at 
25 
o
C; resonances of fluoroalkyl group partially assigned from 
19
F/
13
C HSQC spectrum): 
δ 168.98 (t, 2J(C-F) = 25.9 Hz), 133.24 (d, 
3
J(C-P) = 10.9 Hz), 132.73 (d, 
3
J(C-P) = 11.6 Hz), 
132.03 (d, 
4
J(C-P) = 2.7 Hz), 131.66 (d, 
4
J(C-P) = 2.1 Hz), 129.59 (m, Ni-CF2-), 129.41 (d, 
2
J(C-P) = 10.2 Hz), 129.16 (d, 
2
J(C-P) = 10.9 Hz), 128.46 (d, 
1
J(C-P) = 38.2 Hz), 126.97 (d, 
1
J(C-P) = 41.8 Hz), 110.83 (tt, 
1
J(C-F) = 267.0 Hz, 
2
J(C-F) = 21.8 Hz), 29.91 (dd, 
1
J(C-P) = 34.8 
Hz, 
2
J(C-P) = 17.7 Hz), 21.93 (dd, 
1
J(C-P) = 30.7 Hz, 
2
J(C-P) = 8.9 Hz). 
19
F NMR (CD2Cl2 at 
25 
oC): δ -110.31 (m, 2F), -120.00 (br, 2F). 31P{1H} NMR (CD2Cl2 at 25 
o
C): δ 59.09 (dt, 
2
J(P-P) = 28.6 Hz, 
3
J(P-F) = 20.1 Hz, 1P), 38.46 (apparent quartet, 
2
J(P-P) = 
3
J(P-F) = 30.1 Hz, 
1P). 
19
F/
13
C HSQC NMR (CD2Cl2 at 25 
oC): δF/δC -110.31/129.59, -120.00/110.83. 
19
F/
13
C HMBC NMR (CD2Cl2 at 25 
oC): δF/δC -110.31/110.83, -110.31/129.59 (
1
J 
correlation), -110.31/168.98 -120.00/110.83 (
1
J correlation), -120.00/129.59, -
120.00/168.98. IR (ATR): cm
-1
 3054 (w), 2956 (w), 1698 (s), 1619 (w), 1587 (w), 1483 
(m), 1436 (m), 1351 (m), 1245 (s), 1137 (m), 1098 (s), 1038 (s). Elemental analysis: 
Calculated for NiC29H24F4O2P2 C = 57.94%, H = 4.02%, F = 12.64%; Found: C = 
57.64%, H = 4.02%, F = 12.66%. 
Preparation of (dppe)Ni(CF2CF2CF2COO) (7). 7 was obtained according to the 
general procedure 1 in 422 mg (36%) yield. 
1
H NMR (CD2Cl2 at 25 
oC): δ 7.96-7.90 (m, 
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4H), 7.86-7.80 (m, 4H), 7.66-7.61 (m, 2H), 7.61-7.57 (m, 2H), 7.57-7.51 (m, 8H), 2.46-
2.36 (m, 2H), 2.06-1.96 (m, 2H). 
13
C{H} NMR (CD2Cl2 at 25 
o
C; resonances of 
fluoroalkyl partially assigned from 
19
F/
13C HSQC spectrum): δ 163.72 (t, 2J(C-F) = 22.5 
Hz), 133.47 (d, 
3
J(C-P) = 10.9 Hz), 132.88 (d, 
3
J(C-P) = 10.2 Hz), 132.21 (d, 
4
J(C-P) = 2.0 
Hz), 131.75 (d, 
4
J(C-P) = 2.7 Hz), 129.35 (d, 
2
J(C-P) = 10.2 Hz), 129.17 (d, 
2
J(C-P) = 10.9 
Hz), 127.97 (d, 
1
J(C-P) = 38.8 Hz), 126.87 (d, 
1
J(C-P) = 51.1 Hz), 126.75 (m, -CF2-Ni), 
111.65 (broad triplet, 
1
J(C-F) = 261.6 Hz), 107.79 (tt, 
1
J(C-F) = 260.2 Hz, 
2
J(C-F) = 28.6 Hz), 
30.42 (dd, 
1
J(C-P) = 36.1 Hz, 
2
J(C-P) = 17.7 Hz), 21.23 (dd, 
1
J(C-P) = 30.7 Hz, 
2
J(C-P) = 8.2 
Hz). 
19
F NMR (CD2Cl2 at 25 
oC): δ -100.75 (t, 2J(F-P) = 31.5 Hz, 2F), -120.35 (m, 2F), -
130.03 (br, 2F). 
31
P{
1
H} NMR (CD2Cl2 at 25 
oC): δ 58.29 (dt, 2J(P-P) = 44.25 Hz, 
3
J(P-F) = 
33.6 Hz, 1P), 38.19 (m, 1P). 
19
F/
13
C HSQC NMR (CD2Cl2 at 25 
oC): δF/δC -
100.75/126.75, -120.35/107.79, -130.03/111.65. 
19
F/
13
C HMBC NMR (CD2Cl2 at 25 
o
C): 
δF/δC -100.75/111.65, -120.36/107.79 (
1
J correlation), -120.36/111.65, -120.36/163.79, -
130.03/111.65 (
1
J correlation), -130.03/126.75. IR (ATR): cm
-1
 3064 (w), 2956 (w), 2918 
(w), 1687 (s), 1482 (m), 1434 (m), 1379 (m), 1288 (m), 1221 (m), 1164 (s), 1102 (s), 
1052 (s). Elemental analysis: Calculated for NiC30H24F6O2P2 C = 55.34%, H = 3.72%, 
F = 17.51%; Found: C = 55.19%, H = 3.70%, F = 17.25%. 
Preparation of (dppe)Ni(C3F7)(Cl) (8). 8 was obtained according to the general 
procedure 1 in 570 mg (47%) yield. Compound slowly decomposes in solution. 
Analytical sample contains some unidentified decomposition product (~15% based on 
31
P 
NMR) with (dppe)NiX2 structure. All further attempts to purify the title complex resulted 
in extensive decomposition. 
1
H NMR (CDCl3 at 23 
oC): δ 7.91-7.80 (m, 8H), 7.28-7.40 
(m, 12H), 2.20-2.08 (m, 2H), 1.99-1.88 (m, 2H). 
13
C{H} NMR (CDCl3 at 23 
oC): δ 
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133.72 (d, 
3
J(C-P) = 10.2 Hz), 133.81 (Low intensity multiplet that overlaps with nearby 
peaks. Resonance observed in 
19
F/
13
C HSQC spectrum.), 133.51 (d, 
3
J(C-P) = 10.9 Hz), 
131.71, 131.29, 128.92-128.61 (four overlapping doublets.), 118.42 (qt, 
1
J(C-F) = 286.8 
Hz, 
2
J(C-F) = 40.87 Hz), 111.62 (tq, 
1
J(C-F) = 256.8 Hz, 
2
J(C-F) = 32.8 Hz), 29.66 (dd, 
1
J(C-P) 
= 34.7 Hz, 
2
J(C-P) = 18.4 Hz), 24.63 (dd, 
1
J(C-P) = 27.2 Hz, 
2
J(C-P) = 9.9 Hz). 
19
F NMR 
(CDCl3 at 23 
oC): δ -80.42 (t, 3J(F-F) = 9.6 Hz, 3F), -89.88 (m, 2F), -115.33 (br, 2F). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 60.36 (dt, 2J(P-P) = 48.7 Hz, 
3
J(P-F) = 35.0 Hz, 1P), 
44.39 (dt, 
2
J(P-P) = 48.8 Hz, 
3
J(P-F) = 27.6 Hz, 1P). 
19
F/
13
C HSQC NMR (CDCl3 at 25 
o
C): 
δF/δC -80.54/118.43, -89.99/133.81, -115.44/111.63. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
oC): δF/δC -80.42/111.72, -80.42/118.55 (
1
J correlation). IR (ATR): cm
-1
 3055 (w), 1485 
(m), 1438 (s), 1326 (s), 1211 (s), 1188 (s). Elemental analysis: Calculated for 
NiC29H24ClF7P2 C = 52.65%, H = 3.66%, Cl = 5.36% F = 20.10%; Found: C = 
53.02%, H = 3.81%, Cl = 5.46, F = 18.16%. 
Preparation of (dppe)Ni(C6F5)(Cl) (9). 9 was obtained according to the general 
procedure 1 in 775 mg (65%) yield. 
1
H NMR (CD2Cl2 at 23 
oC): δ 7.97 (m, 4H), 7.68 (m, 
4H), 7.60 (m, 2H), 7.57-7.52 (m, 6H), 7.41 (m, 4H), 2.44-2.32 (m, 2H), 2.11-1.98 (m, 
2H). 
13
C{
1
H} NMR (CD2Cl2 at 23 
oC): δ 145.89 (dd, 1J(C-F) = 226.8 Hz, 
3
J(C-P) = 27.3 Hz), 
138.19 (d, 
1
J(C-F) = 240 Hz), 137.16 (d, 
1
J(C-F) = 252 Hz), 133.62 (d, 
3
J(C-P) = 10.2  Hz), 
132.95 (d, 
3
J(C-P) = 10.2 Hz), 131.81 (d, 
4
J(C-P) = 2.7 Hz), 131.81 (d, 
4
J(C-P) = 2.0 Hz), 
129.15 (d, 
1
J(C-P) = 43.6 Hz), 128.90 (d, 
2
J(C-P) = 10.2 Hz) 128.67 (d, 
2
J(C-P) = 10.9 Hz), 
128.63 (d, 
1
J(C-P) = 41.8 Hz), 123.37 (m), 27.80 (dd, 
1
J(C-P) = 31.3 Hz, 
2
J(C-P) = 18.4 Hz), 
22.94 (dd, 
1
J(C-P) = 28.6 Hz, 
2
J(C-P) = 12.3 Hz). 
19
F NMR (CD2Cl2 at 23 
oC): δ -118.61 (m, 
2F), -161.67 (apparent t, 
3
J(F-F) = 19.9 Hz, 1F), -163.55 (m, 2F). 
31
P{
1
H} NMR (CD2Cl2 at 
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23 
oC): δ 61.55 (d, 2J(P-P) = 51.9 Hz), 48.03 (broad doublet, 
2
J(P-P) = 51.9 Hz). 
19
F/
13
C 
HSQC NMR (CD2Cl2 at 25 
oC): δF/ δC -118.63/145.87, -162.66/137.03, -164.41/135.79. 
19
F/
13
C HMBC NMR (CD2Cl2 at 25 
oC): δF/ δC -118.55/123.44, -118.55/135.84, -
118.55/137.01, -162.57/135.84, -162.57/137.01 (
1
J correlation), -162.57/145.86, -
164.35/123.44, -164.35/135.84 (
1
J correlation), -164.35/137.01, -164.35/145.86. IR 
(ATR): cm
-1
 3076 (w), 1495 (s), 1448 (s),1435 (s), 1343 (m), 1102 (s). 
Preparation of (PPh3)2Pd(COCF3)(OCOCF3) (10). A Schlenk flask was charged 
with a stirbar and (PPh3)4Pd (8.00 g; 6.92 mmol). The flask was sealed, evacuated under 
reduced pressure and then refilled with nitrogen four times. Dry THF (250 mL) was 
added via cannula. Trifluoroacetic anhydride (TFAA) (3.40 mL; 24.0 mmol) was then 
added dropwise over the period of 10 minutes. The resulting solution was stirred at rt for 
20 minutes and then volatiles were removed under reduced pressure. The white 
crystalline residue was suspended in EtOAc (100 mL), filtered and washed with several 
portions of EtOAc. After drying in vacuum 5.23 g (90%) of a white solid was obtained. 
1
H NMR (CDCl3 at 25 
oC): δ 7.64-7.58 (m, 12H), 7.49-7.44 (m, 6H), 7.44-7.38 (m, 12H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 219.54 (q, 2J(C-F) = 38.2 Hz), 159.69 (q, 
2
J(C-F) = 36.2 
Hz), 134.39 (t, 
2
J(C-P) = 6.9 Hz), 131.0, two overlapping triplets 128.55 (t, 
3
J(C-P) = 4.9 Hz) 
and 128.54 (t, 
1
J(C-P) = 23.5 Hz), 115.51 (q, 
1
J(C-F) = 291.5 Hz), 111.65 (qt, 
1
J(C-F) = 301.3 
Hz, 
3
J(C-P) = 16.6 Hz). 
19
F NMR (CDCl3 at 25 
oC): δ -75.01 (s, 3F), -75.46 (s, 3F). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 17.53 (s). 19F/13C HSQC NMR (CDCl3 at 25 
oC): δF/ 
δC -75.14/111.82, -75.59/115.66. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
oC): δF/δC -
75.01/219.52, -75.60/111.82 (
1
J correlation), -75.46/159.66, -75.46/115.54 (
1
J 
correlation). IR (ATR): cm
-1
 3059 (w), 1752 (w), 1684 (s), 1665 (s), 1481 (s), 1436 (s), 
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1422 (s), 1229 (s), 1177 (s), 1136 (s), 1095 (s). FAB MS (m/z): [M – CF3COO]
+
 calcd for 
C38H30F3OP2Pd, 727.1; Found, 727.5, [(PPh3)2PdCF3]
+
 calcd for C37H30F3P2Pd, 
699.1; Found, 699.5 Elemental analysis: Calculated for PdC40H30F6O3P2 C = 57.12%, 
H = 3.60%, F = 13.55%; Found: C = 57.09%, H = 3.70%, F = 13.66%. 
Preparation of (P(o-Tol)3)2Pd(COCF3)(OCOCF3) (15). A Schlenk flask was 
charged with a stirbar and Pd[P(o-Tol)3]2 (4.00 g; 6.92 mmol). The flask was sealed, 
evacuated under reduced pressure and then refilled with nitrogen. The flask was 
evacuated and refilled with nitrogen three more times. Dry THF (100 mL) was added via 
cannula. Trifluoroacetic anhydride (TFAA) (1.13 mL; 8 mmol) was then added dropwise 
over the period of 10 minutes. The resulting solution was stirred at rt for 20 minutes and 
then filtered through a pad of celite. Volatiles were removed under reduced pressure. The 
residue was suspended in diethyl ether (100 mL). Product slowly separated over the 
period of 4 hours in a form of yellowish crystals. Precipitate was filtered and washed with 
several portions of diethyl ether. After drying in vacuum 5.08 g (91%) of a white solid 
was obtained. 
1
H NMR and elemental analysis showed that crystallized compound 
contains exactly one equivalent of diethyl ether that could not be removed even after 
prolonged drying under vacuum. The cocrycstallized ether was taken into account when 
the reaction yield was calculated. 
1
H-, 
19
F- and 
31
P-NMR spectra of 15 contain only very 
broad resonances. We explain this with reversible dissociation of the P(o-Tol)3 ligand and 
dynamic equilibrium between several species in the solution. This is supported by the fact 
that 
31
P-NMR spectrum of 15 contains a singlet at -29.6 ppm corresponding to a free P(o-
Tol)3 ligand. 
1
H NMR (CDCl3 at 23 
oC): δ 10.0-6.0 (br, 24H), 4.0-1.0 (br, 18 H), 3.48 (q, 
J = 7.1 Hz, 4H, diethyl ether), 1.21 (t, J = 7.1 Hz, 6H, diethyl ether). 
19
F NMR (CDCl3 at 
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23 
oC): δ -73.2 (br, 3F), -74.8 (br, 3F).  31P{1H} NMR (CDCl3 at 23 
oC): δ 20.5-6.7 (br). 
IR (ATR): cm
-1
 3058 (w), 2973 (m), 1700 (s), 1677 (s), 1590 (m), 1566 (m), 1444 (s), 
1405 (s), 1381 (m), 1279 (m), 1231 (m), 1191 (s). Elemental analysis: Calculated for 
PdC46H42F6O3P2*C2H5OC2H5 C = 60.10%, H = 5.24%, F = 11.41%; Found: C = 
60.03%, H = 5.32%, F = 11.69%. 
Preparation of (P(o-Tol)3)2Pd(CF3)(OCOCF3) (16). (P(o-
Tol)3)2Pd(COCF3)(OCOCF3) (15) (2.50 g; 2.70 mmol) was refluxed in benzene (150 mL) 
for 1 hour. Reaction mixture was then filtered through a pad of celite and volatiles were 
removed under reduced pressure. The residue was dissolved in diisopropyl ether (150 
mL) and product slowly separated in a form of yellowish crystals over the period of 4 
hours. Product was collected by filtration and washed with several portions of 
diisopropylether. After drying under reduced pressure, 1.82g (67%) of a yellowish solid 
was obtained. 
1
H NMR and elemental analysis showed that crystallized 16 contains 
exactly one equivalent of diisopropyl ether that could not be removed even after 
prolonged drying under vacuum. The cocrystallized diisopropyl ether was taken into 
account when the reaction yield was calculated. 
1
H-, 
19
F- and 
31
P-NMR spectra of 16 
contain broad resonances. We explain this with reversible dissociation of the P(o-Tol)3 
ligand and dynamic equilibrium between several species in the solution. This is supported 
by the fact that 
31
P-NMR spectrum of 16 contains a singlet at -29.6 ppm corresponding to 
a free P(o-Tol)3 ligand.  NMR of 16 spectra are not reported here but they are provided in 
the SI. IR (ATR): cm
-1
 3059 (w), 2968 (m), 2870 (w), 1698 (s), 1591 (m), 1566 (m), 1445 
(s), 1405 (m), 1380 (m), 1281 (m), 1190 (s). FAB MS (m/z): [M – CF3COO]
+
 calcd for 
C43H42F3P2Pd, 783.2; Found, 783.5,  Elemental analysis: Calculated for 
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PdC45H42F6O2P2*C3H7OC3H7 C = 61.29%, H = 5.65%, F = 11.41%; Found: C = 
60.04%, H = 5.34%, F = 11.50%. 
Preparation of (dppe)Pd(CF3)(OCOCF3) (17). (P(o-
Tol)3)2Pd(CF3)(OCOCF3)*C3H7OC3H7 (16) (250 mg;  0.25 mmol) and 1,2-
bis(diphenylphosphino)ethane (dppe) (115 mg; 0.29 mmol) were dissolved in a small 
amount of DCM (~7 mL). Reaction mixture was stirred at rt for 5 minutes and then 
filtered through a pad of celite. Diisopropylether was slowly added to the solution until 
the product started to crystallize. Mixture was cooled to 5 
o
C for 4 hours and crystallized 
product was then collected by filtration. Product was washed with several portions of 
diisopropyl ether and dried under reduced pressure. Thus 17 was prepared in 154 mg 
(90%) yield. Analytical sample was obtained after crystallization (3 times) from 
DCM/diisopropyl ether. 
1
H NMR (CD2Cl2 at 25 
oC): δ 7.87-7.80 (m, 4H), 7.77-7.71 (m, 
4H), 7.66-7.61 (m, 2H) 7.60-7.49 (m, 10H), 2.51-2.42 (m, 2H), 2.28-2.18 (m, 2H). 
13
C{
1
H} NMR (CD2Cl2 at 25 
oC): δ 160.73 (q, 3J(C-F) = 36.1 Hz), 136.15 (qdd, 
1
J(C-F) = 
381.47 Hz,
 2
J(C-P) = 215.9 and 8.9 Hz),  133.50 (d, 
3
J(C-P) = 11.6 Hz), 133.08 (d, 
3
J(C-P) = 
11.6 Hz), 132.39 (d, 
4
J(C-P) = 2.7 Hz), 131.89 (d, 
4
J(C-P) = 2.7 Hz), 129.36-129.16 (two 
overlapping doublets), 127.92 (d, 
1
J(C-P) = 40.9 Hz), 127.24 (d, 
1
J(C-P) = 55.2 Hz), 116.22 
(qd, 
1
J(C-F) = 290.9 Hz,
 4
J(C-P) = 7.5 Hz), 30.61 (dd, 
1
J(C-P) = 36.8 Hz, 
2
J(C-P) = 18.4 Hz), 
23.66 (dd, 
1
J(C-P) = 30.0 Hz, 
2
J(C-P) = 8.2 Hz). 
19
F NMR (CD2Cl2 at 25 
oC): δ -26.61 (dd, 
3
J(F-P) = 66.3 and 26.5 Hz, 3F), -74.60 (s, 3F).  
31
P{
1
H} NMR (CD2Cl2 at 25 
oC): δ 56.55 
(apparent quintet, 
2
J(P-P) = 
3
J(P-F) = 25.9 Hz, 1P), 44.04 (qd, 
3
J(P-F) = 65.6 Hz,
 2
J(P-P) = 27.5  
Hz, 1P). 
19
F/
13
C HSQC NMR (CD2Cl2 at 25 
oC): δF/δC -74.60/116.25 (Peak 
corresponding to the Pd-CF3 group was not observed in 
19
F/
13
C HSQC. However Pd-CF3 
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group was observed in 
19
F/
13
C HMBC as a 
1
J artifact. 
19
F/
13
C HMBC NMR (CD2Cl2 at 
25 
o
C): δF/δC -26.61/136.31 (
1
J correlation), -74.60/116.39 (
1
J correlation), -
74.60/160.77. IR (ATR): cm
-1
 3068 (w), 2976 (w), 1682 (s), 1486 (m), 1436 (s), 1418 
(m), 1314 (m), 1182 (s), 1136 (s), 1082 (s). HRMS electrospray (m/z): [M – OCOCF3]
+
 
calcd for C27H24F3P2Pd, 573.0335; Found, 573.0348, [M – CO2CF3 + CH3CN]
+
 calcd 
for C29H27F3NP2Pd, 614.0600; Found, 614.0610. Elemental analysis: Calculated for 
PdC29H24F6O2P2 = 50.71%, H = 3.52%, F = 16.60%; Found: C = 50.46%, H = 3.59%, 
F = 16.37%. 
General procedure 2: Preparation of dppe supported perfluoroalkylpalladium 
complexes 18-20. A Schlenk flask was charged with a stirbar and Pd[P(o-Tol)3]2 (2.00g; 
3.46 mmol). The flask was sealed, evacuated under reduced pressure and then refilled 
with nitrogen four times. Dry THF (100 mL) was added via cannula. Corresponding 
anhydride (5.0 mmol) was then added dropwise over the period of 5 minutes. The 
resulting solution was stirred at rt for 20 minutes, it was then filtered through a pad of 
celite and volatiles were removed under reduced pressure. Residue was refluxed in 150 
mL of benzene for approximately 30 minutes, until the color of the solution changed 
from yellow to deep red and then back to yellow. Benzene solution was cooled to rt and 
dppe (1.35 g; 3.4 mmol) was added. Reaction mixture was filtered through a pad of celite 
and benzene was removed under reduced pressure. The residue was dissolved in 
diisopropyl ether (100 mL). Product slowly separated over the period of 4 hours in a form 
of yellowish crystals. Product was collected by filtration and washed with several 
portions of diisopropylether. Analytical sample was obtained after several crystallizations 
from DCM/isopropylether. 
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Preparation of (dppe)Pd(C2F5)(OCOC2F5) (18). 18 was obtained according to 
the general procedure 2 in 87% yield. 
1
H NMR (CD2Cl2 at 25 
oC): δ 7.85-7.79 (m, 4H), 
7.74-7.69 (m, 4H), 7.66-7.61 (m, 2H), 7.60-7.50 (m, 10H), 2.43-2.34 (m, 2H), 2.24-2.14 
(m, 2H). 
13
C{
1
H} NMR (CD2Cl2 at 25 
o
C; resonances of fluoroalkyl groups are assigned 
from 
19
F/
13C HSQC spectrum): δ 160.85 (t, 3J(C-F) = 25.2 Hz), 133.62 (d, 
3
J(C-P) = 11.6 
Hz), 133.28 (d, 
3
J(C-P) = 11.6 Hz), 132.31 (d, 
4
J(C-P) = 2.7 Hz), 131.88 (d, 
4
J(C-P) = 2.7 Hz), 
129.68 (m, Pd-CF2-), 129.24-129.07 (two overlapping doublets), 127.67 (d, 
1
J(C-P) = 42.2 
Hz), 127.27 (d, 
1
J(C-P) = 54.5 Hz), 121.15 (m, CF3), 118.50 (qt, 
1
J(C-F) = 286.1 Hz, 
2
J(C-F) = 
35.4 Hz, CF3) 106.56 (m, CO-CF2-), 30.48 (dd, 
1
J(C-P) = 36.1 Hz, 
2
J(C-P) = 17.7 Hz), 24.28 
(dd, 
1
J(C-P) = 29.3 Hz, 
2
J(C-P) = 8.9 Hz). 
19
F NMR (CD2Cl2 at 25 
oC): δ -81.49 (s, 3F), -
83.51 (s, 3F), -96.55 (dd, 
3
J(F-P) = 39.8 and 31.5 Hz, 2F), -119.55 (s, 2F). 
31
P{
1
H} NMR 
(CD2Cl2 at 25 
oC): δ 55.90 (td, 3J(P-F) = 31.8 Hz, 
2
J(P-P) = 26.5 Hz, 1P), 44.14 (tdq, 
3
J(P-F) = 
39.2 Hz,
 2
J(P-P) = 26.5 Hz, 
4
J(P-F) = 3.2 Hz, 1P). 
19
F/
13
C HSQC NMR (CD2Cl2 at 25 
o
C): 
δF/δC -81.60/121.15, -83.64/118.50, -96.67/129.68, -119.68/106.56. 
19
F/
13
C HMBC NMR 
(CD2Cl2 at 25 
oC): δF/δC -81.60/121.15 (
1
J correlation), -81.60/129.68, -83.64/106.56, -
83.64/118.50 (
1
J correlation), -96.67/121.15, -119.68/118.50, -119.68/160.91. IR (ATR): 
cm
-1
 3066 (w), 1693 (s), 1485 (w), 1437 (s),1386 (m), 1319 (s), 1300 (s), 1226 (m), 1150 
(s), 1104 (s). HRMS electrospray (m/z): [M – OCOC2F5]
+
 calcd for C28H24F5P2Pd, 
623.0303; Found, 623.0312, [M – CO2C2F5 + CH3CN]
+
 calcd for C30H27F5NP2Pd, 
664.0568; Found, 664.0575. Elemental analysis: Calculated for PdC31H24F10O2P2 C = 
47.32%, H = 3.07%, F = 24.14%; Found: C = 47.08%, H = 3.02%, F = 24.05%. 
Preparation of (dppe)Pd(C3F7)(OCOC3F7) (19). 19 was obtained according to 
the general procedure 2 in 50% yield. 
1
H NMR (CDCl3 at 25 
oC): δ 7.82-7.76 (m, 4H), 
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7.73-7.68 (m, 4H), 7.60-7.46 (m, 12H), 2.38-2.26 (m, 2H), 2.19-2.08 (m, 2H). 
13
C{
1
H} 
NMR (CDCl3 at 25 
o
C; resonances of fluoroalkyl groups are assigned from 
19
F/
13
C 
HSQC spectrum): δ 161.15 (t, 3J(C-F) = 25.9 Hz), 133.66 (d, 
3
J(C-P) = 12.3 Hz), 132.59 (m, 
Pd-CF2-), 133.27 (d, 
3
J(C-P) = 11.6 Hz), 132.25 (d, 
4
J(C-P) = 2.7 Hz), 131.88 (d, 
4
J(C-P) = 2.7 
Hz), 129.26 (d, 
2
J(C-P) = 10.2 Hz), 129.14 (d, 
2
J(C-P) = 11.6 Hz), 127.70-127.27 (two 
overlapping doublets), 118.51 (m, -CF3), 117.85 (m, -CF3), 110.87 (m, -CF2-), 108.47 (m, 
-CF2-), 108.41 (m, -CF2-), 30.20 (dd, 
1
J(C-P) = 36.1 Hz, 
2
J(C-P) = 17.7 Hz), 24.17 (dd, 
1
J(C-P) 
= 29.3 Hz, 
2
J(C-P) = 8.9 Hz). 
19
F NMR (CDCl3 at 25 
oC): δ -80.31 (t, 3J(F-F) = 8.3 Hz, 3F), -
80.78 (t, 
3
J(F-F) = 8.3 Hz, 3F), -93.34 (m, 2F), -116.49 (q, 
3
J(F-F) = 10.0 Hz, 2F), -120.43 
(s, 2F), -126.96 (s, 2F).  
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 55.90 (apparent quartet, 2J(P-P) 
= 
3
J(P-F) = 27.5 Hz, 1P), 44.14 (td, 
3
J(P-F) = 39.7 Hz,
 2
J(P-P) = 27.5  Hz, 1P). 
19
F/
13
C HSQC 
NMR (CDCl3 at 25 
oC): δF/δC -80.43/118.51, -80.91/117.85, -93.43/132.59, -
116.61/108.47, -120.54/110.87, -127.08/108.41. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
o
C): 
δF/δC -80.43/110.87, -80.91/108.47, -116.61/108.47, -116.61/161.51, -120.54/110.87 (
1
J 
correlation), -120.54/118.51, -127.08/108.47, -127.08/117.85. IR (ATR): cm
-1
 3065 (w), 
1494 (s), 1486 (m),1438 (s), 1384 (m), 1331 (s), 1210 (s), 1175 (s). HRMS electrospray 
(m/z): [M – OCOC3F7]
+
 calcd for C29H24F7P2Pd, 673.0271; Found, 673.0278, [M – 
CO2C3F7 + CH3CN]
+
 calcd for C31H27F7NP2Pd, 714.0536; Found, 714.0540. Elemental 
analysis: Calculated for PdC33H24F14O2P2 = 44.69%, H = 2.73%, F = 29.99%; Found: 
C = 44.76%, H = 2.74%, F = 29.91%. 
Preparation of (dppe)Pd(CF2CF2CF2COO) (20). 20 was obtained according to 
the general procedure 2 in 16% yield. Methyl tert-butyl ether (MTBE) was used for 
crystallizations instead of diisopropyl ether. In order to remove cocrystallized solvent, the 
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analytical sample was dried under vacuum at at 90 
o
C for 8 hours. 
1
H NMR (CD2Cl2 at 25 
oC): δ 7.81-7.73 (m, 8H), 7.65-7.61 (m, 2H), 7.59-7.50 (m, 10H), 2.66-2.56 (m, 2H), 
2.26-2.17 (m, 2H). 
13
C{
1
H} NMR (CD2Cl2 at 25 
o
C; resonances of fluoroalkyl partially 
assigned from 
19
F/
13C HSQC spectrum): δ 164.01 (t, 2J(C-F) = 25.2 Hz), 133.60 (d, 
3
J(C-P) = 
11.6 Hz), 132.76 (d, 
3
J(C-P) = 11.6 Hz), 132.56 (d, 
4
J(C-P) = 2.7 Hz), 131.92 (d, 
4
J(C-P) = 2.1 
Hz), 129.48 (d, 
2
J(C-P) = 10.2 Hz), 129.25 (d, 
2
J(C-P) = 11.6 Hz), 128.30 (d, 
1
J(C-P) = 39.5 
Hz), 128.15 (m, -CF2-Pd), 126.39 (d, 
1
J(C-P) = 55.9 Hz), 113.08 (broad triplet, 
1
J(C-F) = 
265.7 Hz), 108.81 (tt, 
1
J(C-F) = 260.9 Hz, 
2
J(C-F) = 30.5 Hz), 31.09 (dd, 
1
J(C-P) = 36.8 Hz, 
2
J(C-P) = 18.4 Hz), 21.83 (dd, 
1
J(C-P) = 30.7 Hz, 
2
J(C-P) = 8.2 Hz). 
19
F NMR (CD2Cl2 at 25 
oC): δ -96.04 (m, 2F), -118.93 (m, 2F), -128.66 (br, 2F). 31P{1H} NMR (CD2Cl2 at 25 
oC): δ 57.49 (td, 3J(P-F) = 41.3 Hz, 
2
J(P-P) = 32.84 Hz, 1P), 37.30 (m, 1P). 
19
F/
13
C HSQC 
NMR (CD2Cl2 at 25 
oC): δF/δC -96.04/128.15, -118.93/108.81, -128.66/113.08. 
19
F/
13
C 
HMBC NMR (CD2Cl2 at 25 
oC): δF/δC -96.04/113.08, -96.04/128.15 (
1
J correlation), -
118.93/108.81 (
1
J correlation), -118.93/113.08, -118.93/164.01, -128.66/108.81, -
128.66/113.08 (
1
J correlation), -128.66/128.15. IR (ATR): cm
-1
 3058 (w), 2919 (w), 1680 
(s), 1483 (m), 1436 (s), 1374 (m), 1276 (m), 1222 (m), 1161 (s), 1104 (s), 1056 (s), 992 
(s). HRMS electrospray (m/z): [M + H]
+
 calcd for C30H25F6O2P2Pd, 699.0263; Found, 
699.0262. 
Preparation of (dppe)Pd(CHF2)(Cl) (23). A Schlenk flask was charged with a 
stirbar and Pd[P(o-Tol)3]2 (2.00g; 3.46 mmol). The flask was sealed, evacuated under 
reduced pressure and then refilled with nitrogen four times. Dry THF (100 mL) was 
added via cannula. Difluoroacetic anhydride (4.0 mmol; 0.89 mL) was then added 
dropwise over the period of 5 minutes. The resulting solution was stirred at rt for 20 
 174 
 
minutes, and then filtered through a pad of celite and volatiles were removed under 
reduced pressure. Residue was refluxed in 150 mL of benzene for approximately 30 
minutes, until the color of the solution changed from yellow to deep red and then back to 
yellow. Reaction mixture was cooled to rt and then dppe (1.35 g; 3.4 mmol) was added. 
Reaction mixture was filtered through a pad of celite and resulting benzene solution was 
stirred intensively with brine for 3 hours. Benzene layer was separated from the brine, 
dried over anhydrous Na2SO4 and evaporated under reduced pressure. The residue was 
dissolved in methyl tert-butyl ether (150 mL). Product slowly separated in a form of 
yellowish crystals. Product was collected by filtration and washed with several portions 
of MTBE. After drying in vacuum 1.19 g (72%) of product was obtained. Analytical 
sample was obtained after several crystallizations from DCM/MTBE. 
1
H NMR (CDCl3 at 
25 
oC): δ 7.90-7.79 (m, 4H), 7.75-7.65 (m, 4H), 7.55-7.35 (m, 12H), 6.85 (tdd, 2J(H-F) = 
49.3 Hz, 
3
J(H-P) = 20.7 Hz and 2.9 Hz, 1H), 2.51-2.33 (m, 2H), 2.22-2.06 (m, 2H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 133.94 (tdd, 1J(C-F) = 304.5, 
2
J(C-P) = 177.1 Hz and 
19.1 Hz), 133.56 (d, 
3
J(C-P) = 12.3 Hz), 133.26 (d, 
3
J(C-P) = 11.6 Hz), 131.74 (d, 
4
J(C-P) = 
2.1 Hz), 131.06 (d, 
4
J(C-P) = 2.1 Hz), 130.28 (d, 
1
J(C-P) = 34.1 Hz), 129.07 (d, 
2
J(C-P) = 10.2 
Hz), 128.98 (d, 
2
J(C-P) = 10.9 Hz),  128.46 (d, 
1
J(C-P) = 50.4 Hz), 30.57 (dd, 
1
J(C-P) = 34.1 
Hz, 
2
J(C-P) = 20.4 Hz), 23.65 (dd, 
1
J(C-P) = 26.6 Hz, 
2
J(C-P) = 10.2 Hz). 
19
F NMR (CDCl3 at 
23 
oC): δ -89.00 (apparent quartet, 2J(F-H) = 
3
J(F-P) = 48.1 Hz). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 53.71 (td, 3J(P-F) = 48.8 Hz, 
2
J(P-P) = 35.1 Hz), 31.66 (td, 
3
J(P-F) = 53.4 Hz, 
2
J(P-P) = 
35.1 Hz).  
19
F/
13
C HSQC NMR (CDCl3 at 25 
oC): δF/δC -89.05/133.82. IR (ATR): cm
-1
 
3053 (w), 2898 (w), 1572 (w), 1482 (m), 1434 (s), 1408 (s), 1310 (m), 1277(m), 1242 
(m), 1186 (m), 1102 (s), 1010 (s), 996 (s). HRMS electrospray (m/z): [M – Cl]+ calcd for 
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C27H25F2P2Pd, 555.0429; Found, 555.0436, [M – Cl + CH3CN]
+
 calcd for 
C29H28F2NP2Pd, 596.0694; Found, 596.0693, [M – CHF2]
+
 calcd for C26H24ClP2Pd, 
539.0071; Found, 539.0074. Elemental analysis: Calculated for PdC29H26F4O2P2 C = 
54.84%, H = 4.26%, Cl = 6.00%, F = 6.43%; Found: C = 54.95%, H = 4.32%, Cl = 
5.94%, F = 6.28%. 
General procedure 3: Preparation of complexes 24-26 with (dppe)Pd(Rf)(Ph) 
general structure. In a glovebox, a Schlenk flask was charged with a stirbar, 
diphenylzinc (120 mg; 0.55 mmol) and corresponding (dppe)Pd(Rf)(OOCRf) complex 
(0.36 mmol). The flask was sealed and removed from glovebox. Dry THF (20 mL) was 
added via cannula. The resulting solution was stirred at rt for 20 minutes, then water (0.2 
mL) was introduced via septum. Reaction mixture was stirred at rt for additional 20 
minutes until Zn(OH)2 had completely precipitated. Then the THF solution was dried 
over anhydrous Na2SO4, filtered and volatiles were removed under reduced pressure. 
Residue was crystallized from diethylether. Product was collected by filtration, washed 
with several portions of ether and dried under vacuum. Analytical sample was obtained 
after several crystallizations from DCM/isopropylether. 
Preparation of (dppe)Pd(CF3)(Ph) (24). 24 was obtained according to the general 
procedure 3 in 79% yield. 
1
H NMR (CDCl3 at 25 
oC): δ 7.80-7.74 (m, 4H), 7.52-7.44 (m, 
6H), 7.43-7.38 (m, 2H), 7.33-7.26 (m, 10H), 7.20 (t, J = 6.9 Hz, 2H), 6.81 (apparent t, J = 
6.9 Hz, 2H), 6.77 (t, J = 6.9 Hz, 1H), 2.34-2.16 (m, 4H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 158.85 (apparent doublet of quintets, 2J(C-P) = 112.4 Hz, 
3
J(C-F) = 
2
J(C-P) = 8.9 Hz), 
143.63 (qdd, 
1
J(C-F) = 373.3 Hz, 
2
J(C-P) = 195.5 Hz and 13.6 Hz), 136.70, 133.35-133.19 
(two overlapping doublets), 131.43 (d, 
1
J(C-P) = 34.1 Hz), 130.83 (d, 
4
J(C-P) = 2.1 Hz), 
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130.76 (d, 
4
J(C-P) = 2.1 Hz), 130.19 (d, 
1
J(C-P) = 41.5 Hz), 128.95 (d, 
2
J(C-P) = 9.5 Hz), 
128.66 (d, 
2
J(C-P) = 10.2 Hz), 126.64 (d, 
3
J(C-P) = 7.5 Hz, Pd-C–CH), 122.34, 27.48 (dd, 
1
J(C-P) = 25.9 Hz, 
2
J(C-P) = 18.4 Hz), 26.40 (dd, 
1
J(C-P) = 25.2 Hz, 
2
J(C-P) = 15.0 Hz). 
19
F 
NMR (CDCl3 at 25 
oC): δ -17.48 (dd, 3J(F-P) = 51.4 Hz and 11.8 Hz, 3F).  
31
P{
1
H} NMR 
(CDCl3 at 25 
oC): δ 40.11 (qd, 3J(P-F) = 50.4 Hz, 
2
J(P-P) = 16.8 Hz), 38.26 (apparent 
quintet, 
3
J(P-F) = 
2
J(P-P) = 18.3 Hz). 
19
F/
13
C HSQC NMR (CDCl3 at 25 
oC): δF/δC -
17.62/143.74. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
oC): δF/δC -17.48/143.74 (
1
J 
correlation), -17.48/158.84. IR (ATR): cm
-1
 3052 (w), 1565 (m), 1470 (m), 1434 (s), 
1308 (w), 1239 (m), 1103 (m), 1080 (s), 950 (s). HRMS electrospray (m/z): [M – Ph]+ 
calcd for C27H24F3P2Pd, 573.0335; Found, 573.0343, [M – F]+ calcd for 
C33H29F2P2Pd, 631.0742; Found, 631.0747.  
Preparation of (dppe)Pd(C2F5)(Ph) (25). 25 was obtained according to the 
general procedure 3 in 90% yield. 
1
H NMR (CDCl3 at 25 
oC): δ 7.77-7.72 (m, 4H), 7.52-
7.45 (m, 4H), 7.41 (t, J = 7.2 Hz, 2H), 7.33-7.29 (m, 4H), 7.29-7.24 (m, 4H), 7.15 (t, J = 
7.0 Hz, 2H), 6.75 (apparent t, J = 7.3 Hz, 2H), 6.72 (t, J = 6.8 Hz, 1H), 2.24-2.14 (m, 
4H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 158.22 (apparent doublet, 2J(C-P) = 107.7 Hz), 
136.93, 136.11 (m, Pd-CF2-),  133.35 (d, 
3
J(C-P) = 12.3 Hz), 133.21 (d, 
3
J(C-P) = 11.6 Hz), 
131.55 (d, 
1
J(C-P) = 33.4 Hz), 130.77 (d, 
4
J(C-P) = 2.0 Hz), 130.73 (d, 
4
J(C-P) = 2.1 Hz), 
130.24 (d, 
1
J(C-P) = 42.2 Hz), 128.85 (d, 
2
J(C-P) = 10.2 Hz), 128.66 (d, 
2
J(C-P) = 10.2 Hz), 
126.50 (d, 
3
J(C-P) = 7.5 Hz, Pd-C-CH), 122.72 (qtd, 
1
J(C-F) = 284.8 Hz, 
2
J(C-F) = 30.0 Hz, 
3
J(C-P) = 9.5 Hz, -CF3), 122.02, 27.01 (dd, 
1
J(C-P) = 25.9 Hz, 
2
J(C-P) = 18.4 Hz), 26.60 (dd, 
1
J(C-P) = 25.9 Hz, 
2
J(C-P) = 15.0 Hz). 
19
F NMR (CDCl3 at 25 
oC): δ -80.11 (s, 3F), -89.55 
(dd, 
3
J(F-P) = 41.5 Hz and 31.5 Hz, 2F). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 39.60 (tdq, 
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3
J(P-F) = 31.8  Hz, 
2
J(P-P) = 17.0 Hz, 
4
J(P-F) = 3.2 Hz, 1P), 38.90 (td, 
3
J(P-F) = 41.3 Hz,
 2
J(P-P) 
= 17.0  Hz, 1P). 
19
F/
13
C HSQC NMR (CDCl3 at 25 
oC): δF/δC -80.11/122.72, -
89.55/136.11. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
oC): δF/δC -80.11/122.72 (
1
J 
correlation), -80.11/136.11, -89.55/122.72. IR (ATR): cm
-1
 3055 (w), 1564 (m), 1472 
(m), 1434 (s), 1292 (s), 1191 (s), 1145 (s), 1099 (m). HRMS electrospray (m/z): [M – 
Ph]
+
 calcd for C28H24F5P2Pd, 623.0303; Found, 623.0314, [M – Ph + CH3CN]
+
 calcd 
for C30H27F5NP2Pd, 664.0568; Found, 664.0577. Elemental analysis: Calculated for 
PdC34H29F5P2 C = 58.26%, H = 4.17%, F = 13.55%; Found: C = 58.22%, H = 4.15%, 
F = 13.46%. 
Preparation of (dppe)Pd(C3F7)(Ph) (26). 26 was obtained according to the 
general procedure 3 in 92% yield. 
1
H NMR (CDCl3 at 25 
oC): δ 7.77-7.72 (m, 4H), 7.52-
7.45 (m, 4H), 7.42 (t, J = 7.5 Hz, 2H), 7.33-7.29 (m, 4H), 7.29-7.25 (m, 4H), 7.17 (t, J = 
7.0 Hz, 2H), 6.75 (apparent t, J = 7.3 Hz, 2H), 6.72 (t, J = 6.9 Hz, 1H), 2.24-2.14 (m, 
4H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 157.87 (apparent dd, 2J(C-P) = 117.1 and 12.3 
Hz), 139.31 (m, Pd-CF2-), 136.98, 133.38 (d, 
3
J(C-P) = 12.3 Hz), 133.17 (d, 
3
J(C-P) = 10.9 
Hz), 131.57 (d, 
1
J(C-P) = 32.7 Hz), 130.74 (two overlapping signals), 130.3 (d, 
1
J(C-P) = 
42.9 Hz), 128.81 (d, 
2
J(C-P) = 9.5 Hz), 128.67 (d, 
2
J(C-P) = 7.5 Hz), 126.50 (d, 
3
J(C-P) = 7.5 
Hz, Pd-C-CH), 121.99, 119.21 (qt, 
1
J(C-F) = 289.5 Hz, 
2
J(C-F) = 34.7 Hz, -CF3), 112.04 (tq, 
1
J(C-F) = 252.0 Hz, 
2
J(C-F) = 30.7 Hz, -CF2CF3), 26.97 (dd, 
1
J(C-P) = 24.5 Hz, 
2
J(C-P) = 18.4 
Hz), 26.42 (dd, 
1
J(C-P) = 25.2 Hz, 
2
J(C-P) = 15.7 Hz). 
19
F NMR (CDCl3 at 23 
oC): δ -79.66 
(t, 
3
J(F-F) = 13.0 Hz, 3F), -87.62 (m, 2F), -118.33 (s, 2F).  
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 39.47-38.92 (two overlapping multiplets). 19F/13C HSQC NMR (CDCl3 at 25 
o
C): 
δF/δC -79.66/119.21, -87.62/139.31, -118.33/112.04. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
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oC): δF/δC -79.66/112.04, -79.66/119.21 (
1
J correlation), -87.62/112.04, -118.33/112.04 
(
1
J correlation), -118.33/119.21. IR (ATR): cm
-1
 3061 (w), 1566 (m), 1473 (m), 1436 (s), 
1325 (s), 1213 (s), 1180 (s), 1142 (s), 1099 (m). HRMS electrospray (m/z): [M – Ph]+ 
calcd for C29H24F7P2Pd, 673.0271; Found, 673.0283, [M – Ph + CH3CN]
+
 calcd for 
C31H27F7NP2Pd, 714.0536; Found, 714.0542. Elemental analysis: Calculated for 
PdC35H29F7P2 C = 55.98%, H = 3.89%, F = 17.71%; Found: C = 55.86%, H = 3.89%, 
F = 17.90%. 
Preparation of (dppe)Pd(CF3)(CH3) (27). A Schlenk flask was charged with a 
stirbar and (dppe)Pd(CF3)(OOCCF3) (300 mg; 0.44 mmol). The flask was sealed, 
evacuated under reduced pressure and then refilled with nitrogen four times. Dry THF 
(15 mL) was added via cannula followed by dimethylzinc (1 mL of 1.2 M solution in 
THF). The resulting solution was stirred at rt for 20 minutes, then water (0.2 mL) was 
introduced via septum. Reaction mixture was stirred at rt for additional 20 minutes until 
Zn(OH)2 had completely precipitated. Then THF solution was dried over anhydrous 
Na2SO4, filtered and volatiles were removed under reduced pressure. Residue was 
crystallized from diethylether. Product was collected by filtration, washed with several 
portions of ether and dried under vacuum affording 27 as a white crystaline solid (207 
mg, 80%). Analytical sample was obtained after crystallization from 
DCM/isopropylether. 
1
H NMR (CDCl3 at 25 
oC): δ 7.71-7.65 (m, 4H), 7.62-7.57 (m, 4H), 
7.49-7.38 (m, 12H), 2.34-2.24 (m, 2H), 2.21-2.12 (m, 2H), 0.59 (apparent triplet, 
3
J(H-P) = 
6.6 Hz, 3H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 146.60 (qdd, 1J(C-F) = 374.7 Hz, 
2
J(C-P) = 
201.0 Hz and 15.6 Hz), 133.35 (d, 
3
J(C-P) = 11.6 Hz), 133.18 (d, 
3
J(C-P) = 12.9 Hz), 132.03 
(d, 
1
J(C-P) = 31.3 Hz), 130.95 (d, 
4
J(C-P) = 2.1 Hz), 130.56 (d, 
4
J(C-P) = 1.4 Hz), 130.29 (d, 
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1
J(C-P) = 40.2 Hz), 128.95 (d, 
2
J(C-P) = 9.5 Hz), 128.79 (d, 
2
J(C-P) = 9.5 Hz), 28.44 (dd, 
1
J(C-
P) = 27.2 Hz, 
2
J(C-P) = 19.8 Hz), 27.38 (dd, 
1
J(C-P) = 25.2 Hz, 
2
J(C-P) = 15.7 Hz), 0.25 (ddq, 
2
J(C-P) = 89.2 Hz and 8.9 Hz, 
3
J(C-F) = 6.8 Hz). 
19
F NMR (CDCl3 at 25 
oC): δ -19.27 (dd, 
3
J(F-P) = 53.1 Hz and 18.2 Hz, 3F). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 47.42 (qd, 3J(P-F) = 
51.9 Hz, 
2
J(P-P) = 15.9 Hz), 47.42 (apparent quintet, 
3
J(P-F) = 
2
J(P-P) = 16.9 Hz). 
19
F/
13
C 
HSQC NMR (CDCl3 at 25 
oC): δF/δC -19.41/146.78. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
oC): δF/δC -19.27/0.25, -19.27/146.60 (
1
J correlation). IR (ATR): cm
-1
 3053 (w), 2955 
(w), 2888(w), 1587 (w), 1573 (w), 1483 (m), 1435 (s), 1411 (m), 1309 (m), 1186 (m), 
1158 (m), 1102 (m), 1074 (s). HRMS electrospray (m/z): [M – CH3]
+
 calcd for 
C27H24F3P2Pd, 573.0335; Found, 573.0342, [M – CH3 + CH3CN]
+
 calcd for 
C29H27F3NP2Pd, 614.0600; Found, 614.0603. Elemental analysis: Calculated for 
PdC28H27F3P2 C = 57.11%, H = 4.62%, F = 9.68%; Found: C = 56.04%, H = 4.57%, F 
= 9.81%. 
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Chapter 5: Catalytic Cycle of Trifluoromethylation with TFAA 
as a CF3 Source
1
 
 
5.1 Introduction 
In the previous chapter we introduced the concept of decarbonylative 
trifluoromethylation (Scheme 4.5 and Scheme 4.7). We also demonstrated that with 
appropriately selected supporting ligands the two key steps of decarbonylative 
trifluoromethylation catalytic cycle are facile at nickel and palladium. Specifically, 
TFAA and pentafluorophenyl trifluoroacetate undergo clean oxidative addition to 
Ni(COD)2/PPh3 and Pd[P(o-Tol)3]2 and the resulting (PR3)2M(COCF3)(O2CCF3) (M = Ni 
and Pd) intermediates decompose to (PR3)2M(CF3)(O2CCF3) with elimination of carbon 
monoxide. Even though these initial results are very encouraging, there are several major 
complications that have to be solved before catalytic turnover is attempted. These issues 
will be addressed in this chapter. 
First, highly electrophilic TFAA and to a lesser degree TFA esters are 
incompatible with organolithium, organomagnesium and other reactive transmetallating 
agents. Additionally, TFAA is likely incompatible also with electron-rich phosphine 
ligands. Therefore, milder alternatives to TFAA and less reactive transmetallating 
reagents have to be found for decarbonylative trifluoromethylation. 
Second, the relative rates of all elementary steps in the catalytic cycle have to be 
considered. To obtain the desired trifluoromethylated product it is essential that CO 
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deinsertion is faster than transmetallation. There is an example in the literature of 
palladium catalyzed trifluoroacetylation of boronic acids (Scheme 5.1).
2
 A viable 
catalytic cycle was proposed for this reaction (Scheme 5.2). This catalytic cycle differs 
from the one of decarbonylative trifluoromethylation only by fast transmetallation 
relative to decarbonylation. 
 
Scheme 5.1 Palladium catalyzed trifluoroacetylation 
 
 
Scheme 5.2 Mechanism of palladium catalyzed trifluoroacetylation 
 
 
Thirdly, C–CF3 bond forming reductive elimination from palladium and nickel 
has extremely high activation barrier.
3
 While PPh3 and P(o-Tol)3 are suitable ligands for 
oxidative addition and decarbonylation, these ligands will likely inhibit reductive 
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elimination.
3
 Therefore, for the development of decarbonylative trifluoromethylation 
methodology, single supporting ligand has to be selected enabling all elementary steps of 
the catalytic turnover. Several ligands have been reported in the literature to promote C–
CF3 bond forming reductive elimination. For example, heating of 
[XantphosPd(CF3)(C6H5)] to 80 
o
C affords trifluorotoluene in essentially quantitative 
yield.
4
 Furthermore, in 2010, the palladium-catalyzed synthesis of trifluoromethylated 
compounds via a classical cross-coupling catalytic manifold was reported by Buchwald 
and coworkers (Scheme 5.3).
5
 The biarylmonophosphines BrettPhos and RuPhos were 
shown to be the most effective ligands for this methodology. BrettPhos was also 
demonstrated to promote C–CF3 bond forming reductive elimination from well defined 
Pd
II
 model complexes. 
 
Scheme 5.3 Trifluoromethylation developed by Buchwald and coworkers 
 
 
In order to address these issues and select appropriate reagents and reaction 
conditions for the proposed trifluoromethylation sequence, we sought to assess the 
feasibility of each elementary step in the proposed catalytic cycle with RuPhos 
supporting ligand. Based on results presented in the previous chapter we envisaged that 
biarylmonophosphine ligand such as RuPhos is also likely to promote not only reductive 
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elimination but also CO deinsertion at Pd
II
 under reasonable reaction conditions. 
Specifically, sterically bulky biarylmonophosphines (e.g., RuPhos or XPhos) often act as 
bidentate ligands with the aromatic ring of the biaryl functionality serving as the second 
binding site.
6
 Such binding of Pd
II
 to the aromatic ring is weak and thus coordinatively 
unsaturated tricoordinate Pd
II
 species are readily accesible. We hypothesized that bulky 
biarylmonophosphines such as RuPhos would enable CO deinsertion at Pd
II
 via 
tetracoordinate transition state according to the mechanism depicted in Scheme 4.14.
7,8 
 
5.2 Oxidative Addition of TFA Esters to (RuPhos)nPd
0
 
A RuPhos-ligated Pd
0
 species was generated by treatment of (Cp)Pd(allyl) with 2 
equiv of RuPhos at 60 
o
C for 30 min (Scheme 5.4).
9
 Then, the in situ formed 
(RuPhos)nPd
0
 (1) was reacted with slight excess of TFAA and TFA esters.
10
 Reaction 
progress was monitored by 
19
F-NMR and 
19
F/
13
C HMBC NMR spectroscopy. Use of 
TFAA resulted in the formation of trifluoroacetate complex 2 (Scheme 5.4). tert-Butyl- 
and phenyl- trifluoroacetate showed no reactivity with (RuPhos)Pd
0
 at rt or 60 
o
C. Use of 
methyl- and ethyl- trifluoroacetate resulted in the formation of mixture of products.  Such 
an outcome can be rationalized with β-hydride elimination from the alkoxide. 
 
Scheme 5.4 Reaction of (RuPhos)nPd
0
 with TFAA 
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Fortunately, when pentafluorophenyl trifluoroacetate was used, NMR showed 
formation of the oxidative addition product 3 within 30 min at rt (Scheme 5.5). Upon 
workup, 3 undergoes ligand exchange with trifluoroacetate (presumably generated by 
hydrolysis of the excess ester) to yield 4 as the product in 73% isolated yield. Such an 
outcome was not unexpected since Pd(PPh3)4 and Pd[P(o-Tol)3]2 exhibited similar 
reactivity with C6F5OCOCF3 (Scheme 4.11 and Scheme 4.15). 
 
Scheme 5.5 Reaction of (RuPhos)nPd
0
 with C6F5OCOCF3 
 
 
The structure of 4 was determined by 1D 
13
C-, 
31
P- and 
19
F-NMR as well as 2D 
heteronuclear correlation NMR experiments and HRMS. In particular, C–F and C–P 
couplings observed in the 
13
C-NMR spectrum of 4 provide strong evidence in support of 
the assigned structure. For example, signals of the trifluoroacetyl ligand are observed as 
quartet of doublets at 207.5 ppm (
2
J(C-F) = 38.2 Hz and 
3
J(C-P) = 7.5 Hz) and quartet of 
doublets at 110.0 ppm (
1
J(C-F) = 300.4 Hz and 
3
J(C-P) = 17.0 Hz). In contrast, signals of the 
trifluoroacetate ligand are observed as quartet at 160.7 ppm (
2
J(C-F) = 34.7 Hz) and quartet 
of doublets at 117.4 ppm (
1
J(C-F) = 292.2 Hz, 
4
J(C-P) = 7.5 Hz). This assignment is 
confirmed by 2D 
19
F/
13
C HSQC and HMBC NMR experiments. 
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In addition, the 
13
C NMR spectrum of 4 shows a doublet at 106 ppm (JC-P = 4.1 
Hz) corresponding to a carbon atom bound to Pd as shown in in Scheme 5.5. Such 
chemical shift and splitting is consistent with coordination of RuPhos through both 
phosphorous and the carbon atoms. Similar bidentate binding of biarylmonophosphines 
has been reported previously.
11
 
The structure of 4 was confirmed also by independent synthesis through an 
alternative route (Scheme 5.6). Previously synthesized 5 (Scheme 4.15) underwent fast 
ligand exchange with 1.1 equiv of RuPhos to afford 4 in 78% isolated yield. The 
approach shown in Scheme 5.6 could also be used to prepare the perfluoroethyl complex 
7 starting from Pd[P(o-Tol)3]2 and pentafluoropropionic anhydride. 
 
Scheme 5.6 Synthesis of (RuPhos)Pd(CORf)(OCORf) via ligand exchange 
 
 
5.3 Decarbonylative Decomposition of (RuPhos)Pd(CORf)(OCORf) 
We next investigated CO deinsertion reactions of the perfluoroacyl complexes 4 
and 7 (Scheme 5.7). We were pleased to find that heating benzene solutions of 4 and 7 to 
reflux for 1.5 h resulted in clean conversion to the corresponding perfluoroalkyl 
complexes 8 and 9. The reactions were quantitative by 
19
F and 
31
P NMR spectroscopy, 
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and pure products could be isolated via crystallization in 78% and 62% yield, 
respectively. 
 
Scheme 5.7 Preparation of (RuPhos)Pd(Rf)(OCORf) complexes 
 
 
Figure 5.1 
19
F- and 
31
P{
1
H}-NMR spectra of RuPhosPd(CF3)(OCOCF3) 
   
(spectra acquired at 500 MHz) 
 
The identity of 8 and 9 was confirmed through independent synthesis. Treatment 
of previously synthesized complexes 10 and 11 with slight excess of RuPhos for 5 min at 
rt resulted in quantitative formation of 8 and 9, correspondingly (Scheme 5.7). 8 and 9 
were characterized by NMR, IR and HRMS. 
3
JP-F coupling (~30 Hz) observed both in 
31
P{
1
H} NMR 
19
F NMR 
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19
F- and 
31
P{
1
H}-NMR spectra corroborates the assigned structures of 8 and 9 (Figure 
5.1). 
Interestingly, when benzene solutions of 4 are allowed to stand at room 
temperature completely different reactivity is observed (Scheme 5.8). Under these 
conditions, 4 slowly decomposes to form the dicationic dipalladium(I) complex 12, 
which was isolated in 44% yield after 12 h at room temperature. 
 
Scheme 5.8 Formation of [(RuPhos)2Pd2](CF3COO)2 
 
 
The structure of 12 was determined based on NMR and HRMS analysis. 
Specifically, 8 is C2h symmetric; therefore, both phosphine ligands are chemically 
equivalent and only one set of signals is observed in 
13
C- and 
1
H-NMR spectra. However, 
virtual coupling is detected in the 
13
C NMR spectrum, which is a very characteristic 
feature of symmetric trans-diphosphine complexes.
12
 In addition, in the 
13
C NMR 
spectrum signals of the carbon atoms C1-C4 are shifted to 94.1, 151.4, 86.7 and 80.5 
ppm, correspondingly (see Scheme 5.8 for labeling). Such chemical shifts present strong 
evidence that aromaticity in the benzene rings is partially lost due to π-coordination to the 
dicationic Pd-Pd unit. Moreover, a molecular ion isotope pattern between 571-575 Da 
with 0.5 Da spacing in the HRMS of 12 is indicative of a species with molecular formula 
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[(RuPhos)2Pd2]
2+
.
13
 A preliminary X-ray diffraction analysis further confirmed the 
connectivity of 12; however, the low quality of crystals precluded obtaining a high 
resolution structure. While the exact mechanism for the formation of 12 is unclear, it 
likely involves conproportionation between (RuPhos)Pd
0
 and a (RuPhos)Pd
2+
 species.
14
 
A number of related dinuclear Pd
I
-Pd
I
 complexes stabilized by π-coordination to arenes 
have been reported in the literature.
15
  
 
5.4 Transmetallation and Reductive Elimination 
 
Scheme 5.9 Transmetallation and reductive elimination reactions 
 
 
We next investigated transmetallation reactions of the (RuPhos)Pd(Rf)(OCORf) 
complexes 8 and 9 (Scheme 5.9). We found that diarylzincs are particularly effective 
transmetallating reagents for this system. Specifically, the reaction of 8 and 9 with 
diphenylzinc and diorthotolylzinc afforded complexes 13-16 in 42-92% isolated yields. It 
is essential to use salt-free zinc reagents in this reaction. Use of diarylzincs containing 
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LiCl led to a formation of complex mixture of products. 
19
F and 
31
P NMR analysis of the 
crude reaction mixtures of 13-16 showed no side products; thus the variation in isolated 
yield simply reflects loss of product during the isolation process. The structures of 13-16 
were determined using 1D 
1
H-, 
13
C-, 
31
P- and 
19
F-NMR as well as by 2D 
19
F/
13
C and 
1
H/
13
C NMR correlation experiments. The stereochemistry of 13-16 was assigned based 
on 
1
H/
1
H ROESY NMR spectra. 
With 13-16 in hand we next set to investigate aryl–CF3 bond-forming reductive 
elimination (Scheme 5.9). We found that complexes 13-16 are stable in both CDCl3 and 
benzene solution at room temperature for at least 10 h. However, heating benzene 
solutions of 13-16 at 90 
o
C for 12 h resulted in reductive elimination to yield 17-20. The 
yields of 17-20 were determined using 
19
F-NMR spectroscopy with 1,4-
di(trifluoromethyl)benzene as an internal standard. In all cases, complete conversion of 
the starting complexes 13-16 was observed. Compounds 17 and 18 were obtained in only 
13% and 20% NMR yields respectively. However, the 2-tolylpalladium complexes 15 
and 16 afforded reductive elimination products 19 and 20 in more respectable 65% and 
55% yields. These results are consistent with Buchwald’s prior report of the 
trifluoromethylation of aryl chlorides with TESCF3.
4
 In this system, RuPhos provided 
modest yields with simple aryl chlorides; however, a dramatic enhancement in yield was 
observed with sterically hindered aryl chlorides. Interestingly, in our system the 
conversion rate for for all of the complexes 13-16 is approximately the same. This 
suggests that additional steric bulk on the aryl ligand does not significantly increase the 
rate of reductive elimination but more likely prevents unproductive decomposition 
pathways. 
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5.5 Conclusions 
Each step of the proposed catalytic cycle has been interrogated using RuPhos as 
supporting ligand. It was found that pentafluorophenyltrifluoroacetate undergoes 
oxidative addition to (RuPhos)nPd
0
 under mild conditions. The resulting product 
(RuPhos)Pd(COCF3)(CO2CF3) eliminates CO in refluxing benzene 80 
o
C to afford 
(RuPhos)Pd(CF3)(CO2CF3). Next, transmetallation with diarylzinc reagents yields 
(RuPhos)Pd(CF3)(Aryl). Finally, heating of (RuPhos)Pd(CF3)(Aryl) complexes to 90 
o
C 
for 12 h affords Aryl-CF3 reductive elimination products. These results demonstrate the 
potential feasibility of using perfluoroalkyl esters as CF3 sources in cross-coupling 
reactions.  The current challenge is to integrate these elementary steps into a complete 
catalytic cycle for arene fluoroalkylation. Key to this enterprise is identifying 
perfluoroalkyl ester and transmetalating reagents that are compatible with one another. In 
addition, the relative rates of CO deinsertion, transmetalation, and reductive elimination 
must be controled such that the desired aryl-RF bond-formation outcompetes undesired 
aryl-CORF coupling. 
 
5.6 Experimental Section 
General Procedures. All syntheses were conducted under nitrogen unless 
otherwise stated. All reagents were purchased from commercial sources and used as 
received. Pd[P(o-Tol)3]2 was obtained according to literature procedure.
16
 
Tetrahydrofuran, dichloromethane and diethyl ether were purified using an Innovative 
Technologies (IT) solvent purification system consisting of a copper catalyst, activated 
 192 
 
alumina, and molecular sieves. NMR spectra were acquired using 400, 500 and 700 MHz 
Varian spectrometers. All 
1
H/
1
H NOESY and 
1
H/
1
H ROESY correlation spectra were 
acquired on a 500 MHz instrument. 
1
H, 
19
F and 
13
C chemical shifts are reported in parts 
per million (ppm) relative to TMS, with the residual solvent peak used as an internal 
reference. 
1
H
 
and 
19
F multiplicities are reported as follows: singlet (s), doublet (d), triplet 
(t), quartet (q), broad resonance (br) and multiplet (m). Overlapping signals in 
1
H-NMR 
spectra were also reported as (m). 
Preparation of (RuPhos)Pd(COCF3)(OCOCF3) (4). Method 1: oxidative 
addition of CF3COOC6F5 to in situ generated (RuPhos)nPd
0
. CpPd(allyl) (200 mg; 0.94 
mmol) and RuPhos (933 mg; 2.00 mmol) were sealed in a Schlenk flask. The Schlenk 
flask was flushed with nitrogen for 15 minutes and then degassed THF (20 mL) was 
added via cannula. Resulting red solution was heated to 60 
o
C for 30 minutes. Solution 
was cooled to -78 
o
C and CF3COOC6F5 (840 mg; 3.00 mmol) was added dropwise over 
the period of 5 minutes. Reaction mixture was slowly warmed to rt. After being stirred at 
rt for 1h, reaction mixture was concentrated under reduced pressure at rt. Residue was 
dissolved in 100 mL of isopropylether and the solution was filtered through celite. 60 mL 
of hexanes were added to the isopropylether solution and the resulting mixture was left at 
-20 
o
C for 8 hours. During this period product separated in a form of yellowish crystals. 
Product was collected by filtration and it was washed with two 5 mL portions of cold 
isopropylether. After drying in vacuum 541 mg (73%) of yellowish crystalline solid was 
obtained.  Method 2: ligand exchange reaction of P(o-Tol)3)2Pd(COCF3)(OCOCF3) with 
RuPhos. Under nitrogen atmosphere solution of P(o-Tol)3)2Pd(COCF3)(OCOCF3)Et2O 
(1.00 g, 1.00 mmol) and RuPhos (513 mg; 1.1 mmol) in THF (20 mL) were stirred at 0 
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o
C for 10 minutes. The solution was then concentrated under reduced pressure at 0 
o
C. 
Diethylether (10 mL) was added to the residue and resulting suspension was stirred at 0 
o
C for 15 minutes. Product was separated by filtration and then washed with two 5 mL 
portions of cold ether. After drying in vacuum 615 mg (78%) of yellowish crystalline 
solid was obtained. 
1
H NMR (acetone-d6 at 25 
oC): δ 7.87 (apparent triplet, J = 7.7 Hz, 
1H), 7.56 (t, J = 7.5 Hz, 1H), 7.53-7.48 (m, 2H), 6.85 (dd, J = 7.9 and 3.2 Hz, 1H), 6.59 
(d, J = 8.6 Hz, 2H), 4.64 (septet, J = 6.1 Hz, 2H), 2.40 (m, 2H), 2.24 (m, 2H), 1.90 (m, 
2H), 1.83 (m, 4H), 1.73 (m, 2H), 1.57 (m, 2H), 1.44 (m, 2H), 1.40 (d, J = 6.1 Hz, 6H), 
1.36 (m, 2H), 1.16 (m, 2H), 1.04 (m, 2H), 1.02 (d, J = 6.1 Hz, 6H). 
13
C{
1
H} NMR 
(acetone-d6 at 25 
oC): δ 207.53 (qd, 2J(C-F) = 38.2 Hz, 
3
J(C-P) = 7.5 Hz), 161.99, 160.65 (q, 
2
J(C-F) = 34.7 Hz), 145.61 (d, J = 17.7 Hz), 138.25, 133.92 (d, J = 45.0 Hz), 132.76-
132.40 (three overlapping signals as revealed by 
1
H/
13
C HMBC), 127.82 (d, J = 6.1 Hz), 
117.37 (qd, 
1
J(C-F) = 292.2 Hz, 
4
J(C-P) = 7.5 Hz), 109.99 (qd, 
1
J(C-F) = 300.4 Hz, 
3
J(C-P) = 
17.0 Hz), 106.12 (d, 
2
J(C-P) = 4.1 Hz), 106.05, 71.83, 33.31 (d, J = 29.3 Hz), 29.56 (d, J = 
2.1 Hz), 29.05 (d, J = 1.3 Hz), 27.27 (d, J = 14.3 Hz), 27.09 (d, J = 11.6 Hz), 26.76, 
22.08, 21.92. 
19
F NMR (acetone-d6 at 25 
oC): δ -74.32 (s, 3F), -75.03 (s, 3F). 31P{1H} 
NMR (acetone-d6 at 25 
oC): δ 45.45 (s). 19F/13C HSQC NMR (acetone-d6 at 25 
oC): δF/δC 
-74.32/109.99, -75.03/117.37. 
19
F/
13
C HMBC NMR (acetone-d6 at 25 
oC): δF/δC -
74.32/207.53, -75.03/117.37 (
1
J correlation), -75.03/160.65. IR (ATR): cm
-1
 2978 (w), 
2937 (m), 2853 (m), 1747 (m), 1702 (s), 1686 (s), 1588 (m), 1450 (m), 1410 (m), 1377 
(w), 1256 (s), 1224 (s), 1190 (s), 1178 (s), 1128 (s), 1108 (s). HRMS electrospray (m/z): 
[M – OOCCF3]
+
 calcd for C32H43F3O3PPd, 669.1931 Found, 669.1947, [M – OOCCF3 
- CO]
+
 calcd for C31H43F3O2PPd, 641.1982; Found, 641.2001. 
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Preparation of (RuPhos)Pd(COC2F5)(OOC2CF5) (7). A Schlenk flask was 
charged with a stirbar and Pd[P(o-Tol)3]2 (1.90 g; 2.66 mmol). The flask was sealed, 
evacuated under reduced pressure and then refilled with nitrogen. The flask was 
evacuated and refilled with nitrogen three more times. Dry THF (100 mL) was added via 
cannula. Perfluoropropionic anhydride (0.66 mL, 3.0 mmol) was then added dropwise 
over the period of 5 minutes. The resulting solution was stirred at rt for 20 minutes at r.t., 
then it was filtered through a pad of celite and volatiles were removed under reduced 
pressure. The residue was redissolved in benzene (35 mL) and RuPhos (700 mg; 1.5 
mmol) was added in one portion. The homogenous solution was stirred at rt for 20 
minutes and then volatiles were removed under reduced pressure. The residue was 
dissolved in butylether (30 mL). Product then slowly separated in the form of yellowish 
crystals. Product was collected by filtration and washed with several portions of 
butylether and then with hexanes. After drying in vacuum 989 mg (74% based on 
RuPhos) of product was obtained. NMR (CDCl3 at 25 
o
C): δ 7.59 (apparent triplet, J = 
7.5 Hz, 1H), 7.49 (t, J = 8.4 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 7.39 (t, J = 7.3 Hz, 1H), 
6.76 (dd, J = 7.5 and 2.2 Hz, 1H), 6.48 (d, J = 8.5 Hz, 2H), 4.54 (septet, J = 6.0 Hz, 2H), 
2.22-2.15 (m, 4H), 1.85-1.76 (m, 6H), 1.72-1.66 (m, 2H), 1.62-1.53 (m, 2H), 1.40-1.31 
(m, 2H), 1.36 (d, J = 6.0 Hz, 6H), 1.29-1.22 (m, 2H), 1.22-1.12 (m, 4H), 1.00 (d, J = 6.0 
Hz, 6H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 207.98 (td, 2J(C-F) = 40.2 Hz, 
3
J(C-P) = 7.0 
Hz), 161.37 (t, 
2
J(C-F) = 25.9 Hz), 161.04, 144.68 (d, J = 17.0 Hz), 137.38, 133.07 (d, J = 
43.6 Hz), 131.78 (d, J = 11.6 Hz), 131.47 (d, J = 1.7 Hz), 130.94, 126.71 (d, J = 6.1 Hz), 
121.44-114.17 (two overlapping multiplets, 2 x CF2),  106.64 (m, CF3), 105.98, 105.29, 
101.53 (tqd, 
1
J(C-F) = 269.8 Hz, 
2
J(C-F) = 36.1 Hz, 
3
J(C-P) = 14.3 Hz), 71.19, 34.28 (d, J = 
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29.3 Hz), 28.26 (two overlapping signals), 26.75 (two overlapping doublets), 25.85, 
21.74, 21.67. 
19
F NMR (CDCl3 at 25 
oC): δ -80.18 (s, 3F), -82.40 (s, 3F), -112.23 (s, 2F), 
-118.44 (broad s, 2F). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 42.25 (s). 19F/13C HSQC NMR 
(CDCl3 at 25 
oC): δF/δC -80.18/117.33, -82.40/118.70, -112.23/101.53, -118.44/106.64. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
oC): δF/δC -80.18/101.53, -80.18/117.33 (
1
J 
correlation), -112.23/101.53 (
1
J correlation), -112.23/117.33, 112.23/207.98. IR (ATR): 
cm
-1
 2978 (w), 2987 (w), 2937 (m), 2855 (w), 1716 (s), 1684 (s), 1588 (m), 1569 (m), 
1451 (s), 1384 (m), 1327 (s), 1256 (s), 1202 (s), 1162 (s), 1110 (s), 1069 (s). HRMS 
electrospray (m/z): [M – OOCC2F5]
+
 calcd for C33H43F5O3PPd, 719.1899 Found, 
719.1916, [M – OOCCF3 - CO]
+
 calcd for C32H43F5O2PPd, 691.1950; Found, 
691.1969.  
Preparation of (RuPhos)Pd(CF3)(OOCCF3) (8). (RuPhos)Pd(COCF3)(OCOCF3) 
(4) (300 mg; 0.38 mmol) was refluxed in benzene (25 mL) for 1.5 hours. 
19
F- and 
31
P-
NMR analysis of the crude reaction mixture showed complete conversion to product 8. 
The benzene solution was filtered through a pad of celite and volatiles were removed 
under reduced pressure. The residue was dissolved in diisopropylether (5 mL). The 
product slowly crystallized over the period of 12 hours. Yellowish crystals were collected 
by filtration, washed with small amount of diisopropylether and dried under vacuum. 227 
mg (78%) of product was obtained. 
1
H NMR (CDCl3 at 25 
oC): δ 7.63 (apparent triplet, J 
= 7.3 Hz, 1H), 7.54 (t, J = 8.5 Hz), 7.43 (t, J = 7.3 Hz), 7.38 (t, J = 7.3 Hz), 6.68 (broad 
doublet, J = 6.2 Hz), 6.50 (d, J = 8.5 Hz), 4.60 (septet, J = 6.2 Hz), 2.26 (m, 2H), 2.16 
(m, 2H), 1.90 (m, 2H), 1.80 (m, 4H), 1.68 (m, 2H), 1.58 (m, 2H), 1.41-1.11 (m, 8H), 1.30 
(d, J = 5.8 Hz, 6H), 0.99 (d, J = 6.2 Hz, 6H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC): δ 163.49, 
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161.25 (q, J = 34.1 Hz), 144.85 (d, J = 16.3 Hz), 138.82, 134.17 (d, J = 44.3 Hz), 131.75 
(d, J = 12.3 Hz), 131.54 (d, J = 1.5 Hz), 131.40, 126.58 (d, J = 6.1 Hz), 118.59 (qd, 
1
J(C-F) 
= 379.4 Hz, 
3
J(C-P) = 15.0 Hz), 116.39 (q, 
1
J(C-F) = 290.9 Hz), 105.73, 102.92, 71.60, 35.93 
(d, J = 27.9 Hz), 29.28, 29.01, 27.00 (two overlapping doublets), 25.93, 21.96, 21.30. 
19
F 
NMR (CDCl3 at 25 
oC): δ -10.38 (d, J = 29.8 Hz, 3F), -74.90 (s, 3F). 31P{1H} NMR 
(CDCl3 at 25 
oC): δ 51.35 (q, J = 29.7 Hz). 19F/13C HSQC NMR (CDCl3 at 25 
oC): δF/δC -
10.38/118.59, -74.90/116.39. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
oC): δF/δC -
74.90/161.33. IR (ATR): cm
-1
 2978 (w), 2931 (m), 2856 (m), 1698 (s), 1589 (m), 1445 
(s), 1405 (m), 1378 (m), 1258 (s), 1193 (s), 1173 (s), 1130 (s), 1108 (s), 1068 (s). HRMS 
electrospray (m/z): [M – OOCCF3]
+
 calcd for C31H43F3O2PPd, 641.1982; Found, 
641.1994.  
Preparation of (RuPhos)Pd(C2F5)(OOCC2F5) (9). 
(RuPhos)Pd(COC2F5)(OCOC2F5) (7) (220 mg; 0.25 mmol) was refluxed in benzene (50 
mL) for 1.5 hours. 
19
F- and 
31
P-NMR analysis of the crude reaction mixture showed 
complete conversion to product 9. The benzene solution was filtered through a pad of 
celite and volatiles were removed under reduced pressure. The residue was dissolved in 
diethylether (5 mL). The product slowly crystallized over the period of several hours. 
Yellowish crystals were collected by filtration, washed with small amounts of ether and 
dried under vacuum. 133 mg (62%) of 9 was obtained. 
1
H NMR (CDCl3 at 25 
oC): δ 7.63 
(apparent triplet, J = 7.3 Hz, 1H), 7.54 (t, J = 7.5 Hz), 7.42 (t, J = 7.7 Hz), 7.37 (t, J = 7.7 
Hz), 6.69 (broad doublet, J = 7.3 Hz), 6.46 (d, J = 8.5 Hz), 4.55 (septet, J = 6.2 Hz), 2.29 
(m, 2H), 2.22 (m, 2H), 1.91 (m, 2H), 1.81 (m, 4H), 1.69 (m, 2H), 1.61 (m, 2H), 1.38-1.22 
(m, 6H), 1.34 (d, J = 5.8 Hz, 6H), 1.18 (m, 2H), 1.00 (d, J = 6.2 Hz, 6H). 
13
C{
1
H} NMR 
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(CDCl3 at 25 
oC): δ 163.45, 161.63 (t, J = 22.5 Hz), 144.78 (d, J = 16.4 Hz), 139.14, 
133.86 (d, J = 44.3 Hz), 131.90 (d, J = 11.6 Hz), 131.41 (d, J = 1.4 Hz), 131.30, 126.54 
(d, J = 6.1 Hz), 121.53-115.68 (three overlapping multiplets CF2, CF3 and CF3), 106.69 
(tqd, 
1
J(C-F) = 263.0 Hz, 
2
J(C-F) = 37.5 Hz, 
3
J(C-P) = 6.8 Hz), 105.61, 103.01, 71.60, 36.14 
(d, J = 26.6 Hz), 29.32, 28.92 (d, J = 3.4 Hz), 27.22-26.96 (two overlapping doublets), 
25.96, 21.73, 21.48. 
19
F NMR (CDCl3 at 25 
oC): δ -76.10 (d, J = 34.8 Hz, 2F), -78.98 (s, 
3F), -82.58 (s, 3F), -119.10 (s, 3F). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 49.11 (t, J = 33.9 
Hz). 
19
F/
13
C HSQC NMR (CDCl3 at 25 
oC): δF/δC -76.10/118.35, -78.98/118.46, -
82.58/118.75, -119.10/106.64. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
oC): δF/δC -
76.10/118.35 (
1
J correlation), -76.10/118.46, -78.98/118.35, -78.98/118.46 (
1
J 
correlation), -82.58/106.64, -82.58/118.75 (
1
J correlation), -119.10/106.64 (
1
J 
correlation), 119.10/118.75, 119.10/161.61. IR (ATR): cm
-1
 2987 (w), 2938 (m), 2922 
(m), 2859 (m), 1692 (s), 1588 (s), 1570 (m), 1447 (s), 1386 (s), 1333 (s), 1287 (m), 1255 
(s), 1206 (s), 1161 (s), 1108 (s), 1061 (s), 1026 (s). HRMS electrospray (m/z): [M – 
OOCCF3]
+
 calcd for C32H43F5O2PPd, 691.1950; Found, 691.1962.   
Preparation of [(RuPhos)2Pd2](CF3COO)2 (12). A solution of 
(RuPhos)Pd(COCF3)(OCOCF3) (7) (200 mg; 0.26 mmol) in benzene (7 mL) was left 
unperturbed for 24 hours. During this time the color of the solution changed from yellow 
to deep red and bright red crystals slowly separated from the solution. The benzene 
supernatant was decanted and two 2 mL portions of benzene were used to wash the 
crystals. After drying under vacuum 78 mg (44%) of bright orange powder was obtained. 
1
H NMR (acetone-d6 at 25 
o
C): δ 8.61 (m, 1H), 8.12 (m, 1H), 7.80 (t, J = 7.3 Hz, 1H), 
7.75 (t, J = 7.7 Hz, 1H), 7.41 (d, J = 7.7 Hz, 1H), 5.60 (d, J = 7.0 Hz, 2H), 4.39 (septet, J 
 198 
 
= 6.1 Hz), 3.26 (m, 2H), 2.19-2.09 (m, 4H), 1.83 (m, 4H), 1.74 (m, 2H), 1.59 (m, 2H), 
1.51 (m, 2H), 1.46-1.35 (m, 4H), 1.23 (m, 2H), 0.95 (d, J = 6.1 Hz, 6H), 0.81 (d, J = 6.0 
Hz, 6H). 
13
C{
1
H} NMR (acetone-d6 at 25 
oC):  δ 159.03 (q, J = 36.7 Hz), 151.39, 144.54 
(virtual triplet, J = 27.2 Hz), 138.27 (virtual triplet, J = 42.2 Hz), 133.31, 132.90, 131.41 
(virtual triplet, JC-P = 16.4 Hz), 129.37 (virtual triplet, JC-P = 6.2 Hz), 116.42 (q, J = 290.9 
Hz), 94.08, 86.69, 80.45, 73.30, 36.18 (virtual triplet, J = 20.6 Hz), 29.83, 29.32, 26.17-
26.00 (two overlapping triplets), 25.74, 20.58, 19.95. 
19
F NMR (acetone-d6 at 25 
oC): δ -
76.38 (s). 
31
P{
1
H} NMR (acetone-d6 at 25 
oC): δ 61.46 (s). 19F/13C HSQC NMR (acetone-
d6 at 25 
oC): δF/δC -76.38/116.45. 
19
F/
13
C HMBC NMR (acetone-d6 at 25 
oC): δF/δC -
76.38/116.45 (
1
J correlation), -76.38/159.03. HRMS electrospray (m/z): [M – OCOCF3]
+
 
calcd for C62H86F3O6P2Pd, 1257.3905; Found, 1257.3921, [M – 2OCOCF3]
2+
 calcd for 
[C30H43O2PPd]
2+
, 572.2030; Found, 572.2049. 
 
NMR Assignment for 12  (based on 
1
H/
1
H COSY and 
1
H/
13
C HSQC and HMBC) 
 
carbon δ (ppm)  proton δ (ppm) 
C
1
 144.54 (virtual triplet, JC-P = 27.2 Hz)   
C
2
 138.27 (virtual triplet, JC-P = 42.2 Hz)   
C
3
 131.41 (virtual triplet, JC-P = 16.4 Hz) H
3
 8.12 (multiplet) 
C
4
 129.37 (virtual triplet, JC-P = 6.2 Hz) H
4
 7.75 (t, J = 7.7 Hz) 
C
5
 133.31 H
5
 7.80 (t, J = 7.3 Hz) 
C
6
 132.90 H
6
 7.41 (d, J = 7.7 Hz) 
C
7
 94.08   
C
8
 151.39   
C
9
 86.69 H
9
 5.60 (d, J = 7.0 Hz) 
C
10
 80.45 H
10
 8.61 (multiplet) 
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Preparation of (RuPhos)Pd(CF3)(Ph) (13). A Schlenk flask was charged with a 
stirbar, diphenylzinc (200 mg; 0.91 mmol) and (RuPhos)Pd(CF3)(OOCCF3) (8) (450 mg; 
0.60 mmol). The flask was sealed, evacuated under reduced pressure and then refilled 
with nitrogen. The flask was evacuated and refilled with nitrogen three more times. Dry 
THF (20 mL) was added via cannula. The resulting solution was stirred at rt for 20 
minutes, then water (0.2 mL) was introduced via septum. Reaction mixture was stirred at 
rt for additional 20 minutes. Then, the THF solution was dried over anhydrous Na2SO4 
and filtered. Volatiles were removed under reduced pressure. The residue was dissolved 
in diisopropyl ether and product slowly crystallized over the period of several hours. 
Colorless crystals were collected by filtration, washed with small amount of 
diisopropylether and dried under vacuum. 180 mg (42%) of 13 was obtained. 
1
H NMR 
(CDCl3 at 25 
oC): δ 7.53 (apparent triplet, J = 6.9 Hz, 1H), 7.42-7.32 (m, 3H), 7.23 (d, J 
= 7.4 Hz, 2H), 7.18 (broad d, J = 4.7 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.88 (t, J = 7.4 
Hz, 2H), 6.82 (t, J = 7.1 Hz, 1H), 4.52 (septet, J = 6.0 Hz, 2H), 1.88-1.78 (m, 2H), 1.76-
1.44 (multiple peaks, 12H, Cy protons), 1.32-1.02 (m, 8H, Cy protons), 1.28 (d, J = 6.0 
Hz, 6H), 0.99 (d, J = 6.0 Hz, 6H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC):  δ 154.11, 145.09 
(broad), 141.31 (d, J = 13.6 Hz), 140.84 (m, CF3), 136.54 (d, J = 2.0 Hz), 134.73 (d, J = 
6.8 Hz), 130.73, 129.81, 128.60, 127.20 (d, J = 21.8 Hz), 126.56 (d, J = 4.1 Hz), 126.09, 
123.34, 122.57, 110.93, 74.09, 31.82 (d, J = 19.8 Hz), 28.20, 27.28 (d, J = 13.0 Hz), 
26.87 (d, J = 9.5 Hz), 26.67, 25.99, 22.30, 21.18. 
19
F NMR (CDCl3 at 25 
oC): δ -27.80 (d, 
J = 44.8 Hz). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 14.77 (q, J = 45.8 Hz). 19F/13C HSQC 
NMR (CDCl3 at 25 
oC): δF/δC -27.80/140.84. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
o
C): 
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δF/δC -27.80/140.84 (
1
J correlation), -27.80/145.09. IR (ATR): cm
-1
 3051 (w), 2968 (w), 
2928 (s), 2850 (m), 1598 (m), 1579 (w), 1566 (m), 1450 (s), 1374 (m), 1331 (w), 1270 
(s), 1224 (m), 1088 (s), 1046 (s). HRMS electrospray (m/z): [M – F]+ calcd for 
C37H48F2O2PPd, 699.2389; Found, 699.2383.  
Preparation of (RuPhos)Pd(CF3)(o-C6H4CH3) (14).  2-Iodotoluene (6.00 g; 
27.5 mmol) and dry diethyl ether (120 mL) were introduced into a flame-dried 250 mL 
Schlenk flask. The ether solution was cooled to -78 
o
C and 2.5 M solution of nBuLi in 
hexanes (11.5 mL; 28 mmol) was added dropwise. The resulting suspension was stirred 
at -78 
o
C for 30 minutes. Then 1.9 M ZnCl2 solution in 2-methyltetrahydrofuran (7.2 mL; 
13.7 mmol) was added slowly over the period of 10 minutes (at -78 
o
C). Reaction mixture 
was warmed to rt and stirred at rt for 30 minutes. Volatiles were removed via the sidearm 
of the Schlenk flask and the residue was washed with several portions of dry pentane. 
Dry toluene (25 mL) was added to the residue and resulting suspension was cannula-
transferred to a septum-sealed centrifuge tube. LiCl precipitate was separated by 
centrifugation and remaining clear toluene solution of Zn(o-C6H4CH3)2 reagent was used 
directly in the step below. It was assumed that the concentration of the Zn(o-C6H4CH3)2 
reagent in toluene is 0.5 M. 
A Schlenk flask was charged with a stirbar and (RuPhos)Pd(CF3)(OOCCF3) (9) 
(400 mg; 0.50 mmol). The flask was sealed, evacuated under reduced pressure and then 
refilled with nitrogen. The flask was evacuated and refilled with nitrogen three more 
times. Dry THF (20 mL) was added via cannula. The resulting solution was cooled to -78 
o
C and then Zn(o-C6H4CH3)2 solution in toluene (1.2 mL; approximately 0.6 mmol) was 
added dropwise. Reaction mixture was stirred at rt for 20 minutes, then water (0.2 mL) 
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was introduced via septum. Reaction was stirred at rt for additional 20 minutes. Then the 
THF solution was dried over anhydrous Na2SO4 and filtered. Volatiles were removed 
under reduced pressure. Residue was dissolved in acetone (1.5 mL) and product slowly 
crystallized over the period of several hours. Crystals were collected by filtration, washed 
with a small amount of acetone and dried under vacuum. 230 mg (63%) of colorless 
crystals was obtained. 
 Analytical data for 14. Rotation about Pd-(o-Tol) bond is hindered on 
the NMR timescale at 25 
o
C. Therefore several signals in 
1
H- and 
13
C-
NMR spectra are broadened at 25 
o
C. VT 
1
H-NMR experiments revealed that at -40 
o
C 
rotation about Pd-(o-Tol) is slow on the 
1
H-NMR timescale (RuPhos fragment loses the 
plane of symmetry in the 
1
H-NMR spectrum). 
1
H NMR (CDCl3 at 25 
oC): δ 7.50 
(apparent triplet, J = 6.6 Hz, 1H), 7.39-7.33 (m, 3H), 7.17 (d, J = 7.5  Hz, 1H), 7.14 (br, 
1H), 7.00 (br, 2H),  6.81 (dd, J = 8.3, 1.0  Hz, 1H), 6.77 (t, J = 7.0 Hz, 1H), 6.71 (t, J = 
7.7 Hz, 1H), 4.59-4.50 (two overlapping septets, 2H), 2.47 (s, 3H), 1.99-0.63 
(overlapping broad resonances, 22H, Cy protons), 1.31 (d, J = 6.0 Hz, 3H), 1.27 (broad d, 
J = 5.5 Hz, 3H), 1.01 (broad d, J = 4.6 Hz, 3H), 0.97 (d, J = 6.1 Hz, 3H). 
13
C{
1
H} NMR 
(CDCl3 at 25 
oC):  δ 154.40, 154.33, 146.47 (broad), 141.65 (d, J = 12.9 Hz), 141.35, 
140.35 (m, CF3), 135.84, 134.58 (broad), 130.91 (broad), 129.93 (broad), 128.61 (broad), 
127.88 (broad d, J = 19.1 Hz), 127.42, 126.48 (d, J = 4.1 Hz), 123.14 (broad), 122.92 
(broad), 122.58, 110.83, 110.72, 73.98 (broad), 73.74 (broad), 32.55 (two overlapping 
broad resonances, Cy signals), 28.61-25.59 (overlapping broad resonances, Cy signals), 
27.47, 27.40, 26.19, 22.34, 22.27, 21.24 (two overlapping broad resonances). 
19
F NMR 
(CDCl3 at 25 
oC): δ -27.74 (d, J = 53.6 Hz). 31P{1H} NMR (CDCl3 at 25 
oC): δ 13.79 (q, 
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J = 45.8 Hz). 
19
F/
13
C HSQC NMR (CDCl3 at 25 
oC): δF/δC -27.74/140.19. 
19
F/
13
C HMBC 
NMR (CDCl3 at 25 
oC): δF/δC -27.74/140.19 (
1
J correlation), -27.74/146.47. IR (ATR): 
cm
-1
 3064 (w), 2918 (s), 2850 (m), 2361 (w), 2338 (w), 2162 (w), 1599 (m), 1578 (m), 
1453 (s), 1384 (m), 1373 (m), 1269 (m), 1225 (m), 1105 (m), 1084 (s), 1040 (s), 978 (s). 
HRMS electrospray (m/z): [M – F]+ calcd for C39H50F4O2PPd, 763.2519; Found, 
763.2514, [M – o-C6H4CH3]
+
 calcd for C32H43F5O2PPd, 691.1956; Found, 691.1929.  
Preparation of (RuPhos)Pd(C2F5)(Ph) (15). A Schlenk flask was charged with a 
stirbar, diphenylzinc (180 mg; 0.82 mmol) and (RuPhos)Pd(C2F5)(OOCC2F5) (7) (500 
mg; 0.58 mmol). The flask was sealed, evacuated under reduced pressure and then 
refilled with nitrogen. The flask was evacuated and refilled with nitrogen three more 
times. Dry THF (20 mL) was added via cannula. The resulting solution was stirred at rt 
for 20 minutes, then water (0.2 mL) was introduced via septum. Reaction mixture was 
stirred at rt for additional 20 minutes. Then, the THF solution was dried over anhydrous 
Na2SO4 and filtered. Volatiles were removed under reduced pressure. Residue was 
dissolved in diethyl ether and product slowly crystallized over the period of several 
hours. Colorless crystals were collected by filtration, washed with a small amount of 
diethyl ether and dried under vacuum. 413 mg (92%) of 15 was obtained. 
1
H NMR 
(CDCl3 at 25 
oC): δ 7.52 (apparent triplet, J = 6.7 Hz, 1H), 7.41-7.36 (m, 2H), 7.34 (t, J = 
7.1 Hz, 1H), 7.18 (ddd, J = 7.5, 3.2, 1.2 Hz, 2H), 7.11 (d, J = 7.5 Hz, 1H), 7.02 (d, J = 8.3 
Hz, 1H), 6.81 (t, J = 6.7 Hz, 2H), 6.78 (t, J = 7.2 Hz, 1H), 4.50 (septet, J = 6.1 Hz, 2H), 
1.81-1.73 (m, 2H), 1.73-1.67 (m, 2H), 1.63-1.56 (m, 6H, Cy protons), 1.50-1.40 (m, 2H), 
1.34-1.27 (m, 2H), 1.25 (d, J = 6.1 Hz, 6H), 1.18-1.09 (m, 4H), 1.08-1.00 (m, 2H), 0.98 
(d, J = 6.0 Hz, 6H). 
13
C{
1
H} NMR (CDCl3 at 25 
oC):  δ 153.98, 143.41 (broad), 141.34 
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(d, J = 14.3 Hz), 136.63 (d, J = 2.7 Hz), 134.69 (d, J = 7.5 Hz), 133.08 (m, CF2), 130.80, 
129.40, 128.55, 127.37 (d, J = 21.8 Hz), 126.49 (d, J = 4.8 Hz), 125.94, 123.69, 122.40, 
122.26 (qtd, 
1
J(C-F) = 286.1 Hz, 
2
J(C-F) = 31.3 Hz, 
3
J(C-P) = 8.2 Hz), 111.10, 74.05, 32.02 (d, 
J = 19.1 Hz), 28.15, 27.30 (d, J = 12.3 Hz), 27.10 (d, J = 4.1 Hz), 26.92 (d, J = 9.5 Hz), 
26.01, 22.28, 21.19. 
19
F NMR (CDCl3 at 25 
oC): δ -79.83 (s, 3F), -102.50 (d, J = 23.2 Hz, 
2F). 
31
P{
1
H} NMR (CDCl3 at 25 
oC): δ 13.57 (t, J = 28.6 Hz). 19F/13C HSQC NMR 
(CDCl3 at 25 
oC): δF/δC -79.83/122.26, -102.50/133.08. 
19
F/
13
C HMBC NMR (CDCl3 at 
25 
oC): δF/δC -79.83/122.26 (
1
J correlation), -79.83/133.08. IR (ATR): cm
-1
 3057 (w), 
2974 (w), 2929 (m), 2848 (w), 1596 (m), 1564 (m), 1452 (s), 1384 (m), 1292 (m), 1267 
(m), 1231 (w), 1187 (m), 1138 (m), 1101 (m), 1039 (s). HRMS electrospray (m/z): [M – 
F]
+
 calcd for C38H48F4O2PPd, 749.2363; Found, 749.2345, [M – Ph]+ calcd for 
C32H43F5O2PPd, 691.1956; Found, 691.1938.  
Preparation of (RuPhos)Pd(C2F5)(o-C6H4CH3) (16). A Schlenk flask was 
charged with a stirbar and (RuPhos)Pd(C2F5)(OOCC2F5) (9) (400 mg; 0.50 mmol). The 
flask was sealed, evacuated under reduced pressure and then refilled with nitrogen. The 
flask was evacuated and refilled with nitrogen three more times. Dry THF (20 mL) was 
added via cannula. The resulting solution was cooled to -78 
o
C and then Zn(o-C6H4CH3)2 
solution in toluene (1.2 mL; approximately 0.6 mmol) was added dropwise. Reaction 
mixture was stirred at rt for 20 minutes, then water (0.2 mL) was introduced via septum. 
Reaction was stirred at rt for additional 20 minutes. Then, the THF solution was dried 
over anhydrous Na2SO4 and filtered. Volatiles were removed under reduced pressure. 
The residue was dissolved in methanol (1.5 mL) and product slowly crystallized over the 
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period of several hours. Crystals were collected by filtration, washed with small amount 
of methanol and dried under vacuum. 214 mg (55%) of 16 was obtained. 
Analytical data for 16. 
1
H-, 
19
F- and 
13
C-NMR spectra showed that 
rotation about Pd-(o-Tol) bond is slow on the NMR timescale at 25 
o
C. 
Accroding to 
1
H- and 
13
C-NMR spectra RuPhos fragment does not 
poses the plane of symmetry. Moreover, according to 
19
F-NMR spectrum fluorine atoms 
of the CF2 group are diastereotopic. 
1
H NMR (CDCl3 at 25 
oC): δ 7.52 (apparent triplet, J 
= 6.5 Hz, 1H), 7.40-7.34 (m, 2H), 7.32 (t, J = 7.3 Hz, 1H), 7.19 (m, 2H), 7.12 (m, 1H), 
6.85 (d, J = 8.3  Hz, 1H), 6.70 (m, 2H), 6.65 (m, 1H), 4.56-4.48 (two overlapping septets, 
2H), 2.23 (m, 1H, Cy proton), 2.12 (s, 3H), 1.93-0.83 (many overlapping multiplets, 19H, 
Cy protons), 1.21 (two overlapping doublets, 6H), 1.12 (d, J = 6.0 Hz, 3H), 0.78 (d, J = 
6.0 Hz, 3H), 0.63 (m, 1H, Cy proton), 0.46 (m, 1H, Cy proton). 
13
C{
1
H} NMR (CDCl3 at 
25 
oC):  δ 155.45, 153.24, 144.63 (broad), 141.31 (d, J = 15.0 Hz), 140.98, 136.94, 
134.73 (d, J = 8.2 Hz), 133.23 (m, CF2), 131.06, 129.63, 128.58 (d, J = 2.0 Hz), 127.76 
(broad d, J = 22.9 Hz), 127.54, 126.38 (d, J = 4.1 Hz), 123.56 (broad multiplet), 122.74, 
122.50, 122.45 (m, CF3), 112.35, 109.54, 76.73, 71.03, 34.32 (d, J = 19.1 Hz), 32.07 (d, J 
= 18.4 Hz), 29.83, 29.80, 27.62 (d, J = 12.3 Hz), 27.13 (d, J = 10.3 Hz), 26.97 (d, J = 2.3 
Hz), 26.92 (d, J = 8.8 Hz), 26.71 (d, J = 12.9 Hz), 26.41, 26.35 (d, J = 3.4 Hz), 25.98, 
25.87, 22.45, 21.95, 21.64, 20.91. 
19
F NMR (CD2Cl2 at 25 
oC): δ -79.87 (s, 3F), -101.19 
(dd, 
2
J(F-F) = 31.5 Hz, 
3
J(F-P) = 275.3 Hz, 1F), -102.44 (dd, 
2
J(F-F) = 275.3 Hz, 
3
J(F-P) = 23.2 
Hz, 1F). 
31
P{
1
H} NMR (CD2Cl2 at 25 
oC): δ 11.31 (broad multiplet). 19F/13C HSQC 
NMR (CDCl3 at 25 
oC): δF/δC -79.87/122.45. 
19
F/
13
C HMBC NMR (CDCl3 at 25 
o
C): 
δF/δC -79.87/122.45 (
1
J correlation), -79.83/133.23. IR (ATR): cm
-1
 3048 (w), 2976 (w), 
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2927 (m), 2850 (m), 1596 (m), 1577 (m), 1449 (s), 1384 (m), 1373 (m), 1292 (m), 1266 
(m), 1228 (m), 1185 (s), 1148 (s), 1101 (s), 1037 (s). HRMS electrospray (m/z): [M – F]+ 
calcd for C38H50F2O2PPd, 713.2551; Found, 713.2546. 
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